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In the second part of the 20th century, cancer became an important health problem 
worldwide. Life expectancy increased for many western populations from about 70 
years in the 1950s to more than 80 years in 2010. Thereby the life span to develop 
cancer increased, as age is the most important risk indicator of cancer. The Danish 
Cancer Registry, the oldest nationwide cancer registry, showed that cancer incidence 
almost doubled in the last 70 years. In the Netherlands, cancer incidence increased 
with 50% since the 1970s. Fortunately, mortality from cancer started to decrease 
from the 1980s (Figure 1.1). 
Figure 1.1 | Long-term incidence trends of total cancer (except non-melanoma skin cancers). 
As a reaction to the enormous increase in cancer incidence, governments in the US 
and Europe started to make cancer plans. President Nixon even declared a ‘war on 
cancer’ in 1971 by signing the ‘National Cancer Act’. This National Cancer Program 
planned to create new cancer centres, stimulate cancer research and develop cancer 
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control activities, such as prevention programs.1 Since that first National Cancer 
Program, the United States has invested over $200 billion on cancer research.2 Europe 
followed with the ‘Europe against cancer program’ in 1986, developed together 
with the ‘European Code Against Cancer’. The main goal of the cancer program 
was to lower cancer mortality in 2000 by 15%, by focusing on three major themes: 
prevention (particularly tobacco control), screening (particularly for breast, cervical 
and colon cancer) and education and training (e.g., stimulation of collaborative 
cancer research and development of cancer registries).3 
 To evaluate outcomes of cancer programs, cancer incidence, prognosis and 
mortality are useful outcome measures. In the Netherlands, a national cancer registry 
was started in 12 regions in 1953 under auspices of and financed by the Dutch Cancer 
Society. These regional cancer registries developed each in their own way. Possibly 
because of that, from 1968 only the regional registries of The Hague, Rotterdam, 
Friesland and Southeast-North Brabant survived. The financing was stopped in 1974, 
because of lack of perspective for and incompleteness of the registries. However, 
the registry of Southeast-North Brabant persisted and expanded its catchment 
area to North and Middle Limburg.4 In the mid 1970s the Comprehensive Cancer 
Centres developed to improve cancer care at the regional level. The Netherlands 
Cancer Registry was born in 1984 and reached a national coverage in 1989. Data on 
prognosis have become available more recently (since 2007) by an annual link of the 
cancer registry with the nationwide database of all municipal population registries. 
These registries have information on all deceased Dutch citizens. Data on cancer 
mortality were already available since the beginning of the 20th century through 
the Causes of Death Registry of Statistics Netherlands. 
DutCH CANCEr trENDs iN tHE PAst
incidence trends
In the 1970s, Harmse and De Waard5 described Dutch trends in cancer incidence 
for the first time. These trends covered the time period 1960-1969 and were based 
on incidence data from Friesland, The Hague and Rotterdam. They observed an 
increasing incidence of cancer of the colon, kidney and malignant lymphoma in both 
sexes, an increasing incidence of cancer of the larynx, lung, prostate and bladder 
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cancer among males, a decreasing incidence of oral cancer among males and an 
increasing incidence of cancers of the breast, ovary and cervix among females. 
 Later on, Coebergh et al.4 published incidence data over 1975-1986 based on 
data from the Eindhoven cancer registry, which covered Southeast-North Brabant 
and North Limburg. The total cancer incidence among males increased to 424 per 
100,000 person-years (European Standardised Rate(ESR)) until 1983 and thereafter 
decreased to 407 in 1984-1986. Among females the total cancer incidence steadily 
increased over time to 292 per 100,000 person-years in 1984-1986.
 Since the national coverage of the Netherlands Cancer Registry in 1989 many 
trend publications were published, like the annual reports published initially by 
the Dutch Cancer Society and later on by the Comprehensive Cancer Centres. The 
first long-term incidence trends were published for the period 1989-1998. During 
this period incidence increased for cancer of the pharynx, oesophagus and skin 
melanoma while cancers of the stomach and gallbladder decreased among both 
sexes. For males, colorectal, prostate and testicular cancer increased and cancer of 
the lip, larynx, lung, pancreas, bladder, renal pelvis and ureter showed decreasing 
trends. For females, cancer of the head and neck, larynx, lung and breast increased 
and ovarian and cervical cancer showed decreasing trends.6, 7 Most of these national 
trends had previously been observed in the southeastern part of the Netherlands.4,8 
In a later publication with trends updated until 2003, it was shown that these 
increasing and decreasing incidence trends continued. New observations were the 
increase in liver cancer among males and increase in colon cancer among females. 
Overall, the total cancer incidence among males remained stable at about 445 per 
100,000 person-years (ESR) and slightly increased for females from 313 per 100,000 
person-years in 1989 to 358 in 1998.9
 All these changes in cancer incidence resulted in changes in the five most 
common cancer types among males and females, excluding non-melanoma skin 
cancers (Figure 1.2). Most remarkable are the increase of testicular cancer from the 
third place in 1989-1991 to the first place in 2007-2009 among young men (30-44 yr) 
and the replacement of lung cancer as the most common cancer by prostate cancer 
among males aged 45 and older. For females, breast cancer remained the most 
common cancer except for females aged 75 and older where breast cancer was 
replaced by colorectal cancer. Lung cancer became more common among females 
and skin melanoma among both sexes. 
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  A – males  B- Females
Figure 1.2 | Five most common cancer types (exclusive non-melanoma skin cancer) by gender 
and age group in 1989-1991 and 2007-2009, the Netherlands
survival trends
Survival trends based on population-based cancer registry data were first published 
by Coebergh et al.10 During 1975-1985, the overall 5 and 10-year relative cancer 
survival proportions were 33% and 27% for males and 51% and 44% for females. 
Improvements in survival were seen for females and patients younger than 45 
years. However, the cancer registry of the southeastern part of the Netherlands has 
survival data from 1955, which were published later on and showed that between 
1955 and 2002 cancer survival improved with about 20%. Five and 10-year relative 
survival improved from 38% and 30% in 1955-1969 to 60% and 50% in 2000-2002.11
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The impressive survival improvement was only seen since the 1970s, first for the 
younger patients and later on also for the elderly. For patients aged 15-44 the 5 and 
10-year relative survival improved from 55% and 44% in 1970-1979 to 75% and 70% 
in 2000-2002; for patients aged 45-69 from 40% and 33% in 1970-1979 to almost 
60% and 50% in 2000-2002; for patients aged 70 and over from 34% and 28% in 
1970-1979 to 50% and 40% in 2000-2002. These improvements were mainly due to 
survival improvements for patients with cancer of the rectum, female breast, cervix, 
ovary, prostate, testis, skin melanoma and Hodgkin lymphoma.8,11-18 In the past, no 
survival improvements were found for patients with cancer of the stomach, kidney 
and liver and survival even worsened for patients with non-cardia carcinomas of the 
stomach.19-22
mortality trends
The first Dutch cancer mortality data were described by Korteweg23 for the time 
period 1918-1922. He found that before the age of 60 more women died of cancer 
than men, while after the age of 60 the gap between both sexes increased in 
disadvantage for men (Figure 1.3). 
Figure 1.3 | Cancer mortality in Amsterdam per 10,000 inhabitants by gender, 1919-192223 
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In the mid-1950s, Hoogendoorn24 described the cancer mortality trends over the first 
part of the 20th century and showed that cancer mortality had slightly increased 
until the mid-1940s. In the 1980s, he published an update of cancer mortality 
trends up to 1980.25 He observed that since the 1970s cancer mortality decreased 
for all female age groups and for males aged 60 and below. Above this age cancer 
mortality increased. 
 Since the 1970s, cancer mortality among males increased with 12% until the 
end of the 1980s (from 278 per 100,000 person-years in 1970 to 312 in 1987 (ESRs)). 
Thereafter mortality decreased with 27% to 228 per 100,000 person-years in 2009. 
Among females, cancer mortality decreased during the 1970s with 10% (from 177 
per 100,000 person-years in 1970 to 160 in 1980), was stable during the 1980s and 
was followed by a decrease of 13% to 152 per 100,000 person-years in 2009.26 
 Compared to other causes of death, the decrease in cancer mortality was not 
that strong as for mortality from cardiovascular diseases (CVD), which was therefore 
even surpassed by cancer mortality (Figure 1.4). In 2005, for the first time the cancer 
mortality rate per 100,000 person-years became higher than the CVD mortality rate 
and in 2008 the absolute numbers of cancer deaths became higher. Among the 
population aged 60 and below, the cancer mortality rate already surpassed the CVD 
mortality rate since the 1970s and over time the gap has been growing. In 1970, 
27% of total mortality among the young population (≤60 years) was attributed 
to cancer and 24% to CVD, while in 2009 these percentages were 42% and 17%, 
respectively. Since the mid-1990s, the mortality rate from cancer was higher than 
from CVD among the population aged 60-74. While in 1970, cancer mortality among 
this age group was 29% of total mortality and CVD mortality was 47%, in 2009 these 
percentages were 49% and 23%, respectively. For the elderly, the CVD mortality rate 
remained higher than the cancer mortality rate, although the gap became smaller 
over time. Seventeen percent of total mortality was due to cancer mortality and 
54% due to CVD mortality in 1970 and these percentages were 22% and 33% in 
2009, respectively.26 
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Figure 1.4 | Trends in total mortality and mortality from cardiovascular diseases and cancer 
(European standardised rate) by age, the Netherlands 1970-2009. 
EFForts iN tHE ‘wAr AgAiNst CANCEr’ iN tHE NEtHErlANDs
Cancer incidence and survival trends can be influenced by external factors, such as 
changes in risk factor prevalence, primary and secondary prevention and changes in 
diagnostics and treatment (Figure 1.5). Below the main initiatives and developments 
in prevention and cancer management in the Netherlands are described.
main initiatives focusing on primary prevention 
Smoking
Besides ageing, smoking is the most important risk factor for cancer, particularly 
for cancer of the lung, head and neck, oesophagus and bladder cancer. In the past, 
initiatives on primary prevention against smoking were taken mainly by the Dutch 
government and carried out through regional public health organizations. Anti-
smoking policies, like increasing tobacco taxes and installing smoking-free public 
areas, are examples. Particularly, the foundation of STIVORO, the Dutch expert 
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centre for tobacco control, in 1974 by the Dutch Cancer Society, the Netherlands 
Heart Foundation and the Netherlands Asthma Foundation played an important 
role in these initiatives. As a result of these initiatives the smoking prevalence 
decreased from 75% among males and 40% among females in the 1970s to 28% 
and 26% in 2010, respectively.27 However, the prevalence did not decrease as fast as 
in other Western countries and remained more or less stable since 2000. Countries 
like Canada and Australia are much more aggressive in their anti-smoking policy 
and consequently, the smoking prevalence was 17% in 2010 and 19% in 2007, 
respectively.28,29 In the Netherlands, the lobby of the tobacco industry was and is 
still strong, because of having a large tobacco industry. This strong lobby resulted 
in late action of the Dutch government against smoking. Recently, the government 
even reversed the smoking ban in small pubs. In the 1990s, it became clear that this 
industry, present in the south-east Netherlands, had also a big influence on the local 
community. The percentage of male smokers in the south-east Netherlands was 
approximately the same between 1958 and 1981, while this percentage decreased 
with 50% on the national level. The lung cancer incidence for men was also clearly 
higher in this region.30 
Changes in risk factor 
prevalence / Primary 
prevention
Secondary prevention 
(e.g. screening)
Changes in diagnostics
Changes in cancer 
treatment
Cancer incidence
(stage, subsite, histology)
Cancer prognosis
Cancer mortality
Changes in registration
Figure 1.5 | Relationship between incidence and prognosis of and mortality from cancer
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Alcohol
Alcohol is a risk factor for cancer of the oral cavity, pharynx, larynx, oesophagus, 
liver, colorectal and breast. The risk of getting cancer increases as consumption and 
frequency of consumption increases.31-34
 In the Netherlands, alcohol consumption per capita increased with the increase 
of prosperity since the 1950s and was highest during the 1970s and early 1980s.35,36 
The prevalence of alcohol drinkers among the Dutch population aged 16 and over 
increased from 80% in 1989 to 86% in 1999 and thereafter slightly decreased to 83% 
in 2009. Alcohol use among males is higher than among females.37 Compared to 
other European countries the per capita consumption of alcohol in the Netherlands 
is moderate.36
 The strong increases in alcohol use during the 1970s did not provoke any 
strong negative reaction, either from the public at large or from the government. 
Moreover, the Dutch government had no tradition in developing and implementing 
a restrictive alcohol policy.38 Since 1977, there is an advertising code for alcoholic 
beverages and this changed in 2000 to a voluntary advertising ban for all media 
when 25% of the public is below 18 years of age. Since 2009, alcohol advertising 
at radio and television is prohibited during day time. Furthermore, there are the 
alcohol taxes and a national campaign ‘Drank maakt meer kapot dan je lief is’ 
initiated by the government, started in 1986 aiming to reduce health risks and social 
problems by alcohol abuse.39 Recently, the Minister of Health decided to stop such 
behavior changing campaigns from 2012 on. 
Excessive sun exposure
Since the mid 20th century the popularity of sunbathing increased a lot among 
the Dutch population and excessive sun exposure is an important risk factor for 
skin melanoma. At the end of the 1990s, Van der Rhee and Coebergh40 advocated 
primary prevention by focusing on avoiding sunburns in young people under the 
age of 20 and providing extra information by medical doctors to high-risk patients. 
The Dutch Cancer Society organized many information campaigns on the risk of 
excessive sunbathing and sunburns (the so-called ‘verstandig zonnen’ campaigns) 
including course materials for primary schools. At the moment, there is even a ‘Sun 
app’,41 which can measure the UV-index, has a skin type test and gives a personal 
advice for sun protection. and a ‘Skin monitor app’,42 which can compare suspected 
lesions with examples of melanomas. 
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Overweight and physical activity
Overweight has been endemic in the Netherlands since the early 1990s and is 
strongly associated with cancer of the oesophagus (only adenocarcinoma), colon, 
gallbladder, thyroid, kidney and endometrium. Weaker positive associations are 
found for cancers of the postmenopausal breast, pancreas, rectum, skin melanoma, 
leukemia, multiple myeloma and non-Hodgkin lymphoma.43 In the Netherlands, the 
prevalence of overweight (25<BMI>30 kg/m2) increased from 33% in 1981 to 41% 
in 2009 among males, and among females from 23% to 30%. The prevalence of 
obesity (BMI>=30 kg/m2) increased more dramatically from 4% in 1981 to 11% in 
2009 among males and among females from 6 to 12%.26 
 In the past, many campaigns and actions were organized to inform the Dutch 
population about the importance of healthy food and sufficient physical activity 
to reduce the risk of overweight. These campaigns were (partly) financed by the 
government. Examples of healthy food campaigns are the so-called ‘Balance day’ 
(‘Balansdag’) and healthy school cantines (‘De gezonde schoolkantine’) organized 
by The Netherlands Nutrition Centre Foundation. Pregnant women are informed 
about the influence of nutrition during pregnancy and breastfeeding on the risk 
of overweight of their child. To stimulate physical activity, the so-called 30 minutes 
movement campaign is going on since 2007 (’30 minuten bewegen’) and organized 
by The Netherlands Institute for Sport and Movement. 
Occupational exposure: Asbestos
Exposure to asbestos has created an important health problem, particularly among 
men. In 1929, a British pathologist concluded that inhalation of asbestos could 
cause pulmonary asbestosis. In the Netherlands the same conclusion was drawn 13 
years later, in 1942. Asbestos as risk factor for mesothelioma was internationally 
acknowledged in the mid-1960s and the Netherlands followed at the end of the 
1960s after the publication of the thesis of Stumphius.44 However, it took until 1993 
before all uses of asbestos were forbidden.45
 For the period 1995-2030 it has been estimated that about 20,000 cases 
of mortality from pleural mesothelioma among men will have been caused by 
occupational exposure to asbestos in the past. The peak will be reached in 2018 
with 700 deaths.46 However, it is also found that environmental exposure to asbestos 
increases the risk of pleural mesothelioma among women who lived nearby an 
asbestos cement facility.47,48
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main initiatives focusing on secondary prevention
Breast cancer screening
In the mid-1970s, two projects on breast cancer screening started in Utrecht (the 
DOM project) and Nijmegen inviting women aged 50-64 years and aged 35-65 
years, respectively. The Nijmegen project with biannual mammography showed 
a mortality reduction of 50% after six years and the DOM project with palpation 
and xeromammography showed even a 70% reduction in breast cancer mortality. 
Results of both studies were published in the Lancet in 1984.49,50 Based on these two 
landmark papers on breast cancer screening and later on the results of a Swedish 
trial51 and a cost-effectiveness study by Van der Maas and his colleagues (Rotterdam; 
not published) caused the government to decide to introduce a population-based 
nationwide breast cancer screening program with biannual mammography in 
women aged 50-70 years. The screening programme reached nationwide coverage 
in 1996 and in 1998 the programme was expanded up to the age of 75. Nowadays, 
annually, one million women are screened for breast cancer in the Netherlands 
preventing approximately 1000 women from dying of breast cancer each year.52 
Cervical cancer screening
The first initiatives for cervical cancer prevention in the Netherlands were taken in 
the 1970s. Three pilot screening programs were started in the regions of Nijmegen, 
Rotterdam and Utrecht, which were soon adopted in other regions. These centrally 
organized programs were stopped by the mid-1980s when decentralized programs 
were introduced in the whole country. Cervical cancer screening using the Pap 
smear test was then offered every three years to all women aged between 35 and 
54. In the early 1990s, evidence gathered pointed towards suboptimal performance 
of the screening program. 53-55 Based on a request from the Ministry of Health for 
possible solutions, new protocols and guidelines were implemented nationally in 
1996.56 The screening interval was lengthened from 3 to 5 years, the age range 
was broadened from 35-54 to 30-60 years, and the invitational coverage was made 
more complete than in the old program. The changes have resulted in increased 
coverage and efficiency of the screening program, and in a decrease of negative 
side effects.57 Recent developments are the introduction of Human Papillomavirus 
(HPV) vaccination for 12-year old girls in 2009 and the positive advice of the Health 
Council of the Netherlands for using HPV DNA test as the primary screen test in the 
cervical screening program.58
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Colorectal cancer screening
Despite the high incidence of colorectal cancer in the Netherlands there is no 
organized national screening program. Since 2005, several feasibility projects were 
started to examine and compare different tests for screening (e.g. immunochemical 
fecal occult blood test (iFOBT), sigmoidoscopy, coloscopy, CT-colography). Based on 
the first results and the positive advice of the Health Council of the Netherlands, the 
Minister of Health decided recently to start colorectal cancer screening using the 
immunochemical fecal occult blood test (iFOBT). From 2013, all persons aged 55-75 
will be invited every 2 years for this national screening program.59,60
Prostate cancer screening
In the early 1990s, opportunistic case finding of prostate cancer by testing serum 
prostate-specific antigen level (PSA) was introduced in the Netherlands.61 First 
mainly used by urologists and later on also by general practitioners. However, the 
introduction of PSA testing was relatively slow in the Netherlands compared to 
other high-income countries.62 According to a survey by Statistics Netherlands in 
2001, only 14% of men aged 45 and over had a PSA test in the previous five years.63 
Until now, PSA testing is not routine practice in the Netherlands because of the 
high risk of overdiagnosis and overtreatment. This outweighs the 20% decrease in 
prostate cancer mortality as an effect of population-based PSA testing as shown by 
the European Randomised Study of Screening for Prostate Cancer (ERSPC).64 
Skin cancer screening
In 1989, clinicians in the western part of the Netherlands took the initiative to do 
a screening campaign on skin cancer in four seaside resorts (Noordwijk, Katwijk, 
Scheveningen and Kijkduin) using a mobile examination room, which was continued 
until 1995. The so-called ‘sproetenbus’ campaign had two aims: firstly to inform the 
population about the risks of excessive sun exposure and the risk of skin cancer 
and secondly to see if screening for skin cancer could be effective. During and after 
the campaign the number of consultations for skin lesions increased as well as the 
number of diagnoses of malignant lesions. The positive predictive value of the 
clinical examination was 83%.65 Based on the results of this screening campaign 
and the literature, clinicians advocated a screening among high risk groups in the 
Netherlands. A dermatologist at the Sint Anna hospital in Oss also took an initiative 
and organized a screening day in 1989. However, these dermatologists doubted 
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about the added value of a national screening program for skin cancer and pointed 
out the increasing workload for general practitioners, dermatologists, surgeons and 
pathologists.66 At the end of the 1990s, Van der Rhee and Coebergh40 advocated 
a secondary prevention by instructing high-risk groups how to check their own 
skin and getting annual check-ups. About 9% of the total population belongs to 
this high-risk group, which has a 40 times higher risk of getting skin melanoma. 
Recently, a ‘Skin monitor app’ was launched, which can compare suspected lesions 
with examples of melanomas.42 
main changes in cancer management
Detection and staging
Since the 1970s, detection and staging of cancer continuously improved by the 
availability of and improved access to new diagnostic techniques. For example, the 
widespread use of flexible endoscopy since the 1980s caused that stomach cancer was 
slightly more often detected in earlier disease stages. For esophageal and colorectal 
cancer no change in stage distribution was seen probably due to treatment of 
benign Barrett’s lesions or polyps.11 Introduction of new diagnostic techniques can 
also cause an increase in cancer incidence which was observed for pancreatic cancer 
during the 1970s and early 1980s caused by the introduction of ultrasound and 
computed tomography (CT-scan) in combination with cytology. A strong increase in 
incidence was also observed for kidney cancer which is probably due to increased 
use of ultrasound and CT-scan.11,67 Diagnosis of lung cancer improved (detection 
and histological verification) by introduction of flexible bronchoscopy and cytology 
in the 1970s. Since 2000, staging of lung cancer improved by introduction of 
Positron Emission Tomography (PET-scan) and immunohistochemistry.11,67 These new 
diagnostic techniques and Magnetic Resonance Imaging (MRI-scan) are useful for 
many other cancers particularly in finding cancers in an earlier stages of disease.68 
Treatment
Surgery
Treatment of cancer patients underwent enormous developments in different 
areas, of which surgery is one of the oldest and one of the most important. One of 
the examples of developments of new surgical techniques is the total mesorectal 
excision (TME) technique in rectal cancer patients in the mid-1990s, which replaced 
conventional blunt dissection of the rectum.69 The introduction of TME resulted 
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in a decreased local recurrence rate.70 Other examples are the breast-conserving 
surgery for breast cancer patients introduced in the 1980s,71 radical prostatectomy 
for prostate cancer patients which became more common since the late 1980s. In 
time, removal of affected organs became more precise and more surrounding tissue/
organs could be saved, which improved the quality of life of cancer patients. For 
example, the introduction of the sentinel lymph node biopsy, which was already 
described for penile cancer at the end of the 1970s, was used as a model for breast 
cancer introduced at the end of the 1990s. In case of a negative sentinel lymph node, 
breast cancer patients could be spared a lymph node dissection and avoiding lymph 
edema. The introduction of the subspecialism ‘surgery oncology’ was an important 
step in the aforementioned developments in oncologic surgery. In 1981, the Dutch 
Association for Surgical Oncology was founded.11,72
 More recent, there is a lot of discussion about the centralisation of surgical 
treatment of rare tumours, like cancer of the stomach, oesophagus, pancreas, 
lung, rectal stage IV cancer, thyroid and bladder. In September 2011, guidelines 
for sarcoma, breast, oesophagus, colorectal, pancreatic, endocrinal, lung and liver 
cancer were introduced by the Dutch Association for Surgery (Surgical Oncology 
included) including the numbers of surgeries needed for a good quality of cancer 
care.73 
Chemotherapy
Since the 1970s, chemotherapy became increasingly important. Particularly a 
combination of different cytostatics appeared to be effective in treating cancer 
patients. Another milestone in cancer treatment was the introduction of the multi-
disciplinary approach using chemotherapy in combination with other therapies, like 
surgery and radiotherapy. One of the examples is breast cancer where from the 
second half of the 1970s and 1980s adjuvant chemotherapy and hormonal therapy 
was introduced as addition to surgery. Since the mid-1990s, adjuvant chemotherapy 
was also more given to late stage colon cancer patients. Unfortunately, chemotherapy 
is also harmful for healthy tissue and causes many unintended side-effects, although 
in time improvements were made and nowadays this treatment has become more 
patient friendly. In 1992, the subspecialism ‘medical oncology’ was introduced and in 
1997 the Netherlands Association for Medical Oncology was founded, both having 
been important for quality improvement of chemotherapy.11,72 
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Radiotherapy
From the 1930s, radiotherapy developed from being a palliative therapy to a more 
curative therapy. The first breakthroughs took place after the Second World War, 
firstly for patients with Hodgkin lymphoma. Later on, good survival results were 
obtained for seminomas and early stages of cancer of the head and neck, larynx, 
endometrium, bladder, prostate, thyroid and cervical cancer. In the 1970s, new 
radiation equipments became available which enables radiation with less side-
effects for cancer patients. At the end of the 20th century, radiotherapy developed 
further because of new ICT possibilities. Clinicians became more accurate in fixing 
the target and surrounding areas by using computer tomography (CT). Besides, 
radiotherapy was more often given in combination with surgery and chemotherapy. 
Radiotherapy in combination with hyperthermia became also popular (e.g. cervical 
cancer patients), because hyperthermia increases the sensitivity of tissue for 
radiation. Important for all these developments was the recognition of radiotherapy 
as separate specialism in the early 1970s.11, 72
Targeted therapies
Since the beginning of the 21st century, targeted therapies were introduced. These 
targeted therapies indicate small molecules and monoclonal anti-bodies, blocking 
specific transcription and signal ways, which are essential for tumour growth. 
Examples of these therapies are the hormonal therapies for breast and prostate 
cancer, blocking specific hormone receptors, blockers of the epidermal growth 
factor receptor (EGFR), blockers of proteins and enzymes who are involved in 
invasion and metastasis, and anti-angiogenesis agents. These are better known as 
the ‘-mabs’ and ‘-nibs’. For example, breast cancer patients with an overexpression of 
Her2neu are often treated with Trastuzumab and for colorectal patients Cetuximab 
and Bevacizumab are common targeted therapies. Rituximab is used in patients 
with non-Hodgkin lymphoma, Sunitinib and Sorafenib in kidney cancer patients 
and so on. At the moment targeted therapy is often given in combination with 
chemotherapy. The hope is that these targeted therapies will replace chemotherapy 
in the future and a lot of research is going on into new monoclonal anti-bodies.11,72
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rEsEArCH quEstioNs
After all the efforts that are made an important question arises: 
How much progress did we make against cancer in the Netherlands since the late 
1980s?
 To get an answer to this important question the project ‘Progress against cancer 
in the Netherlands since the 1970s’ was started in 2007 by the department of Public 
Health, Erasmus MC in cooperation with epidemiologists of seven Comprehensive 
Cancer Centres (CCC; constitute CCC The Netherlands from 2010) and Comprehensive 
Cancer Centre South in Eindhoven. The project was funded by the Dutch Cancer 
Society. Within this project 17 working groups were started to study time trends 
of incidence, survival and mortality in relationship with previous changes in risk 
factors, prevention, screening and cancer management. In total 25 tumour types 
were studied within this project. Part of all this work is presented in this thesis.
The two main research questions in this thesis were:
a. What is the impact of changes in risk factor prevalence, primary and secondary 
prevention, and cancer management on cancer trends?
b. How can we optimize the assessment of progress against cancer and what are 
the pitfalls?
mEtHoDs
Data sources
The studies in this thesis are performed using population-based incidence data from 
the nationwide Netherlands Cancer Registry (NCR), which has a national coverage 
since 1989 and is maintained and hosted by the Comprehensive Cancer Centre the 
Netherlands (IKNL) and the Comprehensive Cancer Centre South (IKZ). The NCR is 
based on notification of all newly diagnosed malignancies in the Netherlands by the 
automated pathology archive (PALGA). An additional source is the national registry 
of hospital discharges, which accounts for up to 8% of newly diagnosed cases. 
Information on patient and tumour characteristics is obtained routinely from the 
medical records six to nine months after diagnosis. The quality of the data is high, 
due to thorough training of the administrators and computerized consistency checks 
at regional and national levels. Completeness is estimated to be at least 95%.74 The 
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information on vital status was actively obtained from the municipal registries and 
from the database of deceased persons of the Central Bureau for Genealogy. The 
vital status was used to calculate follow-up time for each cancer patient. Mortality 
data was derived from Statistics Netherlands.
 To get an overview of the progress against cancer achieved in the Netherlands 
compared to other European countries we described cancer incidence, mortality and 
survival trends of 21 European countries using data from national or regional cancer 
registries.
methods to measure progress against cancer
Many parameters may indicate progress, such as less false positive and false negative 
screening exams, more effective therapies with fewer associated side effects, better 
quality of life, and improved organization of palliative care. All of these are difficult 
to measure and monitor through the standard surveillance instruments, mainly 
cancer registries. However, several of these parameters will influence incidence of, 
survival and/or mortality from cancer, which can be monitored over time. We chose 
to focus on these three measures of cancer burden (i.e. incidence, survival, and 
mortality) combined in order to achieve a more objective assessment of progress 
against cancer, while avoiding over-interpreting findings from one of these measures 
only. 
CoNtENts oF tHis tHEsis
The main aim of this thesis is to determine whether or not we have made progress 
against cancer in the Netherlands since the late 1980s after spending so much time, 
energy and money. First of all, recent cancer trends in Europe and the Netherlands 
are described in Chapter 2. 
 In Chapter 3 the impact of changes in risk factor prevalence and primary 
prevention are described by studying lung and ovarian cancer trends. The impact 
of changes in secondary prevention and cancer management was investigated for 
prostate, ovarian and esophageal cancer in Chapter 4. 
 A useful framework for measuring progress against cancer and pitfalls of 
using incidence, prognosis and mortality as measures for progress are presented in 
Chapter 5. This thesis concludes in Chapter 6 with a general discussion of the main 
findings, their policy implications and recommendations for future research.
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ABstrACt
Background. We present a comprehensive overview of most recent European trends 
in population-based incidence of, mortality from and relative survival for patients 
with cancer since the mid 1990s.
methods. Data on incidence, mortality and 5-year relative survival from the mid 
1990s to early 2000 for the cancers of the oral cavity and pharynx, oesophagus, 
stomach, colorectum, pancreas, larynx, lung, skin melanoma, breast, cervix, corpus 
uteri, ovary, prostate, testis, kidney, bladder, and Hodgkin’s disease were obtained 
from cancer registries from 21 European countries. Estimated annual percentages 
change in incidence and mortality were calculated. Survival trends were analyzed 
by calculating the relative difference in 5-year relative survival between 1990-1994 
and 2000-2002 using data from EUROCARE-3 and -4.
results. Trends in incidence were generally favourable in the more prosperous 
countries from Northern and Western Europe, except for obesity related cancers. 
Whereas incidence of and mortality from tobacco-related cancers decreased for 
males in Northern, Western and Southern Europe, they increased for both sexes 
in Central Europe and for females nearly everywhere in Europe. Survival rates 
generally improved, mostly due to better access to specialized diagnostics, staging 
and treatment. Marked effects of organised or opportunistic screening became 
visible for breast, prostate and melanoma in the wealthier countries. Mortality 
trends were generally favourable, except for smoking related cancers. 
Conclusions. Cancer prevention and management in Europe is moving in the right 
direction. Survival increased and mortality decreased through the combination 
of earlier detection, better access to care and improved treatment. Still, cancer 
prevention efforts have much to attain, especially in the domain of female smoking 
prevalence and the emerging obesity epidemic.
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iNtroDuCtioN
Cancer has become a major public health problem in Europe with an estimated 
prevalence of about 3%, increasing to 15% at old age. Almost 50% of deaths at 
middle age is caused by cancer, partly resulting from lowering mortality from other 
causes of death. In 2002, 26% of all cancer cases in the world were diagnosed in 
Europe.1 Figures 2.1 and 2.2 show the distribution of estimated cancer incidence 
and mortality for 2006; breast, colorectal, prostate and lung cancers were the most 
important cancer types in Europe.2
 The progress against cancer is often focussed on survival of individual cancer 
patients. The recent paper on trends in survival of cancer across Europe up to 2002 
by the EUROCARE group clearly showed that the most marked improvements 
occurred among patients with colorectal, breast, prostate and thyroid cancer and 
lymphomas, both Hodgkin’s and non-Hodgkin’s.3 Little explicit clarification was given 
for the observed differences between the countries. These differences may be due 
to variation in the baseline characteristics of the covered populations, e.g. selective 
areas in a country or state with large proportions of inhabitants having a high socio-
economic status. Other explanations are the potentially selective incompleteness of 
cases at time of detection or diagnosis and during follow-up. 
 In the US, survival improvements were also revealed and largely determined 
by marked improvements in detection, thereby introducing lead time and length 
bias, together with shifts in classification, subtype, and subsite resulting in pseudo-
improvements of survival rates.4 To circumvent these problems, it is preferred to 
study simultaneously trends in cancer incidence and survival, also because both affect 
mortality.5,6 Survival improvements are more often preceded by rises in incidence 
than followed by decreases in mortality. table 2.1 summarizes possible explanations 
for changes in incidence, survival, and mortality.
 In this article we present the most recent trends in incidence, mortality, and 
survival over the last decade across Europe of 17 tumour sites, derived from cancer 
registries and mortality statistics. 
34 | Chapter 2
Figure 2.1 | Distribution of new cancer cases in Europe by gender, 2006 (Source: Ferlay et al.2)
Figure 2.2 | Distribution of cancer deaths in Europe by gender, 2006 (Source: Ferlay et al.2). 
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table 2.1 | Possible explanations for combined changes in trends in incidence of, survival for 
and mortality from cancer
incidence survival mortality Plausible explanation(s) for changes
↑ ↑ ↑ •	 Higher prevalence of risk factors, earlier diagnosis and/or shifts to 
unfavourable subsites/-types. If incidence increased faster than survival, 
mortality rates also increase.
↑ ↑ = •	 ‘Artificial’ increases in incidence due to e.g. screening, leading to increased 
survival rates due to lead time bias, but not resulting in any changes in 
mortality.
•	 Higher prevalence of risk factors, favourable shifts in stage-distribution and/
or subsites/-types and/or improved treatment. The net result is no changes 
in mortality.
↑ ↑ ↓ ‘Artificial’ increase in incidence due to e.g. screening, increased survival due 
to favourable shifts in stage-distribution and/or subsites/-types and effective 
early treatment, resulting in decreasing mortality after 5-10 years.
↑ = ↑ Higher prevalence of risk factors for aggressive tumours.
↑ ↓ ↑ Higher prevalence of risk factors, unfavourable shifts in stage-distribution 
and/or subsites/-types.
= ↑ ↓ Improved treatment.
= = = No changes. 
= ↓ ↑ Worsening case-mix, e.g. when screening manages to detect most if not all 
slow growing tumours.
↓ ↑ ↓ Lower risk factor prevalence and/or pre-malignant screening, more favourable 
case-mix and/or better staging or treatment.
↓ = ↓ Lower risk factor prevalence and/or more restrictive classification and/or pre-
malignant screening – without changes in survival will result in decreasing 
mortality rates.
↓ ↓ = Lower risk factor prevalence and/or more restrictive classification, resulting in 
worsening survival.
All other combinations of 
incidence, survival mortality 
trends
Probably registrion artefacts or problems (e.g. missing cases, incomplete 
follow-up, coding errors).
mEtHoDs
Data of the following 17 tumour sites (and corresponding ICD-10 code) were collected: 
oral cavity and pharynx (C00-14), oesophagus (C15), stomach (C16), colorectal (C18-
21), pancreas (C25), larynx (C32), lung (C33-34), skin melanoma (C43), female breast 
(C50), cervix (C53), corpus uteri (C54-55), ovary (C56), prostate (C61), testis (C62), 
kidney (C64-66/C68), bladder (C67), and Hodgkin’s disease (C81). They were derived 
from 21 European cancer registries, grouped into four regions: Northern Europe 
(Denmark, Finland, Norway, Sweden, Ireland, and the United Kingdom), Western 
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Europe (Austria, France, Germany, The Netherlands, and Switzerland), Southern 
Europe (Croatia, Italy, Malta, Slovenia, and Spain) and Central Europe (Czech 
Republic, Lithuania, and Poland). The sources of age-standardised (World Standard 
Population) incidence, mortality and survival for each country and their coverage 
are summarised in table 2.2. 
 Five-year relative survival estimates were collected from the EUROCARE-3,7-9 
the EUROCARE-4 study,3 and from a variety of national or regional cancer registry 
websites or annual reports. Trends in incidence and mortality between 1994 and 
2006 (for details, see table 2.2) were analyzed by calculating the estimated annual 
percentage change (EAPC) based on the published age-standardised rates per year, 
using the Joinpoint Regression Program (version 3.0) from the Surveillance Research 
Program of the US National Cancer Institute (http://srab.cancer.gov/joinpoint). If the 
EAPC was significantly different from zero it was termed an increasing or decreasing 
trend. The EAPCs for incidence for Switzerland and Lithuania were based on periods 
and not on annual rates. 
 Survival trends were analyzed by calculating the relative difference in 5-year 
relative survival estimates for patients diagnosed between 1990-1994 and 2000-
2002. For cancers of the oral cavity and pharynx, larynx, oesophagus, pancreas, 
ovary, testis and bladder, survival data were retrieved from literature and individual 
cancer registries or consortia of cancer registries, because for these tumours data of 
2000-2002 were not yet available from EUROCARE.
 A survival trend was determined as an increasing or decreasing trend if the 
5-year survival rate changed more than one percent-points in cancers with a poor 
prognosis (5-year relative survival <20%) and more than two percent-points in other 
cancers.
rEsults & CommENts
Results are presented in the accompanying tables, figures and text. Annual incidence 
and mortality rates per registry are provided on-line, and can be accessed at: 
http://www.eurocadet.org/documents/index.php?map=%2FEurocadet+publications
%2FOnline+tables+trends+in+Europe+2008%2F. 
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oral cavity and pharyngeal cancer (C00-14)
Within Europe incidence among males in the most recent period varied substantially 
between 5.9 (Finland) and 32 (France) per 100,000. Mortality rates varied considerably 
less and were highest in countries where incidence was moderate, e.g. in Croatia and 
Lithuania. Incidence rates among females were highest in Northern and Western 
Europe and were consistently lower than those for males. The male-to-female 
ratio decreased during the last 10 years and recently varied between 1.5 and 2.5 in 
Northern Europe to 7.7 in Lithuania. During the past decade incidence and mortality 
rates were stable in most European countries, except for a decrease in incidence in 
Northern Europe and France, Spain, and Slovenia among males, and an increase in 
incidence among females in some Northern and Western European countries (table 
2.3a). Five-year relative survival rates improved during the past decade in Europe, 
especially for oro- and nasopharyngeal cancer (table 2.3b, 2.3c). 
 As smoking is one of the main risk factors for these tumours, the observed trends 
in incidence largely reflect changes in smoking rates, which decreased amongst 
European males and increased among females in many Southern and Central 
European countries. For cancers of the oral cavity, alcohol consumption, especially 
in combination with smoking, is also an important risk factor, as are Epstein-Barr 
virus and Human papillomavirus infections 10. 
oesophageal cancer (C15) 
Oesophageal cancer is relatively uncommon in Western societies with varying 
incidence and mortality patterns during the past decade in Europe. Highest incidence 
and mortality rates were observed in Ireland and the UK. Rates were low in Southern 
and Central Europe, especially among females. Increases in incidence and mortality 
rates were observed among males in Sweden, England, and the Netherlands, and 
among females in Norway, France and Slovenia. Trends were decreasing in French, 
German, Slovenian, and Spanish males and in Finnish, Scottish and Croatian females 
(table 2.4a). Five-year relative survival improved or remained stable varying between 
7 (Slovenian males) and 23% (Germany), except for Italian and Slovenian males, 
where survival decreased (table 2.4b, 2.4c). 
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table 2.4c | Overview of recent trends in incidence of, survival for and mortality from 
oesophageal cancer in Europe
incidence survival mortality Countries
males Females
↑ ­= ↑ UK-England&Wales, Netherlands -
↑ = = - France
↑ ↓ = - Slovenia
↑ ? = Sweden Norway
= ↑ = Norway, UK-Northern Ireland / 
Scotland, Italy
UK-Northern Ireland, Netherlands
= ↑ ↓ Slovenia -
= = = Switzerland UK- England&Wales
= ↓ = - Italy
= ? ↑ Denmark -
= ? = Finland, Ireland, Austria, Czech 
Republic, Lithuania, Poland
Denmark, Sweden, Ireland, Austria, 
Germany, Switzerland, Spain, Czech 
Republic, Lithuania, Poland
= ? ↓ Spain Croatia
↓ ↑ ↓ - UK-Scotland
↓ = ↓ France -
↓ ? = Germany, Croatia Finland
The diverging trends are probably due to geographical variation in the two major 
subgroups that constitute oesophageal cancer: adenocarcinoma and squamous 
cell carcinoma and their risk factors. In the Western world, the incidence of 
adenocarcinoma was mainly rising, while the incidence of squamous cell carcinomas 
remained stable 11. Smoking and alcohol consumption are known to be associated 
with an increased risk of squamous cell carcinoma, while Barrett’s oesophagus, 
largely related to increasing weight and obesity and resulting reflux, is an important 
risk factor for adenocarcinoma.12 Modest improvements in survival seem to have 
occurred during the last decade, most likely related to the increased incidence of 
adenocarcinoma and the increasing regionalization of surgery.13,14 The decreases 
in survival among Italian and Slovenian males are probably due to increasing 
completeness of data.
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stomach cancer (C16)
Incidence and mortality rates of stomach cancer varied considerably within Europe, 
being generally higher in Southern and Central Europe and always twice as high in 
males compared with females. In most European countries, incidence and mortality 
rates have been dropping, while 5-year relative survival slowly improved (table 2.5a, 
2.5b and Figure 2.3). 
 A combination of improved methods of fresh food preservation with higher 
vitamin C content and reduced salting,15 decreased smoking prevalence and, more 
importantly, decreasing infection rates of Helicobacter Pylori,16 has probably resulted 
in the observed decreases in incidence and, subsequently, mortality. Contrary to the 
downward trends for non-cardia cancers, incidence rates for cancers of the cardia, 
initially representing less than 20% of all gastric cancers, have been reported to 
increase or remain stable.17,18 Differences in gastric cancer survival are largely related 
to age, subsite and histological type, with few changes over time19 regardless of 
the country. On one hand the shift from the pylorus to the cardia has negative 
implications for survival because of the worse prognosis of cardia tumours. This may 
be countered however, by earlier detection due to larger availability of endoscopy, 
especially when followed by adequate surgery.20 
Figure 2.3 | Trends in 5-year age-adjusted relative survival for stomach cancer in Europe 
(Sources: EUROCARE-37 and EUROCARE-43)
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table 2.5b | Overview of recent trends in incidence of, survival for and mortality from stomach 
cancer in Europe
incidence survival mortality Countries
males Females
= ↑ ↓ Spain Spain
= = ↓ Switzerland Switzerland
= ? = - Malta
= ? ↓ Malta Denmark, Lithuania
↓ ↑ = - UK-Northern Ireland1
↓ ↑ ↓ Finland, Norway, Sweden, UK1, 
Germany, Italy, Slovenia, Poland
Finland, Norway, Sweden, UK-
England&Wales / Scotland, Germany, 
Italy, Slovenia, Poland
↓ = ↓ Netherlands Netherlands
↓ ↓ ↓ Austria, France Austria, France
↓ ? ↓ Denmark, Ireland, Croatia, Czech 
Republic, Lithuania
Ireland, Croatia, Czech Republic
1 Survival trends of UK-Northern Ireland are based on a report of the North-Ireland Cancer Registry89
Colorectal cancer (C18-21) 
Incidence of colorectal cancer among males increased modestly in most countries 
and markedly in Austria, Croatia, Slovenia, Spain, and the Czech Republic. Among 
females, the incidence rates were stable with some decreases in Scotland, Northern 
Ireland, and Poland, contrasting a clear increase in Spain. The male to female ratio 
remained stable at 1.5. Mortality rates decreased across Europe but remained 
very high in Denmark, Norway, and Ireland in comparison with other Northern 
and Western European countries (table 2.6a). Five-year relative survival increased, 
especially in Poland, Slovenia, and the Czech Republic (Figure 2.4, table 2.6b).
 The increasing incidence rates may be due to a relatively late, but rapid 
transition towards a life style being increasingly rich in sugar, red and processed 
meat, poor in fiber consumption and physical activity, resulting in increasing body 
mass index 21-23. Improvement of survival, especially in younger patients, is probably 
due to positive changes in detection and treatment of colorectal cancer since the 
mid 1990s. This includes a widespread availability of endoscopy, either or not as 
part of screening activities, Total Mesorectal Excision (TME) surgery for rectal cancer, 
and more widespread use of (pre-operative) radiotherapy.24-26 The high mortality 
rate in some Northern European countries is possibly caused by deficient access to 
endoscopic care, and less effective patient management.27
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2
Figure 2.4 | Trends in 5-year age-adjusted relative survival for colorectal cancer in Europe 
(Sources: EUROCARE-39 and EUROCARE-43)
table 2.6b | Overview of recent trends in incidence of, survival for and mortality from colorectal 
cancer in Europe
incidence survival mortality Countries
males Females
↑ ↑ ↑ Spain -
↑ ↑ = Austria, Slovenia -
­↑ ­↑ ↓ Norway, France, Netherlands, Czech 
Republic
France, Netherlands, Spain
­↑ ? = Croatia
­↑ ? ↓ Denmark -
= ­↑ ­↑ Poland -
= ­↑ = UK-Northern Ireland Norway, Austria, Italy, Malta
= ­↑ ↓ Finland, Ireland1, UK-England&Wales / 
Scotland, Germany, Switzerland, Italy, 
Malta
Finland, Ireland1, UK-England&Wales, 
Germany, Switzerland, Slovenia, Czech 
Republic
= ? = Lithuania Denmark, Croatia
= ? ↓ - Lithuania
↓ ­↑ = - Poland
↓ ­↑ ↓ - UK-Northern Ireland / Scotland
1 Survival trends are based on a report of the Ireland Cancer Registry81
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Pancreatic cancer (C25)
Incidence and mortality rates of pancreatic cancer were similar across Europe and 
quite stable over time. However, in Denmark and France, incidence and mortality 
increased, and they decreased in Sweden and Poland (table 2.7a). Rates were higher 
among males than females (male-to-female ratio 1.5). Five-year relative survival 
remained very low varying between 2 and 8% (table 2.7b, 2.7c). 
 Pancreatic mortality rates have increased throughout Europe between the late 
1950s and the 1980s among males, and the 1990s among females followed by a 
leveling off which is confirmed by our data.28 This leveling off is partly due to the 
decline in smoking which is the main risk factor for pancreatic cancer.15,29,30 Factors 
related to obesity, such as type 2 diabetes and high blood glucose levels31 also seem 
to be important risk indicators, as well as occupational exposures to pesticides or 
dyes.32,33 Previously postulated associations with coffee and alcohol consumption 
were not confirmed.34  No major improvements in treatment have occurred, causing 
the survival rates to remain stable. Centralisation of surgery may contribute to 
future improvement in survival of pancreatic cancer.
table 2.7c | Overview of recent trends in incidence of, survival for and mortality from pancreatic 
cancer in Europe
incidence survival mortality Countries
Males Females
↑ ↑ ↑ France -
↑ = ↑ - France
↑ ? = Denmark Denmark
= = = Norway, UK, Netherlands, Italy Norway, UK, Netherlands
= = ↓ - Italy
= ? ↑ Spain Austria
= ? = Finland, Austria, Germany, 
Switzerland, Croatia, Malta, Slovenia, 
Czech Republic, Lithuania
Finland, Ireland, Germany, 
Switzerland, Croatia, Malta, Slovenia, 
Spain, Czech Republic, Lithuania
= ? ↓ Ireland -
↓ ? = Sweden, Poland Sweden, Poland
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laryngeal cancer (C32) 
Incidence and mortality rates of cancer of the larynx varied considerably throughout 
Europe, especially among males. Lowest rates were observed in the Scandinavian 
countries, except in Denmark, and highest rates in Southern and Central Europe 
(table 2.8a). This cancer was 4 (Scotland) to 49 (Spain) times more common among 
males than females. In all European regions, both incidence and mortality rates 
declined over the past decade, especially among males, for incidence more markedly 
in Northern Europe, and mortality in Southern Europe. However, in most countries, 
5-year relative survival did not show marked improvements, except for Northern 
Irish, Scottish and Swiss males (table 2.8b, 2.8c). 
 The most important environmental risk factors are smoking and alcohol 
consumption.35,36 The relative risks of smokers seem to be higher for supraglottic than 
glottic cancer, which is in accordance with the anatomical location of supraglottic 
tissue, being more readily exposed to tobacco smoke than the other laryngeal 
subsites. The decreasing smoking prevalences among (mainly) European males will 
therefore have contributed strongly to the decreases in incidence and mortality. 
Heavy alcohol use is also related to laryngeal cancer, and marked dose-response 
curves have been observed.37 More importantly, there is a strong interaction 
between the effects of smoking and alcohol consumption and their combined effect 
may result in very high relative risks. 
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table 2.8c | Overview of recent trends in incidence of, survival for and mortality from laryngeal 
cancer in Europe
incidence survival mortality Countries
males Females
↑ ? = - Sweden
=  ↑ = UK-Scotland, Switzerland -
= = = - Netherlands, Switzerland, Slovenia
= = ↓ Slovenia France
= ↓ = - UK-Scotland
= ? ↑ - Spain
= ? = Sweden, Ireland, Germany, Croatia, 
Malta
Denmark, Finland, Norway, Ireland, 
Austria, Germany, Croatia, Italy, 
Malta, Czech Republic, Lithuania, 
Poland
= ? ↓ Austria, Italy, Lithuania -
↓  ↑ ↓ UK-England&Wales -
↓ ↑ = Netherlands -
↓ = ↓ France -
↓ ? = Finland, Norway -
↓ ? ↓ Denmark, Spain, Czech Republic, 
Poland
UK-England&Wales
? ↑ = UK-Northern Ireland -
? ↓ = - UK-Northern Ireland
lung cancer (C33-34) 
In most European countries incidence and mortality rates decreased among males 
in the last decade, except in Norway, Sweden, Austria (Tyrol), Switzerland, Croatia, 
Spain, and Lithuania where the rates remained stable. The variation in recent 
incidence among males was about 3-fold, with highest rates in Poland (63 per 
100,000) and lowest in Sweden (22 per 100,000). In contrast to males, incidence and 
mortality rates have increased rapidly among females, except in Denmark and the UK 
(where rates were already very high), Austria, Croatia, Malta, Spain, and Lithuania. 
Recent incidence rates varied 7-fold, with lowest rates in Spain and Lithuania (5 and 
6 per 100,000) and highest rates in Scotland and Denmark (37 and 33 per 100,000). 
The male-to-female ratio decreased and varied from 1.3 to 1.8 in Northern Europe 
(except in Finland with 3.5) to 10 in Spain in the most recent period (table 2.9a). 
Five-year relative survival of lung cancer slightly improved over time from 9 to 11% 
in Europe with a marked relative increase of 107% in Poland (Figure 2.5, table 2.9b).
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2
Geographical variations in lung cancer risk are influenced by past exposure to 
tobacco smoking. There are however indications that rates are starting to decline 
among younger females in some countries, which will translate into declining 
incidence and mortality rates in females in the near future.38 
 Improvement in survival such as in Poland is likely caused by better access to 
care and treatment if there were no changes in data completeness. 
Figure 2.5 | Trends in 5-year age-adjusted relative survival for lung cancer in Europe (Sources: 
EUROCARE-39 and EUROCARE-43)
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table 2.9b | Overview of recent trends in incidence of, survival for and mortality from lung 
cancer in Europe
incidence survival mortality Countries
males Females
↑ ↑ ↑ - Norway, Sweden, Germany, 
Switzerland
↑ ↑ = - Italy
↑ = ↑ - Finland, France1, Netherlands, Slovenia
↑ = = - Ireland2
↑ = ↓ France1 -
↑ ? ↑ - Czech Republic
= ↑ ↑ - UK-England&Wales
= ↑ = Norway UK-Northern Ireland 
= ↑ ↓ Sweden, Switzerland -
= = ↑ - Spain
= = = Austria UK-Scotland, Austria
= = ↓ Spain -
= ↓ = - Malta
= ? ­ - Croatia
= ? = Croatia Denmark, Lithuania
= ? ↓ Lithuania -
↓ ↑ ↑ - Poland
↓ ↑ ↓ UK-Northern Ireland, Germany, Italy, 
Poland
-
↓ = ↓ Finland, Ireland2, UK-England&Wales / 
Scotland, Netherlands, Slovenia
-
↓ ↓ ↓ Malta -
↓ ? ↓ Denmark, Czech Republic -
1 Survival trends are based on a report of FRANCIM93; 2 survival trends are based on a report of the Ireland Cancer 
Registry8
skin melanoma (C43) 
In some European countries incidence rates for skin melanoma continued to increase 
in others, they started to stabilize. In contrast with incidence, mortality rates have 
stabilized in most countries, except for the English, French, Dutch and Polish males 
and Swedish females (table 2.10a). Over the past decade, 5-year relative survival 
rates improved in most countries with a relative increase varying from 1 to 30%. 
Improvements in survival were often stronger in countries with markedly increasing 
incidence rates (Figure 2.6, table 2.10b). 
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Figure 2.6 | Trends in 5-year age-adjusted relative survival for melanoma in Europe (Sources: 
EUROCARE-39 and EUROCARE-43)
table 2.10b | Overview of recent trends in incidence of, survival for and mortality from 
melanoma in Europe
incidence survival mortality Countries
males Females
↑ ↑ ↑ UK, Netherlands -
↑ ↑ = Finland, Malta, Czech Republic Finland, UK-England&Wales, Germany, 
Netherlands, Slovenia, Czech Republic
↑ ↑ ↓ - UK-Northern Ireland
↑ = ↑ France1 Sweden
↑ = = Sweden, Austria Austria, France1
↑ ? = Denmark, Ireland, Croatia Ireland, Croatia
= ↑ ↑ Poland -
= ↑ = Germany, Italy, Slovenia UK-Scotland, Italy, Malta, Poland
= = = Norway, Switzerland Norway, Switzerland
= ? = Lithuania Denmark, Lithuania
? ↑ = Spain Spain
1 Survival trends are based on a report of FRANCIM 93
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The increasing incidence rates of skin melanoma, reported since the 1960s has always 
been attributed to the ever increasing popularity of intensive sunbathing. Recently, 
the incidence rates started to level off or decrease starting among young people in 
the Nordic countries.39 Possibly the efforts of campaigns, like EUROMELANOMA 40 
which aimed to increase the awareness of skin melanoma and the risks of excessive 
sunbathing and sunburns, are starting to show an effect. Screening programs exist for 
people belonging to Familial Atypical Multiple Mole Melanoma (FAMMM) families, 
which are at increased risk of developing a melanoma. Melanomas occurring on the 
trunk generally have a worse prognosis than those occurring on the limbs or head 
and neck.
 In absence of new treatment, the observed improvements of survival can be 
explained by earlier detection accompanied by a more adequate excision of early 
diagnosed melanomas.41 The counterintuitive change in Austria suggest that data 
quality might have been imperfect, e.g. incompleteness of data.
Female breast cancer (C50)
Breast cancer incidence varied considerably in Europe with lowest rates in Central 
Europe, Croatia and Slovenia (41 to 64 per 100,000) and highest rates in the 
Netherlands and Italy (91 per 100,000). Both the highest and lowest mortality 
rates were observed in Northern Europe (in Denmark and Finland, respectively). In 
most European countries, incidence rates increased over the past decade, except in 
Germany, Switzerland, Croatia, Malta, Lithuania and Poland, where rates remained 
stable. Mortality rates decreased in most countries, except for the Danish, German, 
Croatian, Slovenian and Lithuanian females (table 2.11a). Five-year relative survival 
rates have improved in all countries with a relative increase varying from 1% in 
Malta to 20% in Poland (Figure 2.7, table 2.11b).
 The rising breast cancer incidence and survival rates are partly influenced by 
the presence of organised breast cancer screening programmes or opportunistic 
screening through increased detection of smaller and less aggressive tumours 
resulting in a decreasing mortality after 5-8 years.42 This is attributed to lead-time 
bias because of earlier detection of breast cancer and to length bias due to detection 
of slow growing tumours and possibly a real effect on mortality due to effective 
treatment of early detected cancers. However, before the introduction of mass 
screening, incidence rates were already increasing in most countries suggesting the 
role of other risk increasing factors.43 Some of the risk factors, age at menarche, age 
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table 2.11a | Trends in incidence of and mortality from female breast cancer (C50) in Europe
Females
incidence mortality
Country Period wsr
start
wsr
end
EAPC*
(95% Ci)
wsr
start
wsr
end
EAPC*
(95% Ci)
Northern 
Europe
Denmark 1994-20031 75.2 85.3 1.6
(1.1, 2.1)
25.8 24.9 -1.6
(-3.4, 0.3)
Finland 1994-2005 66.4 82.2 1.8
(1.4, 2.2)
15.3 13.7 -1.4
(-1.9, -0.9)
Norway 1994-20052 58.3 75.7 2.3
(1.4, 3.1)
19.9 15.5 -2.5
(-3.2, -1.8)
Sweden 1994-20052 78.6 87.1 1.4
(1.1, 1.8)
16.6 15.6 -1.1
(-1.9, -0.3)
Ireland 1994-20052 69.8 86.0 2.3
(1.8, 2.8)
26.1 21.9 -1.9
(-2.9, -0.8)
UK England & 
Walesa
1995-20043 75.5 88.0 1.6
(1.1, 2.1)
25.1 19.6 -2.3
(-2.6, -2.1)
UK Northern  
Ireland
1994-2005 73.2 80.8 1.1
(0.5, 1.8)
26.1 17.9 -2.6
(-4.1, -1.0)
UK Scotland 1994-20044 76.2 87.5 1.1
(0.5, 1.6)
26.8 19.4 -2.3
(-2.8, -1.7)
Western 
Europe
Austria (Tyrol) 1994-2003 68.8 77.7 1.6
(0.8, 2.5)
22.1 15.8 -3.0
(-4.6, -1.4)
France 1994-20005 78.4 88.9 2.1
(2.1, 2.2)
19.7 18.3 -0.8
(-1.3, -0.3)
Germany  
(Saarland)
1994-2005 73.2 73.8 0.4
(-0.3, 1.2)
21.5 19.8 -1.4
(-2.9, 0.2)
Netherlands 1994-2003 88.2 90.6 0.9
(0.3, 1.6)
26.7 21.8 -2.0
(-2.7, -1.4)
Switzerland 1993-20036 77.3 84.8 1.3
(-5.4, 8.4)
23.0 17.5 -2.4
(-3.7, -1.1)
Southern 
Europe
Croatia 1994-2004 45.7 52.9 1.6
(-1.2, 4.4)
18.1 17.9 -0.6
(-2.0, 1.0)
Italy (Modena) 1994-2005 75.5 91.4 1.6
(0.2, 2.9)
22.9 16.6 -3.8
(-7.1, -0.4)
Malta 1994-20054 65.1 73.6 0.2
(-0.9, 1.2)
36.5 20.4 -5.0
(-7.3, -2.7)
Slovenia 1994-2003 47.8 64.4 2.7
(1.5, 3.8)
21.3 18.7 -1.0
(-2.5, 0.5)
Spain 1994-20027 55.4 73.4 4.0
(0.8, 7.3)
17.5 13.9 -2.6
(-3.2, -2.1)
Central 
Europe
Czech Republic 1994-2004 55.0 62.5 1.8
(1.0, 2.6)
23.5 19.0 -2.1
(-2.6, -1.7)
Lithuania 1993-20048 37.7 43.2 3.3
(-26.5, 45.0)
19.7 17.4 -0.7
(-1.5, 0.0)
Poland 1994-20043 36.2 40.6 0.5
(-0.6, 1.6)
15.9 14.9 -0.9
(-1.3, -0.5)
a Incidence only for England; 1 Mortality until 2001; 2 Mortality until 2004; 3 Mortality until 2005; 4 Mortality until 2006; 5 
Mortality until 2002; 6 Only average incidence for periods 1993-1996, 1997-1999, and 2001-2003 and mortality for 1995-
2004; 7 Mortality until 2003; 8 Only average incidence for periods 1993-1997, 1998-2000, 2001-2002, and 2003-2004; * 
EAPC: estimated annual percentage change, calculated based on the rates during the indicated period
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Figure 2.7 | Trends in 5-year age-adjusted relative survival for female breast cancer in Europe 
(Source: EUROCARE-39 and EUROCARE-43)
table 2.11b | Overview of recent trends in incidence of, survival for and mortality from female 
breast cancer in Europe
incidence survival mortality Countries
Females
↑ ↑ = Slovenia
↑ ↑ ↓ Finland, Norway, Sweden, Ireland1, UK, Austria, France2, Netherlands, Italy, 
Spain, Czech Republic
↑ ? = Denmark
= ↑ = Germany
= ↑ ↓ Switzerland, Poland
= = ↓ Malta
= ? = Croatia, Lithuania
1 Survival trend is based on a report of the Ireland Cancer Registry 81; 2 Survival trend is based on a report of FRANCIM93
at first childbirth, number of children and the proportion of nulliparous women, 
have all changed in an adverse way and had probably a negative impact on the 
trend of breast cancer.44 However these risk factors are difficult to modify.45 Other 
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lifestyle related risk factors are relatively more amenable to primary prevention 
interventions, including post-menopausal obesity, alcohol consumption and low 
physical activity. 
Recent decreases in breast cancer incidence have been attributed to the decreased 
use of hormone replacement therapy, which will continue in the near future in 
countries where usage was high.46,47 
 The continuing rise in survival has also been observed before introduction of 
mass screening suggesting improved staging and treatment, such as application 
of tamoxifen in postmenopausal patients and chemotherapy in premenopausal 
patients. 
Cervical cancer (C53)
Incidence and mortality rates of cervical cancer varied greatly throughout Europe 
with highest rates in Central Europe and Slovenia and lowest rates in Finland, Italy 
and Malta. In contrast with most European countries where incidence and mortality 
rates decreased, rates remained stable in Finland, Ireland, Austria (Tyrol), and 
Italy (Modena). Lithuania was the only country included in this study that showed 
increases in cervical cancer mortality (table 2.12a). Five-year survival improved 
remarkably in Slovenia and Poland with a relative increase between 9 and 16%. In 
other parts of Europe, survival remained stable or decreased. In general the 5-year 
survival was between 60% and 70% (Figure 2.8, table 2.12b). 
 The main cause of cervical cancer is sexually transmitted infection of human 
papilloma virus (HPV).48 Geographical variations are mainly due to historical patterns 
of risk factors like sexual behaviour, age at first coitus, oral contraceptive use, the 
number of sexual partners, smoking, and, the influence of screening activities. 
Screening for cervical cancer can lower incidence rates up to 80%. Such low rates 
have indeed been accomplished in countries with long-running, effective screening 
programs, like Finland and the Netherlands.49 In countries where organised screening 
programs have been recently introduced or improved, decreases in incidence and 
mortality are observed.50-52 The improvement of survival in Slovenia and Poland 
is probably due to improvement of treatment and not yet an effect of screening. 
The decreasing survival rates in some European countries where mortality rates 
were already low can be explained by effective screening, causing a shift in the 
stage distribution by detection of pre-malignant lesions and slow growing tumours 
and leaving the more aggressive tumours with a worse prognosis.53 This might be 
compensated again by advances in treatment that happened during the 1990s. 
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table 2.12a | Trends in incidence of and mortality from cervical cancer (C53) in Europe
Females
incidence mortality
Country Period wsr
start
wsr
end
EAPC*
(95% Ci)
wsr
start
wsr
End
EAPC*
(95% Ci)
Northern 
Europe
Denmark 1994-20031 12.8 10.8 -3.1
(-4.4, -1.7)
4.3 2.9 -4.2
(-8.2, 0.0)
Finland 1994-2005 3.7 3.3 -0.8
(-2.4, 0.9)
1.2 1.0 -1.7
(-5.5, 2.3)
Norway 1994-20052 11.3 9.4 -2.6
(-3.7, -1.5)
3.3 2.0 -4.1
(-5.9, -2.2)
Sweden 1994-20052 7.8 6.6 -1.1 
(-2.1, -0.2)
2.0 1.9 -1.2
(-3.4, 1.0)
Ireland 1994-20052 8.4 9.9 0.6
(-1.4, 2.5)
2.7 3.3 -1.5
(-4.2, 1.3)
UK England & 
Walesa
1995-20043 8.2 6.4 -2.8
(-3.2, -2.3)
3.1 1.9 -4.8
(-5.4, -4.3)
UK Northern  
Ireland
1994-2005 7.4 8.2 -1.6
(-3.7, 0.5)
3.2 1.1 -4.9
(-9.6, -0.0)
UK Scotland 1994-20044 9.9 8.0 -2.8
(-3.9, -1.6)
3.6 2.1 -3.6
(-4.8, -2.4)
Western 
Europe
Austria (Tyrol) 1995-2003 13.7 10.0 0.1
(-4.0, 4.3)
5.5 2.8 -7.9
(-16.7, 2.0)
France 1994-20005 9.1 8.0 -2.1
(-2.4, -1.8)
1.7 1.4 -1.4
(-3.7, 1.0)
Germany  
(Saarland)
1994-2005 12.1 9.0 -2.8
(-5.2, -0.3)
3.4 2.3 -1.6
(-5.8, 2.9)
Netherlands 1994-2003 6.5 4.9 -3.3
(-4.6, -1.9)
1.7 1.4 -2.1
(-5.1, 0.9)
Switzerland 1993-20036 6.9 5.6 -2.7
(-6.5, 1.2)
2.0 1.2 -5.9
(-8.2, -3.4)
Southern 
Europe
Croatia 1994-2004 12.3 9.9 -2.0
(-3.9, -0.2)
2.8 2.3 -2.0
(-3.8, -0.3)
Italy (Modena) 1994-2005 8.4 3.8 -4.5
(-9.0, 0.1)
1.1 0.1 -6.3
(-20.8, 10.9)
Malta 1994-20054 10.1 2.1 -11.3
(-16.8, -5.5)
0.4 1.2 -1.2
(-9.6, 13.2)
Slovenia 1994-2003 13.2 15.0 -0.4
(-3.1, 2.4)
3.3 3.0 -4.0
(-7.0, -0.9)
Spain 1994-20027 No 
data
1.8 1.5 -2.0
(-3.6, -0.5)
Central 
Europe
Czech Republic 1994-2004 17.3 13.9 -1.8
(-2.6, -1.0)
5.8 4.8 -2.1
(-3.1, -1.2)
Lithuania 1993-20048 14.6 20.1 5.4
(-21.5, 41.5)
7.5 8.7 1.7
(0.5, 2.9)
Poland 1994-20043 17.2 11.9 -3.4
(-4.2, -2.5)
7.5 5.7 -2.4
(-3.0, -1.8)
a Incidence only for England; 1 Mortality until 2001; 2 Mortality until 2004; 3 Mortality until 2005; 4 Mortality until 2006; 5 
Mortality until 2002; 6 Only average incidence for periods 1993-1996, 1997-1999, and 2001-2003 and mortality for 1995-
2004; 7 Mortality until 2003; 8 Only average incidence for periods 1993-1997, 1998-2000, 2001-2002, and 2003-2004;
* EAPC: estimated annual percentage change, calculated based on the rates during the indicated period
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Figure 2.8 | Trends in 5-year age-adjusted relative survival for cervical cancer in Europ (Sources: 
EUROCARE-3 7 and EUROCARE-43)
table 2.12b | Overview of recent trends in incidence of, survival for and mortality from cervical 
cancer in Europe
incidence survival mortality Countries
Females
= ↑ ↓ UK-Northern Ireland1
= = = Finland, Austria, Italy
= = ↓ Switzerland
= ? ↑ Lithuania
= ? = Ireland
↓ ↑ ↓ Slovenia, Poland
↓ = = Netherlands, France2
↓ = ↓ Norway, UK-Scotland
↓ ↓ = Sweden, Germany, Malta
↓ ↓ ↓ UK-England&Wales, Czech Republic
↓ ? = Denmark
↓ ? ↓ Croatia
? ↓ ↓ Spain
1 Survival trend is based on a report of the Northern Ireland Cancer Registry89; 2 Survival trend is based on a report of 
FRANCIM93
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Corpus uteri cancer (C54)
The recent incidence rate of corpus uteri cancer varied between 9.2 (France) and 
18 (Czech Republic) per 100,000. In most countries incidence rates remained stable, 
except in Norway, Ireland, the UK and Slovenia where rates were increasing. 
Mortality rates were dropping mostly in Southern and Central Europe, but remained 
still higher than other parts of Europe (table 2.13a). Consistently, in most countries, 
moderate improvements in 5-year survival were observed, except for Malta, where 
the relative improvement was 28% (Figure 2.9, table 2.13b). 
 Geographical variation in cancer incidence of the corpus uteri across Europe 
can be due to variation in prevalence of risk factors like oestrogen replacement 
therapy, sequential oral contraceptives, nulliparity and obesity.34,54 The higher 
mortality in Southern and Central Europe is probably indicating some disparity in 
the early diagnosis and treatment of patients.54 However, the observed increased 
5-year survival in these countries indicates improvements and probably the mortality 
will decrease further. The counterintuitive change of survival in Austria and Spain 
suggest that data quality might have been imperfect, e.g. incompleteness of (follow-
up) data.
ovarian cancer (C56) 
Within Europe, incidence and mortality rates of ovarian cancer were largely similar 
and quite stable or decreasing over time (table 2.14a). Five-year survival improved 
slightly over time in Europe from 37 to 42% (table 2.14b, 2.14c).
 Ovarian cancer has different risk factors like personal or family history of breast 
or ovarian cancer, obesity, oestrogen replacement therapy, no oral contraceptive 
use, late age at last birth and more debatable is the use of fertility drugs and/or 
subfertility.55 Five-year survival rates for ovarian cancer are largely determined by the 
stage at diagnosis: with early diagnosis and treatment, the 5-year relative survival 
rate is over 90%. Unfortunately, ovarian cancer has very non-specific symptoms and 
only a small percentage of cases are found at an early stage. In addition, age is also 
an important prognostic factor.56 Five-year relative survival rates are substantially 
lower for females aged 70 and over compared with younger females (table 2.14b). 
In the south-eastern Netherlands, improvements in survival were accomplished in 
the elderly since the late 90’s only.56 Surgical management of ovarian cancer and 
regionalisation of care were also reported to be related to improved survival.57,58 
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table 2.13a | Trends in incidence of and mortality from corpus uteri cancer (C54) in Europe
Females
incidence mortality
Country Period wsr
start
wsr
end
EAPC*
(95% Ci)
wsr
start
wsr
end
EAPC*
(95% Ci)
Northern 
Europe
Denmark 1994-20031 13.4 12.5 -0.5
(-1.3, 0.4)
2.8 1.9 -3.5
(-8.6, 2.0)
Finland 1994-2005 13.5 14.6 0.3
(-0.8, 1.5)
2.2 2.2 -0.1
(-1.6, 1.4)
Norway 1994-20052 12.3 16.2 2.5
(1.7, 3.2)
2.6 1.6 -2.2
(-5.3, 1.0)
Sweden 1994-20052 13.5 14.7 0.3
(-0.4, 1.1)
1.4 1.1 -0.5
(-2.5, 1.6)
Ireland 1994-20052 8.0 10.7 1.9
(0.5, 3.3)
1.7 1.3 -1.2
(-4.3, 1.9)
UK England & 
Wales a,b
1995-20043 9.6 11.7 2.5
(1.8, 3.2)
2.2 2.4 1.0
(0.0, 2.0)
UK Northern 
Ireland 
1994-2005 8.3 13.4 5.5
(3.7, 7.3)
1.2 0.9 2.6
(-2.3, 7.7)
UK Scotland 1994-20044 8.9 11.1 1.5
(0.4, 2.7)
1.9 1.6 0.8
(-2.1, 3.7)
Western 
Europe
Austria (Tyrol) 1995-2003 12.3 11.9 -1.2
(-4.7, 2.4)
1.5 1.8 -1.7
(-13.3, 11.4)
Francec 1994-20005 9.8 9.2 -1.1
(-1.1, -1.0)
3.5 2.9 -2.1
(-3.0, -1.2)
Germany 
(Saarland)
1994-2005 14.0 12.8 -1.5
(-3.1, 0.1)
1.2 1.1 -0.4
(-6.9, 6.5)
Netherlandsb 1994-2003 11.2 11.6 0.3
(-0.4, 1.0)
2.4 2.0 -0.3
(-1.9, 1.3)
Switzerlandb 1993-20036 12.9 12.4 -0.5
(-1.0, -0.1)
2.5 2.3 -1.5
(-3.6, 0.7)
Southern 
Europe
Croatiab 1994-2004 11.2 12.2 -0.3
(-2.5, 1.9)
4.2 3.1 -3.8
(-6.8, -0.6)
Italy (Modena) 1994-2005 12.9 16.4 2.8
(-0.7, 6.4)
1.2 1.1 -3.7
(-10.5, 3.7)
Maltab 1994-20054 18.4 16.5 -1.0
(-3.1, 1.2)
4.0 3.7 -1.8
(-5.4, 2.0)
Sloveniab 1994-2003 14.9 17.1 1.6
(0.5, 2.6)
5.0 3.7 -4.2
(-7.6, -0.7)
Spainc 1994-20027 11.0 11.2 0.4
(-1.3, 2.0)
3.2 2.6 -2.5
(-3.4, -1.6)
Central 
Europe
Czech Republic 1994-2004 17.9 18.2 -0.1
(-0.5, 0.4)
4.5 4.0 -2.3
(-3.5, -0.9)
Lithuaniab 1993-20048 14.0 16.6 5.2
(-41.4, 88.9)
5.4 3.5 -3.4
(-4.9, -2.0)
Polandb 1994-20043 11.9 13.8 0.6
(-0.9, 2.1)
3.8 3.2 -1.4
(-2.0, -0.7)
a Incidence only for England; b Data valid for C54-55; c Mortality data valid for C54-55; 1 Mortality until 2001; 2 Mortality 
until 2004; 3 Mortality until 2005; 4 Mortality until 2006; 5 Mortality until 2002; 6 Only average incidence for periods 
1993-1996, 1997-1999, and 2001-2003 and mortality for 1995-2004; 7 Mortality until 2003; 8 Only average incidence for 
periods 1993-1997, 1998-2000, 2001-2002, and 2003-2004; * EAPC: estimated annual percentage change, calculated 
based on the rates during the indicated period
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Figure 2.9 | Trends in 5-year age-adjusted relative survival for corpus uteri cancer in Europe 
(Source: EUROCARE-3 7 and EUROCARE-43)
table 2.13b | Overview of recent trends in incidence of, survival for and mortality from corpus 
uteri cancer in Europe
incidence survival mortality Countries
Females
↑ ↑ ↑ UK-England&Wales
↑ ↑ = Norway, UK-Northern Ireland1 / Scotland
↑ ↑ ↓ Slovenia
↑ ? = Ireland
= ↑ = Sweden, Malta
= ↑ ↓ Czech Republic, Poland
= = = Finland, Germany, Netherlands, Italy
= = ↓ Spain
= ↓ = Austria
= ? = Denmark
= ? ↓ Croatia, Lithuania
↓ ↑ ↓ France2
↓ = = Switzerland
1 Survival trend is based on a report of the Northern Ireland Cancer Registry89; 2 Survival trend is based on a report of 
FRANCIM93
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table 2.14a | Trends in incidence of and mortality from ovarian cancer (C56) in Europe 
Females
Incidence Mortality
Country Period WSR
start
WSR
end
EAPC*
(95% CI)
WSR
start
WSR
End
EAPC*
(95% CI)
Northern 
Europe
Denmarka 1994-20031 13.7 11.9 -0.8
(-2.1, 0.4)
9.0 8.4 -0.8
(-3.1, 1.5)
Finlanda 1994-2005 11.2 9.0 -1.0
(-2.2, 0.2)
6.4 5.4 -1.7
(-3.1, -0.3)
Norwaya 1994-20052 14.3 11.2 -1.4
(-2.6, -0.3)
7.9 7.4 -1.2
(-2.9, 0.5)
Swedena 1994-20052 12.9 9.4 -2.3
(-3.0, -1.6)
7.4 6.6 -1.1
(-2.3, 0.1)
Irelanda 1994-20052 12.8 13.2 0.1
(-1.0, 1.3)
8.4 8.2 -0.4
(-2.1, 1.4)
UK England & 
Walesa,b
1995-20043 13.3 12.3 -0.8
(-1.4, -0.2)
8.1 7.1 -1.4
(-2.0, -0.7)
UK Northern 
Ireland
1994-2005 13.4 13.4 0.8
(-0.9, 2.5)
6.7 8.3 1.3
(-0.8, 3.4)
UK Scotland 1994-20044 13.8 12.8 -0.7
(-2.0, 0.5)
9.1 7.1 -1.5
(-2.4, -0.6)
Western 
Europe
Austria (Tyrol)a 1995-2003 16.9 11.4 -4.2
(-7.1, -1.3)
6.1 6.7 -2.7
(-9.3, 4.4)
Francea 1994-20005 9.1 9.0 -0.2
(-0.4, -0.1)
5.5 5.5 -0.2
(-0.6, 0.2)
Germany  
(Saarland)a
1994-2005 11.1 8.7 -0.7
(-2.6, 1.2)
6.2 6.1 0.7
(-1.8, 3.4)
Netherlands 1994-2003 10.7 8.3 -3.0
(-3.5, -2.4)
7.7 5.9 -3.1
(-3.9, -2.3)
Switzerland 1993-20036 11.7 11.4 -0.3
(-7.7, 7.6)
5.8 5.7 -0.4
(-1.8, 1.1)
Southern 
Europe
Croatiaa 1994-2004 11.1 10.8 0.6
(-2.2, 3.4)
6.0 6.2 1.2
(-0.5, 3.0)
Italy (Modena)c 1994-2005 13.9 7.9 -1.6
(-4.6, 1.6)
7.1 4.5 -2.7
(-6.5, 1.2)
Malta 1994-20054 11.7 8.1 -1.9
(-5.6, 2.0)
9.2 5.7 -1.8
(-5.5, 2.0)
Sloveniaa 1994-2003 12.1 11.5 -1.9
(-3.6, -0.1)
7.5 6.8 -1.0
(-3.1, 1.1)
Spaina 1994-20027 No 
data
4.1 4.5 0.7
(-0.0, 1.5)
Central 
Europe
Czech Republic 1994-2004 14.0 14.0 -0.1
(-0.7, 0.5)
7.8 7.1 -0.3
(-1.5, 0.9)
Lithuaniaa 1993-20048 13.8 13.3 0.8
(-16.5, 21.5)
9.8 8.3 -1.8
(-3.3, -0.2)
Polanda 1994-20043 12.0 11.2 -1.2
(-2.0, -0.4)
6.6 7.6 1.5
(1.0, 2.1)
a Data valid for C56-57; b Incidence only for England; c Data until 1999 valid for 183 (ICD-9), and from 2000 valid for 
C56 (ICD-10); 1 Mortality until 2001; 2 Mortality until 2004; 3 Mortality until 2005; 4 Mortality until 2006; 5 Mortality 
until 2002; 6 Only average incidence for periods 1993-1996, 1997-1999, and 2001-2003 and mortality for 1995-2004; 7 
Mortality until 2003; 8 Only average incidence for periods 1993-1997, 1998-2000, 2001-2002, and 2003-2004; * EAPC: 
estimated annual percentage change, calculated based on the rates during the indicated period
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table 2.14b | Trends in 5-year relative survival for ovarian cancer in Europe1
Country Period 5-year relative 
survival
Period 5-year relative 
survival
trend in 
survival
Northern 
Europe
Finland - - 2003-2005 49.0 ?
Norway 1991-1995 39.9 1996-2000 44.1 ↑
UK England&Wales 1991-1995 31.0 2000-2001 41.0 ↑
UK Northern Ireland 1993-1996 41.6 2001-2004 43.6 ↑
UK Scotland 1992-1996 32.8 1997-2001 40.6 ↑
Western 
Europe
France 1992-1994 39.0 1995-1997 40.0 =
Germany (Saarland) - - 2000-2002 48.0 ?
Netherlands 
(Amsterdam)
1993-1996 37.0 2001-2005 40.0 ↑
Netherlands 
(Eindhoven) (<70 years)
1990-1994 47.0 2000-2002 54.0 ­↑
Netherlands  
(Eindhoven) (≥70 years)
1990-1994 18.0 2000-2002 24.0 ­↑
Switzerland (Geneva) 1990-1994 39.0 1994-1998 48.0 ­↑
Southern 
Europe
Italy (Modena) 1990-1997 41.0 1998-2005 36.0 ↓
Italy - - 1995-1999 41.0 ?
Slovenia 1993-1997 37.0 1998-2002 46.0 ↑
Central 
Europe
Czech Republic - - 1995-1999 45.0 ?
Total Europe 1990-19942 36.7 1995-19993 41.6 ↑
1 Data reported by individual cancer registries or consortia of cancer registries (sources are shown in Table 1); 2 Data 
reported by the EUROCARE-3 study 8; 3 Data reported by the EUROCARE-4 study 9
table 2.14c | Overview of recent trends in incidence of, survival for and mortality from ovarian 
cancer in Europe
incidence survival mortality Countries
Females
= ↑ = UK-Northern Ireland, Switzerland
= ↑ ↓ UK-Scotland
= ↓ = Italy
= ? = Denmark, Finland, Ireland, Germany, Croatia, Malta, Czech Republic
= ? ↓ Lithuania
↓ ­↑ = Norway, Slovenia
↓ ­↑ ↓ UK-England&Wales, Netherlands
↓ = = France
↓ ? ­↑ Poland
↓ ? = Sweden, Austria
? ? = Spain
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Prostate cancer (C61)
In contrast to mortality, incidence of prostate cancer varied largely across Europe 
with highest incidence rates in Finland, Sweden and Austria (Tyrol) (114, 112 and 106 
per 100,000 respectively) and lowest rate in Poland (25 per 100,000). A dramatically 
increasing incidence trend was observed in all European countries except for The 
Netherlands and Austria (Tyrol), where rates already increased in previous periods. In 
Slovenia, Lithuania and Poland mortality rates increased while rates were decreasing 
or stable in other European countries (table 2.15a). Relative improvements in five-
year survival rates from 1990-2002 varied between 10% in Germany and the Czech 
Republic to 83% in Poland, resulting in 5-year survival rates of 58% (Czech Republic) 
to 87% (Switzerland) in 2000-2002 (Figure 2.10, table 2.15b). 
 The dramatic increase of incidence is mostly due to the introduction of (non-) 
organized PSA-testing, leading to detection of many latent cancers and artificially 
high survival rates. Differences in intensity of the use of PSA screening and the 
registration of these latent cancers make interpretation of incidence and survival 
complicated.
testicular cancer (C62) 
Recent incidence rates of testicular cancer in Europe varied between 1.9 per 
100,000 in Lithuania to 11 per 100,000 in Norway. Mortality rates were quite similar 
throughout Europe (table 2.16a). In many countries an increased incidence trend 
was observed, in contrast with stable mortality trends. Five-year survival improved 
from 91 to 94% in Europe and varied between 94 and 100% (table 2.16b, 2.16c).
 Previous studies observed that increases in incidence are largely due to increases 
in the incidence of localised tumours among men born after the 1930s.59-61 Factors 
like low birth weight, older maternal age, low birth order, maternal smoking during 
pregnancy, cryptorchidism convey an increased risk.62-64 In all member countries of 
the European Union, maternal age has been increasing since 1994 and family sizes 
have been decreasing, possibly explaining the observed increases in trends.44 The 
increase in survival and the decreases in mortality are attributed to the introduction 
of cisplatin-containing chemotherapy, which has proven to be the most effective 
treatment for non-seminoma testicular cancer, constituting about half of testicular 
cancer cases.61,65 
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table 2.15a | Trends in incidence of and mortality from prostate cancer (C61) in Europe
males
incidence mortality
Country Period wsr
start
wsr
end
EAPC*
(95% Ci)
wsr
start
wsr
end
EAPC*
(95% Ci)
Northern 
Europe
Denmark 1994-20031 29.4 49.9 6.2
(5.4, 7.1)
19.7 20.7 0.3
(-0.9, 1.4)
Finland 1994-2005 57.7 114.0 5.9
(5.1, 6.8)
17.1 14.8 -1.6
(-2.6, -0.7)
Norway 1994-20052 60.5 91.7 3.9
(2.5, 5.4)
23.6 20.5 -1.5
(-2.2, -0.7)
Sweden 1994-20052 62.1 112.4 6.4
(5.4, 7.4)
20.7 21.3 -0.2
(-1.0, 0.6)
Ireland 1994-20052 43.7 88.9 8.0
(6.8, 9.2)
18.1 17.1 -1.2
(-2.1, -0.2)
UK England & 
Walesa
1995-20043 39.7 64.0 6.0
(4.7, 7.4)
17.1 14.9 -0.9
(-1.5, -0.3)
UK Northern  
Ireland
1994-2005 39.2 56.7 4.6
(2.9, 6.2)
16.4 13.8 -1.3
(-2.4, -0.3)
UK Scotland 1994-20044 42.8 56.3 2.3
(1.0, 3.6)
16.6 14.1 -1.1
(-1.7, -0.4)
Western 
Europe
Austria (Tyrol) 1994-2003 117.3 106.4 1.5
(-1.5, 4.5)
19.5 11.6 -4.8
(-7.7, -1.7)
France 1994-20005 51.3 75.3 6.7
(6.5, 6.8)
16.2 14.6 -1.1
(-1.8, -0.4)
Germany  
(Saarland)
1994-2005 52.0 71.0 4.9
(3.0, 6.8)
12.5 15.0 -0.2
(-1.8, 1.4)
Netherlands 1994-2003 55.4 61.4 0.6
(-0.0, 1.3)
19.2 16.3 -2.2
(-2.7, -1.7)
Switzerland 1993-20036 66.0 86.1 3.6
(1.4, 5.9)
20.0 16.3 -2.0
(-2.7, -1.3)
Southern 
Europe
Croatia 1994-2004 21.6 35.1 6.7
(4.7, 8.7)
13.4 15.4 1.8
(-0.4, 4.1)
Italy (Modena) 1994-2005 43.8 91.3 10.9
(6.8, 15.1)
17.5 7.4 -5.1
(-7.8, -2.3)
Malta 1994-20054 23.3 45.9 6.1
(3.9, 8.4)
13.6 7.8 -3.7
(-6.0, -1.2)
Slovenia 1994-2003 24.6 36.7 4.2
(1.8, 6.8)
13.3 21.2 3.7
(1.5, 6.0)
Spain 1994-20027 29.3 56.4 8.9
(4.9, 13.1)
13.8 11.7 -2.1
(-2.8, -1.3)
Central 
Europe
Czech Republic 1994-2004 30.4 52.3 4.8
(3.6, 5.9)
16.3 17.1 0.1
(-0.6, 0.7)
Lithuania 1993-20048 26.0 71.1 12.3
(5.7, 19.4)
15.5 19.2 2.1
(1.4, 2.9)
Poland 1994-20043 16.7 24.5 2.9
(1.4, 4.5)
10.8 12.9 1.9
(1.3, 2.6)
a Incidence only for England; 1 Mortality until 2001; 2 Mortality until 2004; 3 Mortality until 2005; 4 Mortality until 2006; 
5 Mortality until 2002; 6 Only average incidence for periods 1993-1996, 1997-1999, and 2001-2003 and mortality for 
1995-2004; 7 Mortality until 2003; 8 Only average incidence for periods 1993-1997, 1998-2000, 2001-2002, and 2003-
2004; * EAPC: estimated annual percentage change, calculated based on the rates during the indicated period
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Figure 2.10 | Trends in 5-year age-adjusted relative survival for prostate cancer in Europe 
(Sources: EUROCARE-39 and EUROCARE-43)
table 2.15b | Overview of recent trends in incidence of, survival for and mortality from prostate 
cancer in Europe
incidence survival mortality Countries
males
↑ ↑ ↑ Slovenia, Poland
↑ ↑ = Sweden, Germany, Czech Republic
­↑ ­↑ ↓ Finland, Norway, Ireland1, UK2, Switzerland, Italy
­↑ ? ­↑ Lithuania
­↑ ? = Denmark, Croatia
­↑ = ↓ France3
­↑ ? ↓ Malta, Spain
= ­↑ ↓ Austria, Netherlands
1 Survival trend is based on a report of Ireland Cancer Registry81; 2 Survival trend of UK-Northern Ireland is based on a 
report of the Northern Ireland Cancer Registry 89; 3 Survival trend is based on a report of FRANCIM93
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table 2.16a | Trends in incidence of and mortality from testicular cancer (C62) in Europe
males
incidence mortality
Country Period wsr
start
wsr
end
EAPC*
(95% Ci)
wsr
start
wsr
end
EAPC*
(95% Ci)
Northern 
Europe
Denmark 1994-20031 10.6 9.3 -1.4
(-2.7, -0.0)
0.7 0.5 -7.5
(-15.4, 1.2)
Finland 1994-2005 2.3 5.1 5.4
(3.1, 7.7)
0.1 0.2 1.4
(-6.8, 10.4)
Norway 1994-20052 8.3 10.5 2.4
(0.8, 4.1)
0.4 0.4 2.5
(-3.3, 8.7)
Sweden 1994-20052 5.3 6.2 2.3
(0.4, 4.1)
0.2 0.2 -0.1
(-8.1, 8.6)
Ireland 1994-20052 3.6 6.9 4.5
(2.1, 6.9)
0.4 0.1 -5.8
(-13.7, 2.9)
UK England & 
Walesa
1995-20043 5.3 6.1 1.7
(0.1, 3.2)
0.3 0.2 -3.3
(-5.9, -0.6)
UK Northern  
Ireland
1994-2005 5.4 7.3 3.1
(1.0, 5.3)
0.5 0.0 -26.4
(-65.8, 58.4)
UK Scotland 1994-20044 6.9 6.4 1.4
(-0.8, 3.5)
0.3 0.5 1.7
(-2.6, 6.1)
Western
Europe
Austria (Tyrol) 1995-2003 7.7 8.2 -0.1
(-2.9, 2.7)
0.8 0.7 -19.2
(-87.9, 439.9)
France 1994-20005 No 
data
0.3 0.3 1.0
(-2.0, 4.0)
Germany  
(Saarland)
1994-2005 5.3 9.3 2.4
(-1.0, 5.9)
0.1 0.5 -30.4
(-55.5, 8.8)
Netherlands 1994-2003 4.4 6.2 4.4
(2.8, 6.0)
0.2 0.3 2.5
(-4.7, 10.3)
Switzerland 1993-20036 9.1 9.8 1.0
(-4.5, 6.8)
0.4 0.3 -3.7
(-28.6, 30.0)
Croatia 1994-2004 1.8 6.3 11.5
(4.9, 18.5)
0.1 0.6 6.8
(-4.9, 20.1)
Italy (Modena) 1994-2005 4.1 7.5 3.8
(-0.2, 8.0)
0.1 0.0 -43.1
(-80.5, 66.2)
Malta 1994-20052 No 
data
0.8 0.3 14.5
(-58.3, 214.4)
Slovenia 1994-2003 5.3 9.5 5.7
(1.7, 10.0)
0.4 0.7 0.8
(-14.0, 18.2)
Spain 1994-20027 No 
data
0.2 0.2 -2.9
(-11.0, 5.9)
Central 
Europe
Czech Republic 1994-2004 6.2 7.0 1.7
(0.6, 2.8)
1.0 0.5 -4.2
(-8.4, 0.2)
Lithuania 1993-20048 1.6 1.9 1.7
(-4.3, 8.0)
0.6 0.5 -3.4
(-6.0, -0.7)
Poland 1994-20043 2.9 3.9 3.0
(1.0, 5.1)
0.7 0.6 -2.3
(-5.3, 0.8)
a Incidence only for England; 1 Mortality until 2001; 2 Mortality until 2004; 3 Mortality until 2005; 4 Mortality until 
2006; 5 Mortality until 2002; 6 Only average incidence and mortality for periods 1993-1996, 1997-1999, and 2001-2003; 
7 Mortality until 2003; 8 Only average incidence for periods 1993-1997, 1998-2000, 2001-2002, and 2003-2004; * EAPC: 
estimated annual percentage change, calculated based on the rates during the indicated period
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table 2.16b | Trends in 5-year relative survival for testicular cancer in Europe1
Country Period 5-year relative 
survival
Period 5-year relative 
survival
trend in 
survival
Northern 
Europe
Finland - - 2003-2005 94.0 ?
Norway 1991-1995 95.8 1996-2000 96.0 =
UK England&Wales 1991-1995 93.0 2000-2001 98.0 ↑
UK Northern Ireland 1993-1996 92.4 2001-2004 94.0 =
UK Scotland2 1992-1996 95.1 1997-2001 97.7 ­↑
Western 
Europe
France 1992-1994 95.0 1995-1997 96.0 =
Germany (Saarland) - - 2000-2002 100.0 ?
Netherlands (Amsterdam) 1993-1996 97.0 2001-2005 95.0 =
Netherlands (Eindhoven)
(non-seminoma)
1990-1994 91.0 2000-2002 94.0 ↑
Netherlands (Eindhoven)
(seminoma)
1990-1994 98.0 2000-2002 97.0 =
Switzerland (Geneva) 1990-1994 98.0 1994-1998 95.0 ↓
Southern 
Europe
Italy (Modena) 1990-1997 98.0 1998-2005 97.0 =
Italy - - 1995-1999 94.0 ?
Slovenia 1993-1997 96.0 1998-2002 97.0 =
Total Europe 1990-19943 91.4 1995-19994 93.8 ↑
1 Data reported by individual cancer registries or consortia of cancer registries (sources are shown in Table 1); 2 Data 
were calculated for age group 15-74 year; 3 Data reported by the EUROCARE-3 study 8; 4Data reported by the 
EUROCARE-4 study 9
table 2.16c | Overview of recent trends in incidence of, survival for and mortality from testicular 
cancer in Europe
incidence survival mortality Countries
males
↑ ↑ ↓ UK-England&Wales
↑ = = Norway, UK-Northern Ireland, Netherlands, Slovenia
↑ ? = Finland, Sweden, Croatia, Poland
↑ ? = Czech Republic
= ↑ = UK-Scotland
= = = Italy
= ↓ = Switzerland
= ? = Austria, Germany
= ? ↓ Lithuania
↓ ? = Denmark
? = = France
? ? = Malta, Spain
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Another explanation of the improved survival is a shift toward seminomas, which 
have a better prognosis than non-seminomas (table 2.16b). Prognosis is also 
influenced by stage and age at diagnosis, with younger patients exhibiting better 
survival than older patients.66 
Kidney cancer (C64-66 / C68) 
Incidence and mortality of kidney cancer was lowest in Northern Europe and highest 
in Central Europe, especially in the Czech Republic. This tumour was about twice as 
frequent in males compared with females. Trends have been rather diverse across 
Europe, with increasing or stable incidence trends in countries throughout Europe 
and decreases in the Czech Republic, Austria, Sweden, the Netherlands, Poland 
and Finland (table 2.17a). Survival rates improved across Europe (Figure 2.11). This 
explains why, with the observed trends in incidence, mortality trends have been 
stable or decreasing in most countries, except for Irish and Slovenian males (table 
2.1 and 2.20). 
 The most important environmental risk factors for kidney cancer include 
smoking, obesity and possibly hypertension. The observed trends in incidence 
therefore reflect of the generally decreasing smoking prevalence rates of European 
males, and increasing rates of obesity prevalence. For females, the patterns of risk 
factor prevalence differ strongly by European region, explaining the large variation 
in incidence, mortality and survival patterns (table 2.17b). Previously it was believed 
that coffee and tea consumption would increase the risk of kidney cancer, but this 
has not been confirmed, except possibly for cancers of the renal pelvis and urether.37
Bladder cancer (C67)
In the most recent period, incidence of bladder cancer varied across Europe from 
10 (Northern Ireland) to 29 per 100,000 (Denmark, Austria, Italy and Spain). Trends 
in incidence are heavily influenced by changes in coding practices (including in 
situ carcinomas or not). These coding practices also influenced absolute levels of 
incidence and may explain part of the differences between countries. It is better to 
interpret trends in mortality rates, as these did not suffer from this problem. 
 Mortality trends decreased throughout Europe for males. Female mortality 
patterns differed throughout Europe, mostly decreasing or remaining stable with 
the exception of Poland, where mortality rates increased significantly (table 2.18a). 
Five-year survival remained largely stable in Europe (table 2.18b, 21.8c).
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Figure 2.11 | Trends in 5-year age-adjusted relative survival for kidney cancer in Europe 
(Sources: EUROCARE-37 and EUROCARE-43)
table 2.17b | Overview of recent trends in incidence of, survival for and mortality from kidney 
cancer in Europe
incidence survival mortality Countries
males Females
↑ ↑ = UK-England&Wales UK-Enlgand&Wales, France1
↑ = = Norway -
↑ = ↓ France1 -
↑ ? ↑ Ireland -
­ ? = Croatia, Lithuania Ireland
= ­↑ ­↑ Slovenia -
= ­↑ = UK-Northern Ireland2 / Scotland,  
Germany, Switzerland, Italy, Malta, 
Spain
Sweden, UK-Northern Ireland2 
/ Scotland, Austria, Germany, 
Switzerland, Italy, Slovenia, Spain
= = = - Norway
= ? = Denmark Denmark, Croatia, Lithuania
= ­↑ ↓ Austria, Czech Republic Netherlands, Czech Republic
↓ ­↑ = Sweden, Netherlands, Poland Finland, Malta, Poland
↓ ↑ ↓ Finland -
1 Survival trend is based on a report of FRANCIM 93; 2 Survival trend of UK-Northern Ireland is based on a report of the 
Northern Ireland Cancer Registry89
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table 2.18c | Overview of recent trends in incidence of, survival for and mortality from bladder 
cancer in Europe
incidence survival mortality Countries
males Females
↑ = ↓ France -
↑ ?­ = Czech Republic Croatia, Czech Republic
= ↑ = - Norway, UK-Northern Ireland, Italy
= = =­ Norway, UK-Northern Ireland, Slovenia Slovenia
= = ↓ Switzerland, Italy -
= =/↓ = - Netherlands
= ? ↑ - Poland
= ? = Sweden, Austria, Croatia, Spain, PolandDenmark, Sweden, Ireland, Austria, 
Germany, Malta, Spain, Lithuania
= ? ↓ Germany, Lithuania -
↓ ↑ ↓ UK-Scotland
↓ = = - France
↓ = ↓ UK-England&Wales UK-England&Wales / Scotland
↓ ↓ = - Switzerland
↓ =/↓ ↓ Netherlands -
↓ ? = Denmark, Finland, Malta Finland
↓ ? ↓ Ireland -
The favourable mortality trends in males are partly due to the declines in the 
smoking prevalence together with reduced occupational exposure to carcinogens. 
The decreases in females are more difficult to explain, as female smoking prevalence 
rates increased in many countries but mortality rates remained stable or decreased. 
Better control of urinary tract infections probably played a role, while the role of 
diet and other potential urinary tract carcinogens remains undefined.67
 Despite small improvements in treatment, no improvements in survival were 
achieved, which is in line with earlier findings for Sweden since the 1970s.68
Hodgkin’s disease (C81)
In most European countries, incidence and mortality rates of Hodgkin’s disease have 
been stable or slightly decreasing, with the exception of Norwegian, Dutch, Croatian 
and Slovenian males and English, Croatian and Italian females (table 2.19a). Five-
year survival for Hodgkin’s disease was between 70% and 80% and has improved in 
all countries (Figure 2.12, table 2.19b). 
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Figure 2.12 | Trends in 5-year age-adjusted relative survival for Hodgkin’s disease in Europe 
(Sources: EUROCARE-39 and EUROCARE-43)
table 2.19b | Overview of recent trends in incidence of, survival for and mortality from 
Hodgkin’s disease in Europe
incidence survival mortality Countries
males Females
↑ ↑ = Norway, Netherlands, Slovenia UK-England&Wales, Italy
↑ ? = Croatia Croatia
= ↑ ↑ - Austria
= ↑ = Finland, UK-Scotland, Austria, Italy Finland, UK-Scotland, Switzerland, 
Slovenia
= ↑ ↓ UK-England&Wales, Switzerland Norway, Netherlands
= = = UK-Northern Ireland UK-Northern Ireland, France1
= ? = Germany, Malta Denmark, Sweden, Ireland, Germany, 
Malta
= ? ↓ Denmark, Ireland, Poland Lithuania, Poland
↓ = = France1 -
↓ ? = Sweden -
↓ ? ↓ Lithuania -
? ­↑ = - Spain
? ­↑ ↓ Spain -
? ? ↓ Czech Republic Czech Republic
1 Survival trend is based on a report of FRANCIM93
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The observed incidence and mortality trends are in accordance with previous reports 
on trends in Hodgkin’s disease for all ages 69 and children.70 Although there is much 
unclearness regarding the aetiology of Hodgkin’s disease, some factors have been 
identified to contribute to the risk, including poor immunity (organ transplant 
patients, HIV patients) and Epstein Barr virus infection. Over time, new prognostic 
systems were developed stratifying patients into early stages (more or less favourable 
or intermediate), advanced stages and delivering effective chemotherapy suited for 
the individual tumour characteristics.71 The combination of improved staging and 
more appropriate chemotherapy resulted in the observed improvements in survival 
rates.
DisCussioN
This study provides the most recent available overview of the burden of cancer 
in Europe. It is one of the few publications combining incidence, mortality and 
survival statistics of cancer. This combination is important in order to correctly 
interpret (trends in) cancer rates: has real progress been made or are we looking 
at artefacts? Observed increases in cancer incidence for example, might be real, i.e. 
that there are more cancer patients because of increasing risks, or they might be due 
to improvements in the completeness of the cancer registry, changes in diagnostic 
criteria, or effects of early detection methods such as population screening 
(table 2.1). Likewise, improving cancer survival could be due to better treatment, 
improvements in treatment effectiveness because of earlier diagnosis, diagnosis of 
patients that would otherwise have never had clinical disease (i.e. lead time bias), or 
better treatment of co-morbidity.4-6 
 We observed the highest incidence of breast, prostate, testicular cancer 
and melanomas in Northern and Western Europe. However, cancers of the lung, 
cervix and stomach were more common in the South and Central parts of Europe. 
Within Northern Europe, for many tumours, we observed a distinction between 
the Scandinavian countries (excluding Denmark), and the United Kingdom and 
Denmark, with higher rates for most cancers in the latter two countries. 
 During the past decade, many changes in the occurrence, survival and mortality 
of cancer have occurred. Some of the cancer types included in this study showed 
very mixed patterns for incidence, such as corpus uteri and kidney cancers. Rates 
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for colorectal cancer were either stabilising or increasing, presumably due to 
changing dietary habits, increasing obesity and decreasing physical activity levels. 
Prostate, testicular cancer, and melanomas, female lung and breast cancer showed 
persistently increasing trends in incidence throughout Europe, the latter two 
due to the increasing prevalence of smoking females and changing reproductive 
patterns. Incidence trends of pancreatic, laryngeal, ovarian and bladder cancer were 
stabilising or decreasing. The most consistent decreases in incidence were observed 
for gastric, cervical, and male lung cancer due to improved food preservation 
methods, screening and decreased male smoking rates.
 Improvements of cancer survival were observed for oral cavity and pharyngeal, 
stomach, lung, corpus uteri, ovarian and kidney cancer and for Hodgkin’s disease 
throughout Europe. For colorectal, melanoma, breast and prostate cancer 
improvements were seen in all countries, with the exception for Austrian melanoma 
patients. For Austria, this is probably due to problems with the data quality. Over 
time, the survival rates for patients with a cervical cancer have decreased in most 
countries. This is likely due to a worsening case-mix, leading to decreasing survival.51 
Conversely, survival improved in Poland where rates were historically very low and 
have recently been catching up to reach levels comparable with the other European 
countries. Possible explanations for changes in incidence, survival and mortality are 
described in the results section of this paper and summarized in table 2.20.
 Europe is a large continent, with large variations in lifestyle patterns and 
healthcare systems.6,72 Variation in healthcare systems has large influence on the 
possibility of the population to attend programs for early detection (i.e. active/
voluntarily invitation) and access to care and treatment. 
 Some of the improvements in cancer survival may be due to earlier detection 
(breast, prostate) and/or increasing proportions of elderly patients receiving new or 
more aggressive treatment.73 Cervical cancer screening, on the other hand, resulted 
in poorer survival rates: the effect of screening is that less cancers develop, but 
those which do develop are often more aggressive. For some tumours, such as rectal 
tumours and Hodgkin’s lymphomas, staging procedures have improved treatment 
efficacy and survival rates. In many countries, cancer care has been regionalised, 
resulting in more specialised oncologists and, possibly, more optimal care for cancer 
patients and an improved survival. 
 As presented in table 2.2, the results in this paper are based on many sources 
of information, national or (combinations of) regional data, different time periods, 
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and different population sizes. Some registries cover relatively small populations, 
causing fluctuating numbers of cancer patients and rates. Some registries seemed to 
have faced temporary problems with the completeness of the registry; in Lithuania 
for example, in the period 1998-2000 there seems to be an under-registration among 
females in comparison with the period(s) before and after these years (see on-line 
tables). In Croatia, it is known that the marked increase in incidence of most sites in 
1999 was due to the introduction of a new (improved) population data source. The 
effects of these characteristics on cancer incidence, mortality and survival rates are 
extensively described elsewhere.6 
 We used world-standardised rates (WSR) because the available incidence and 
mortality rates are usually standardised to this population. This age-standardisation 
facilitates comparisons between countries, but the reader should keep in mind that 
the world standard population is a much younger population than the population 
of an average European country. The observed trends using WSRs therefore mainly 
represent changes in incidence and/or mortality in the middle-aged population 
groups. European standardised rates would better illustrate changes at older ages, 
although the currently used European standard population is already younger than 
many real European populations. 
 The presented estimated annual percentages change were based on joinpoint 
modelling of the rates – not on the original population numbers, since they were 
not readily available for each registry. The EAPCs and their confidence intervals 
should therefore be interpreted with caution.
 Survival rates presented for oral cavity and pharyngeal, laryngeal, oesophageal, 
pancreatic, ovarian, testis and bladder cancer cannot be directly compared between 
countries. They were not standardised for age, or encompass different time periods.
CoNClusioNs 
The biggest achievement in cancer surveillance over the past 10 years, seems to have 
been the large reductions in smoking prevalence among males, hopefully soon to 
be followed by females.38 Lung cancer is still a very commonly diagnosed cancer, 
with a very poor survival, hence primary prevention by anti-smoking measures 
remains of utmost importance. Obesity, an upcoming problem, should be the target 
for prevention of oesophageal, breast, corpus uteri, cervical, prostate, and kidney 
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cancer.74 Substantial improvements in cancer survival have been achieved, mainly in 
Southern and Central Europe, where survival rates have been traditionally lagging 
behind compared to the rest of Europe.6
 Variations in policies for (mass-) screening, other measures for early detection 
of cancer, access to health care, and treatment policies exist within Europe. These 
variations are largely reflected in the observed incidence, mortality and survival rates, 
which should be interpreted simultaneously in order to really understand whether 
increased survival is merely due to lead time bias, improvements in treatment, 
changing patient and tumour characteristics, or a combination of the above.6 In 
order to plan health services, policy makers of each country or region should make 
a choice of the options for primary and secondary prevention, treatment and health 
care organisation based on results, available budgets and infrastructure.74 The 
results of this study may serve as a basis for these decisions.
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ABstrACt
In some European countries, female lung cancer mortality and incidence have 
started to decrease or flatten out, whereas they are still rising in the Netherlands. 
We present recent mortality and incidence trends of lung cancer and smoking trends 
in the Netherlands to show the end of the lung cancer epidemic in Dutch women. 
Lung cancer mortality and incidence rates by gender were analyzed for 4 age 
groups (20-44, 45-49, 50-54, 55-59) and smoking prevalence rates were examined 
for women using joinpoint regression and birth cohort analysis. Data on mortality 
were collected for the period 1960-2006, incidence for the period 1989-2003, and 
smoking prevalence for the period 1988-2007. Because of decreasing lung cancer 
mortality and incidence rates among males and dramatically increasing rates among 
females, rates of young males were surpassed by those of females after the mid-
1990s. However, although in young women (20-49) mortality increased with 4-5% 
per year, it flattened out (no significant in- or decreases) since 1999. Among older 
women, mortality rates were still increasing markedly. Mortality rates and smoking 
prevalence tended to decrease in women born after the 1950s. This is the first report 
suggesting that the lung cancer epidemic in Dutch women is coming to an end. 
Although the increase in lung cancer incidence and mortality among Dutch women 
has been one of the most dramatic in Europe, the recent decrease in young women 
is expected to be followed by a future leveling off or a slight decrease in overall 
female lung cancer rates.
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iNtroDuCtioN
In the Netherlands, the increase in female lung cancer mortality has been one of the 
most dramatic in Europe1 and lung cancer has become the second cause of death 
from cancer among women since 2000. Lung cancer was responsible for 17% of all 
female cancer deaths in 2006 and it is likely to become the first within five years.2 
In 2006, 3172 women died from lung cancer, almost nine deaths per day. In contrast 
to males, with declining rates since the 1980s, the age-standardised (European 
standard) mortality rate of lung cancer in women has increased dramatically between 
1970 and 2006 from 5 to 30 per 100,000 in the Netherlands.2 Dutch female lung 
cancer incidence and mortality rates are among the highest in Europe.3 As smoking 
prevalence decreased among Dutch women from 40% in the 1970s to 25% in 2007 
(Figure 3.1.1), the rising incidence and mortality rates are expected to flatten out or 
decrease, as already observed in Iceland, Ireland, the UK1 and the USA.4 
 In this short report we present recent age-specific incidence and mortality trends 
of lung cancer and smoking trends at young and middle age in the Netherlands and 
suggest the beginning of the end of the lung cancer epidemic in Dutch women.
Figure 3.1.1 | Age-specific trends in smoking prevalence for ages>15 by gender in The 
Netherlands, 1958–2006 (Source: STIVORO5).
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mAtEriAl AND mEtHoDs
Mortality from malignant neoplasms of the trachea, bronchus and lung for the 
period 1960-2006 were derived from Statistics Netherlands.2 Four revisions of the 
International Classification of Diseases (ICD) were used during this period: the 
seventh (1958-68), eighth (1969-78), ninth (1979-95) and tenth revision since 1996. 
For the whole period, cancer deaths were recoded according to ICD-codes C33/C34 
of the tenth revision of ICD.6
 Data on lung cancer incidence for the period 1989-2003 were obtained from 
the nation-wide Netherlands Cancer Registry (www.ikcnet.nl), which consists of 
9 regional cancer registries since 1989. The cancer registries receive lists of newly 
diagnosed cases on a regular basis from the pathology departments, all participating 
in a nation-wide pathology network (PALGA). In addition, the medical records 
departments of hospitals provide lists of diagnoses of outpatients and hospitalized 
patients with a suspected cancer diagnosis. Following this notification, the necessary 
information of newly diagnosed tumors is abstracted from the medical records by 
trained tumor registration clerks. Topography is coded according to the International 
Classification of Diseases of Oncology.7
 Annual age-specific mortality and incidence rates were calculated for 4 age 
groups: 20-44, 45-49, 50-54 and 55-59. Rates at ages 20-44 were standardized to the 
European standard population using the direct method.
 Joinpoint regression analysis was used to identify years where a significant 
change in the mortality trend occurred.8 The estimated annual percent change 
(EAPC) and the corresponding 95% confidence interval was calculated for each of 
those trends by fitting a regression line to the natural logarithm of the rates, using 
calendar year as regressor variable (i.e., y = mx + b where y = ln(rate) and x = calendar 
year, then EAPC = 100 x (em – 1)). The joinpoint regression models were performed 
using the Joinpoint Regression Program (version 3.0) from the Surveillance Research 
Program of the US National Cancer Institute (http://srab.cancer.gov/joinpoint/). 
 To estimate the effect of birth cohort on trends in mortality of female lung 
cancer, mortality rates for ages 20-59 were calculated for birth cohorts of 10 years. 
These ‘synthetic’ birth cohorts were created based on the year and age of death, 
using 5-year age and 5-year calendar period analysis.
 The effect of birth cohort on smoking trends in women was examined by 
calculating the smoking prevalence rates for ages 15-64 years by 10-year birth 
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cohorts. Smoking prevalence data were available for the period 1988-2007 and were 
collected by STIVORO, the Dutch national expert centre on tobacco prevention. 
rEsults
Figure 3.1.2 shows the dramatic increase of lung cancer mortality among women 
aged 20-59 in the Netherlands since the 1960s. The same increase was observed in 
female lung cancer incidence (national incidence data only available since 1989) 
(Figure 3.1.3). As a result of the decreasing male rates and the increasing female 
rates, male mortality and incidence rates were even surpassed by female rates since 
the mid-1990s, except for those over age 50. The male-to-female (M:F) mortality 
rate ratio decreased from 5.0 in 1970 to 0.7 in 2006 for ages 20-44 and from 11 to 0.9 
at ages 45-49. Incidence M:F rate ratios were 0.8 for ages 20-44 and 45-49 in 2003.
Figure 3.1.2 | Age-specific trends in 
mortality of lung cancer (3-year moving 
averages) for ages 20–59 by gender in The 
Netherlands,1960-2006 (Source: Statistics 
Netherlands2)
Figure 3.1.3 | Age-specific trends in incidence 
of lung cancer (3-year moving averages) for 
ages 20-59 by gender in the Netherlands, 
1989-2003 (Source: Netherlands Cancer 
Registry)
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table 3.1.1 | Results of joinpoint regression analysis of female lung cancer mortality (ages 20-
59) in the Netherlands, 1960-2006
Age-specific mortality rate 
per 100,000
Joinpoint analysis
trend 1 trend 2
Age 1960 2006 Period EAPC1  (95% Ci) Period EAPC1 (95% Ci)
20-44 0.5 3.0 1960-1999 4.3 (3.8, 4.9) 1999-2006  -1.5 (-8.4, 5.8)
45-49 1.5 22.5 1960-2004 5.2 (4.7, 5.7) 2004-2006 -14.1 (-35.4, 14.3)
50-54 5.6 49.6 1960-2006 5.0 (4.7, 5.3)
55-59 6.1 67.1 1960-1990 5.8 (5.0, 6.7) 1990-2006  4.0 (3.0, 5.0) 
1 EAPC: estimated annual percentage change, calculated based on the rates during the indicated period
Figure 3.1.4 | Age-specific mortality rates of 
lung cancer for female birth cohorts in the 
Netherlands (Source: Statistics Netherlands2)
Figure 3.1.5 | Age-specific smoking preva-
lence for female birth cohorts in the Nether-
lands (Source: STIVORO)
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In young women (ages 20-44), lung cancer mortality increased by 4.3% annually, 
from 0.5 per 100,000 in 1960 to 3.5 in 1999. After 1999 however, rates dropped to 
3.0 per 100,000 in 2006. The same reversal of the increasing mortality trend started 
in 2004 in women aged 45-49 (from 31 per 100,000 in 2004 to 23 in 2006). Among 
women aged 50-54 and 55-59 rates kept rising by 4-6% annually (table 3.1.1).
 Figure 3.1.4 gives age-specific mortality rates of female lung cancer by birth 
cohort and showed that mortality tended to decrease in women born after the 
1950s. The same pattern was observed for smoking prevalence among women by 
birth cohort (Figure 3.1.5). Women born after the 1950s started smoking less.
DisCussioN
We demonstrated the beginning of the end of the lung cancer epidemic among 
Dutch women. Although overall female lung cancer mortality and incidence rates 
continued to rise markedly in the Netherlands, reaching levels exceeding those of 
males, we observed a decline in the mortality and incidence trend among young 
women, particularly for the generation born after the 1950s. These findings are in 
line with the decreasing smoking prevalence in women born after the 1950s.
 Although lung cancer is uncommon among young age groups, these lung cancer 
trends are important, particularly since they give information on recent changes in 
risk-factor prevalence (e.g. smoking) and thereby information on the likely future 
trends in middle and elderly age.9,10 The end of the lung cancer epidemic among 
Dutch men was also first observed among young men in the early 1980s.11
 The decrease in smoking prevalence among women occurred mostly between 
1970 and 1989 (-10%). From the 1990s the smoking prevalence became more or 
less stable and between 2000 and 2007 it decreased with another 5%. Based on 
this information we expect first a slight decrease in the overall female lung cancer 
mortality and incidence followed by a leveling off.
 In this study, we focused mainly on lung cancer mortality, because mortality 
data was available for a longer time period than incidence data. As the case-fatality 
of lung cancer is high and therefore mortality trends closely follow incidence 
trends, this main focus on mortality is justified. Furthermore, impressive changes 
in lung cancer survival did not take place in the Netherlands,12,13 which implies that 
mortality is mainly influenced by incidence and therefore by changes in risk-factor 
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prevalence. This is also confirmed by our findings that lung cancer mortality and 
smoking prevalence among women started to decrease in the same generation.
 At the beginning of the 21st century, in Europe there was a general tendency 
for M:F rate ratios for lung cancer mortality to converge towards 1.0.14 Convergence 
of male and female lung cancer rates can be caused by declining male rates and 
rising female rates as observed in this study and in other European countries like 
Finland. In countries like Denmark, Sweden and Ireland convergence of the M:F 
rate ratios were only due to decreasing male rates.14 Jemal et al.15 showed that in 
the USA smoking prevalence converged to 1.0 among young men and women born 
after 1960, resulting in converging male and female lung cancer rates. From the 
available recent data on smoking prevalence by birth cohort in the Netherlands we 
found only an M:F rate ratio of smoking prevalence smaller than 1.0 among young 
adults aged 20-24 and born in the 1960s, which increased up to 1.2 for those born 
in the 1980s (data not shown). This finding is confirmed by the data presented in 
Figure 3.1.1; in the 1980s the smoking prevalence rates among men were surpassed 
by those of women aged 20-34. This is a plausible explanation for the observation 
that male lung cancer rates were surpassed by female rates in the Netherlands. 
However, from the 1990s, again men started smoking more than women in this age 
group, which might result in an increasing M:F ratio for lung cancer trends among 
young adults in the future. 
 Despite the fact that smoking prevalence became equal among young men 
and women in the past, this is not the only explanation for the female lung cancer 
incidence and mortality rates exceeding those of men. Possible other explanations 
include a higher female susceptibility to tobacco smoke,16 a different smoking 
pattern17 or more passive smoking18 among women. 
 On average 57% of lung cancer is avoidable by reducing smoking in Europe,19 
underlining the importance of anti-smoking interventions to attain lower lung cancer 
incidence and mortality among men and women. Such interventions should focus 
on adolescents and young adults to prevent that they start smoking, particularly 
since there was a slight increase of the smoking prevalence among both boys and 
girls aged 15-19 between 1990 and 2000 (Figures 3.1.1 and 3.1.5). This increase was 
not observed among women aged 20-34, their smoking prevalence even continued 
to decrease during this period. This means that many of the 15-19 year old girls who 
started smoking, stopped before reaching the age of 20. From the annual smoking 
monitor among youth in the Netherlands it is known that about 45% of smoking 
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girls aged 15-19 quitted.20 The slight increase of smoking prevalence among girls 
aged 15-19 between 1990 and 2000 is therefore not expected to have a major 
influence on overall female lung cancer mortality and incidence in the future.
 In the light of the recently increased smoking prevalence among adolescents, 
preventing smoking uptake must remain a main public health issue. Besides the 
importance of anti-smoking interventions (i.e. quit smoking campaigns, smoke 
free public places and increasing tax on cigarettes) we should also focus on further 
research to early detection (e.g. screening), better diagnostics and the role of 
estrogens21 and genetics22 in lung cancer to optimize lung cancer treatment and 
thereby reducing lung cancer mortality.
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ABstrACt
objective. Marked changes in reproductive behaviour and disease management 
make it interesting to assess progress against ovarian cancer. 
Design. A population-based study on trends in ovarian cancer incidence, relative 
survival and mortality derived from the Netherlands Cancer Registry and Statistics 
Netherlands.
setting. The Netherlands. 
Population. All patients newly diagnosed with ovarian cancer between 1989 and 
2009 (N=25,278).
methods. Trends were evaluated by the estimated annual percentage of change 
(EAPC) or corresponding p-values. Follow-up was complete until January 2010. 
main outcome measures. Ovarian cancer incidence, 5-year relative survival and 
mortality.
results. The age-standarised incidence rate decreased markedly from 15 per 100,000 
in 1989 to 11 in 2009 (EAPC -2.1%, 95% CI -2.4, -1.8). The mortality rate decreased 
from 13 per 100,000 in 1970 to 11 in 1982 (EAPC -1.6%, 95% CI -2.2, -1.0). After 1994, 
the decrease continued to 8.8 in 2000 (EAPC -3.9%, 95% CI -6.2, -1.6) and rates have 
remained stable since then. These decreasing trends were most pronounced among 
young and middle-aged women, starting among women born after the 1920s. 
Five-year relative survival improved from 36% in 1989-1993 to 42% in 2004-2009 
(p<0.001), coinciding with a histological subtype shift from ‘adenocarcinomas, not 
other specified’ to ‘serous carcinomas’ with a better prognosis.
Conclusions. Ovarian cancer incidence and mortality markedly decreased since 
1989, probably as a result of changes in reproductive behaviour. Five-year relative 
survival increased with 6-percent points, partly as a result of improved diagnostics 
coinciding with a histological shift and stage migration, and treatment, which also 
partly explains the mortality decrease.
Progress against ovarian cancer | 125
3.2
iNtroDuCtioN
In developed areas of the world, ovarian cancer is a common malignancy, ranking 7th 
most frequent for female cancer incidence and mortality not taking non-melanoma 
skin cancer into account. The highest incidence areas are in Europe and North 
America.23,24 In the beginning of the 2000s, incidence rates were relatively low in the 
Netherlands compared to other European countries.3 
 Use of oral contraceptives is shown to confer long-term protection against 
ovarian cancer.25 In the Netherlands women increasingly used oral contraceptives 
since their introduction in the mid 1960s, reaching levels up to 40-45% (www.cbs.nl) 
being one of the highest prevalence rates of use worldwide. During the same period, 
risk factors for ovarian cancer such as low parity and obesity increased among the 
Dutch female population.26 
 The prognosis of ovarian cancer is largely determined by FIGO stage. Only a 
minority of cases are detected at early stages because of non-specific symptoms 
resulting in an overall poor prognosis for ovarian cancer patients. In Europe, the 
average 5-year survival improved only modestly during the 1990s until 2002 from 
37% to 42%3 despite substantial advances in surgical and systemic treatment, i.e. 
more attention for complete debulking and adequate staging, incorporation of 
taxanes into standard platinum based primary chemotherapy and of several other 
active non-platinum cytotoxic agents.27 
 Taking into account the changes in population prevalence of the aforementioned 
protective and risk factors, improved staging and treatment, we studied mortality, 
incidence and survival trends of ovarian cancer in the Netherlands by age, stage and 
histological subtype during 1989-2009.
mAtEriAl AND mEtHoDs
Data collection
Population-based data from the nationwide Netherlands Cancer Registry (NCR), 
which started in 1989 and is maintained and hosted by the Comprehensive Cancer 
Centres, were used.28 The NCR is based on notification of all newly diagnosed 
malignancies in the Netherlands by the automated pathological archive (PALGA). 
Additional sources are the national registry of hospital discharge, haematology 
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departments and regional radiotherapy institutions. Information on patient 
characteristics like gender, date of birth, and tumour characteristics such as date of 
diagnosis, subsite (International Classification of Diseases for Oncology (ICD-O-3),7 
histology, stage (Tumour Lymph Node Metastasis (TNM) classification),29 grade, and 
primary treatment, are obtained routinely from the medical records. The quality of 
the data is high, due to thorough training of the administrators and computerized 
consistency checks at regional and national levels. Completeness is estimated to be at 
least 95%.30 Follow-up of vital status of all patients was calculated as the time from 
diagnosis to death or to 1st January 2010. The information on vital status was initially 
obtained from municipal registries and from 1995 onwards from the nationwide 
population registries network. These registries provide virtually complete coverage 
of all deceased Dutch citizens.
 For the present study, all patients with invasive primary ovarian cancer (ICD-O 
code C56) diagnosed in the period 1989-2009 in the Netherlands were included 
(n=25,278). Patients were divided in four age-groups (20-44, 45-59, 60-74, ≥75 years). 
The study period was divided in four periods: 1989-1993, 1994-1998, 1999-2003, 
and 2004-2009. Tumour stage was defined according the FIGO staging system,31 
based on postoperative histological information. If post-operative information 
was unknown, clinical information was used. Histology subtypes were divided 
into five groups: serous (ICD-0 morphology codes 8441, 8460-61), mucinous (8430, 
8470-82), endometrioid (8380-83), adenocarcinomas not otherwise specified (NOS) 
(8010, 8140, 8260, 8440, 8450) and other (all other ICD-O morphology codes in C56). 
Women younger than 20 years and older than 95 years at diagnosis were excluded 
from the survival analysis, as well as cases diagnosed by autopsy. 
 Mortality data on ovarian cancer for the period 1970-2009 was obtained from 
Statistics Netherlands.
statistical analyses
Annual incidence rates for the period 1989-2009 and annual mortality rates for 
the period 1970-2009 were calculated per 100,000 person-years, using the annual 
mid-year population size as obtained from Statistics Netherlands. Rates were age-
standardised to the European standard population (European Standardised Rates 
(ESR)). Changes were evaluated by calculating the estimated annual percentage 
change (EAPC) and the corresponding 95% confidence interval. A regression line 
was fitted to the natural logarithm of the rates, using the calendar year as regressor 
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variable (i.e. y=ax + b where y = ln(rate) and x = calendar year, then EAPC = 100 * 
(ea – 1)). Joinpoint regression analysis was used to identify years where a significant 
change in the incidence and mortality trend occurred.8 The models were developed 
using the Joinpoint Regression Program (version 3.3.1) from the Surveillance Research 
Program of the US National Cancer Institute (http://srab.cancer.gov/joinpoint/).
 To estimate the effect of birth cohort on trends in mortality since the 1970s, 
rates for ages 20-84 were calculated for birth cohorts of 10 years. These ‘synthetic’ 
birth cohorts were created based on the year and age of death, using 5-year age and 
5-year calendar periods. 
 Traditional cohort-based relative survival analysis was used for the period 1989-
2009 which represents the actual survival of patients diagnosed during 1989-2009. 
Follow-up was available until January 1, 2010. Therefore, 5-year relative survival of 
patients diagnosed in the period 2004-2009 could not be calculated with the cohort-
based method. To estimate the most up-to-date 5-year relative survival of patients 
diagnosed in this time period, we used period-based relative survival analyses.32 
Survival trends were evaluated by a linear regression model of annual survival rates 
and p<0.05 was considered as statistically significant. 
 Multivariable relative survival analyses, using Poisson regression modeling,33 
were performed to estimate relative excess risk (RER) of dying for the periods of 
diagnosis. The variables period, age and stage were included in the model. The 
histology variable was added to investigate the effect of histology on the RER of 
period of diagnosis. Analyses were performed using SAS software (SAS system 9.2, 
SAS Institute, Cary, NC).
rEsults
trends in mortality
The age-standardised mortality rate (ESR) (Figure 3.2.1) decreased from 13 per 
100,000 in 1970 to 11 in 1982 (EAPC -1.6%, 95% CI -2.2, -1.0) and remained stable 
during 1982-1994. After 1994, it continued to decrease to 8.8 per 100,000 in 2000 
(EAPC -3.9%, 95% CI -6.2, -1.6) remained stable since then. During the study period 
mortality decreased markedly among young and middle aged women (20-44 yr: 
3.4 per 100,000 in 1970 to 0.9 in 2009; 45-59 yr: 21 per 100,000 in 1970 to 8.7 in 
2009). For women aged between 60 and 74, mortality started to decrease from 47 
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per 100,000 in 1991 to 32 in 2009. Mortality increased for women aged above 75 
until 1995 and then decreased from 71 per 100,000 to 60 in 2009 (Figure 3.2.2A). 
Age-specific mortality rates of ovarian cancer by birth cohort tended to decrease in 
women born after the 1920s (Figure 3.2.3). 
Figure 3.2.1 | Age-standarised incidence and mortality rates (European Standardised Rate 
(ESR)) of ovarian cancer in the Netherlands, 1989-2009
trends in incidence
The age-standardised incidence rate (ESR) of all ovarian cancers decreased markedly 
from 15 per 100,000 in 1989 to 11 in 2009. The estimated annual percentage change 
(EAPC) in the period 1989-2009 was -2.1% (95% CI -2.4, -1.8; Figure 3.2.1). The 
decreasing incidence trend was most pronounced among young and middle aged 
women (20-44 yr: 5.2 per 100,000 in 1989 to 2.8 in 2009; 45-59 yr: 28 per 100,000 in 
1989 to 17 in 2009). For women aged between 60 and 74 the incidence decreased 
from 47 per 100,000 in 1989 to 35 in 2009. The incidence trend remained stable for 
women aged 75 and over until 1995 and then decreased from 58 per 100,000 to 39 
in 2005. Thereafter, incidence seemed to increase slightly, though not statistically 
significantly (Figure 3.2.2B). Difference in incidence trends between ages resulted 
in a lowering of proportion of young women (20-44 yr) from 12% in 1989-1993 to 
8% in 2004-2009. 
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Figure 3.2.2 | Age-standarised mortality(A) and incidence(B) rates (European Standardised 
Rate) of ovarian cancer by age in the Netherlands
Among all age groups the declines in incidence were most pronounced for FIGO 
stage I and III. FIGO stage IV decreased among women aged 60 and over, but started 
to increase from early 2000. For women aged 60-74 incidence of FIGO stage IV 
decreased from 8.4 per 100,000 in 1989 to 5.6 in 2000 and increased again to 8.7 
per 100,000 in 2009, for the elderly (≥75 years) the incidence decreased from 10.5 
per 100,000 in 1989 to 7.0 in 2003 and increased again to 13.5 per 100,000 in 2009 
(Figure 3.2.4). Recently, fewer young women (20-44 years) were diagnosed with an 
early stage (FIGO stage I and IIA), the proportion decreased from 57% in 1994-1998 
to 49% in 2004-2009. At the same time the proportion of advanced stages (FIGO 
stage IIB/C, III, and IV) increased from 39% to 48%. This shift towards advanced 
stages was also observed for women aged 75 and over (from 15% and 66% in 1994-
1998 to 12% and 74% in 2004-2009, respectively), although this shift was partly due 
to the decrease in patients with unknown stages. For other age groups we observed 
increased proportions of advanced stages (45-59 yrs: from 60% in 1994-1998 to 64% 
in 2004-2009; 60-74 yrs: from 71% to 75%) and no change in the proportion of early 
stages. 
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Figure 3.2.3 | Age-specific mortality rates of ovarian cancer by birth cohort (1900-1979) in the 
Netherlands
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Figure 3.2.4 | Age-standardised incidence rates (European Standardised Rate) of ovarian 
cancer by age and FIGO stage in the Netherlands, 1989-2009
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The decreasing trend in incidence was most striking for adenocarcinomas NOS and 
mucinous carcinomas which constitute up to 30% and 11% of all ovarian cancers, 
respectively. An increasing incidence was observed for serous carcinomas among 
women aged 45 and older since the mid-1990s while incidence of this type declined 
among young women (20-44 yrs) (Figure 3.2.5). These changes in incidence by 
histological subtype resulted in a marked proportional decrease of adenocarcinomas 
NOS among all age groups (20-44 yrs: from 21% in 1989-1993 to 8.6% in 2004-2009; 
45-59 yrs: from 32% to 13%; 60-74 yrs: from 42% to 20%; ≥75 yrs: from 49% to 
38%). This coincided with a marked increase of serous carcinomas (20-44 yrs: from 
26% in 1989-1993 to 32% in 2004-2009; 45-59 yrs: from 26% to 45%; 60-74 yrs: from 
27% to 52%; ≥75 yrs: from 19% to 34%). 
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Figure 3.2.5 | Age-standardised incidence rates (European Standardised Rate) of ovarian 
cancer by age and histological subtypes in the Netherlands, 1989-2009
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Within the histological subtypes the stage distribution shifted to late stages for 
adenocarcinomas NOS (from 80% in 1989-1993 to 87% in 2004-2009) and serous 
carcinomas (from 75% to 84%) due to a decrease in low and unknown stages. For 
endometrioids and mucinous carcinomas the proportion of low stages increased 
(from 43% and 56% to 53% and 64%, respectively).
trends in survival 
Marked improvements were seen for 5-year relative survival which improved from 
36% in 1989-1993 to 42% in 2004-2009 (table 3.2.1). This survival improvement 
was only present among women aged between 45 and 59 (from 46% to 54%), 
and between 60 and 74 (from 28% to 39%). Five-year relative survival improved 
only for advanced FIGO stages (from 18% to 28%). When stratifying according to 
histological subtype, 5-year relative survival improved for women with endometrioid 
(from 53% to 70%) and mucinous carcinomas (from 58% to 64%). Five-year relative 
survival for women with serous carcinoma was 38%, but only 21% for women with 
adenocarcinoma NOS.
table 3.2.1 | Five-year relative survival (Standard Error) from ovarian cancer (>=20 years) in the 
Netherlands, 1989-2009
Period of diagnosis
1989-2009 1989-1993 1994-1998 1999-2003 2004-2009a P trend
All 39.0 (0.4) 35.6 (0.6) 37.5 (0.7) 41.2 (0.7) 42.1 (0.6) <0.001
Age (years)
  20-44 67.8 (1.0) 66.5 (1.8) 70.5 (1.9) 67.9 (2.1) 67.4 (2.0) 0.29
  45-59 50.7 (0.6) 45.8 (1.2) 49.2 (1.2) 53.1 (1.2) 54.2 (1.1) <0.001
  60-74 34.2 (0.6) 28.1 (1.0) 33.2 (1.0) 37.2 (1.1) 39.3 (1.0) <0.001
  >= 75 18.9 (0.7) 18.2 (1.3) 15.6 (1.2) 20.5 (1.4) 21.1 (1.2) 0.18
Figo stage
  I - IIA 82.7 (0.6) 81.8 (1.1) 82.3 (1.1) 82.9 (1.1) 83.7 (1.1) 0.59
  IIB - IV 22.9 (0.4) 17.9 (0.6) 20.1 (0.7) 26.5 (0.8) 27.9 (0.7) <0.001
  unknown 17.7 (1.0) 18.8 (1.9) 17.7 (1.8) 15.4 (2.0) 18.8 (2.2) 0.58
Histological subtype
  adenocarcinoma 21.1 (0.5) 19.4 (0.9) 20.8 (1.0) 24.6 (1.2) 21.3 (1.1) 0.10
  endometrioid 62.5 (1.2) 52.8 (2.4) 59.7 (2.2) 67.7 (2.2) 69.9 (2.0) <0.001
  mucineus 59.3 (1.0) 58.0 (1.8) 56.6 (1.9) 62.3 (2.2) 64.1 (2.1) 0.02
  serous 38.1 (0.6) 37.4 (1.3) 36.8 (1.2) 37.6 (1.1) 38.5 (1.0) 0.39
  other 46.4 (0.9) 44.7 (1.8) 44.9 (1.7) 47.4 (1.8) 48.8 (1.6) 0.72
a 5-year relative survival calculated by period-analyses 
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In the multivariable relative survival model the improvement over time remained 
significant after adjusting for age and stage. After adding histology to the model 
survival improvement became smaller, which means that part of the survival 
improvement during 1989-2009 was explained by the histology shift from 
adenocarcinomas NOS to serous carcinomas (table 3.2.2).
table 3.2.2 | Multivariate relative 5-year survival analysis of ovarian cancer (>=20 years) in the 
Netherlands, 1989-2009
multivariate 1
(adjusted for age and stage)
multivariate 2
(adjusted for age, stage and histology)
rEr (95% Ci) rEr 95% Ci
Period of diagnosis
1989-1993 1 1
1994-1998 0.94 (0.90-0.98) 0.97 (0.93-1.02)
1999-2003 0.76 (0.73-0.80) 0.82 (0.78-0.86)
2004-2009 0.69 (0.66-0.72) 0.78 (0.74-0.82)
Abbreviations: RER, Relative Excess Risk of dying; 95% CI, 95% Confidence Interval
DisCussioN
Mortality from ovarian cancer markedly decreased since the 1970s in the Netherlands. 
This decrease was most pronounced among young and middle aged women (<60 
years) and since 1992 this decrease was also visible among the elderly (>= 60 years), 
particularly among women born after the 1920s. This means that about one third of 
ovarian cancer deaths were prevented in 2009 compared to the situation in the early 
1970s. The decreasing incidence of ovarian cancer was most likely the main cause 
of the observed decline in ovarian cancer mortality since the mid-1990s because 
the strength (EAPCs) of the decreasing incidence trends was almost equal to the 
strength of the decreasing mortality trends. Beside ageing of the patient population 
and increase of advanced stages, 5-year relative survival improved by 6 percent-
points which should also have contributed to the mortality decrease. This survival 
improvement coincided with the histological shift from adenocarcinomas NOS to 
serous carcinomas which have a better prognosis.
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trends in incidence and mortality
The mortality decrease prior to 1982 seems to be largely caused by changes in 
treatment, like the introduction of cisplatin-containing combination chemotherapy 
in the late 1970s. These changes resulted in an improvement of the 5-year relative 
survival from 28% in 1975-1980 to 42% in 1981-1985, while the incidence remained 
stable.34 
 Since 2000, total ovarian cancer mortality remained stable despite decreases 
in incidence. This stable mortality was also observed among the elderly (≥60 years), 
although only significantly stable for women aged 60-74. Possibly, this is caused 
by the observed increase in FIGO stage IV among the elderly since the early 2000s. 
The incidence of FIGO stage IV was higher in 2009 than in 1989, partly explained by 
improved staging but probably partly also being real. Besides, among the elderly 
the increasing incidence of serous carcinomas is not only explained by a decline in 
adenocarcinomas NOS, but also by a decline in mucinous carcinomas (proportional 
decrease from 10% in 1989-1993 to 6% in 2004-2009). Women with a serous 
carcinoma had a worse prognosis than women with a mucinous carcinoma (5-year 
relative survival 1989-2009: 38% and 59%, respectively). 
 The birth cohort analysis performed in this study, suggests that the mortality 
trend is also influenced by a birth cohort effect; mortality decreased for those born 
after the 1920s which explains why we observed that mortality started to decrease 
later among the elderly (>= 60 years). This pattern was also observed among other 
northern European women.35 In England and Wales the fall in risk of getting ovarian 
cancer for women born after the 1920s coincided with the rapidly increasing 
use of oral contraceptives (OC).36 In a collaborative reanalysis of data from 45 
epidemiological studies, every five years of oral contraceptive use resulted in a 21% 
risk reduction. This risk reduction persisted for more than 30 years after ceasing oral 
contraceptive use, although it attenuated somewhat over time. It was estimated 
that due to the increased number of ever-OC users in high income countries, about 
13% of ovarian cancers among women aged under 75 are being prevented in the 
2000s.25 In the Netherlands, OCs became available at the end of 1961, but initially 
was used only by women late in their reproductive life, mainly for birth control. 
Since the late 1960s, OCs became a popular method of contraception at young ages. 
The prevalence of OC use among women aged between 16 and 50 years increased 
from less than 5% in the mid-60s to 45% in the mid-1990s and 39% in 2010. Among 
young women (18-24 years) 66% is using OCs.26,37
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Other protective factors for ovarian cancer are multiparity, late age at first childbirth 
and breastfeeding. Different cohort studies showed that each birth gives a 10-20% 
reduction in risk of getting ovarian cancers.38-40 In the Netherlands, the average 
number of children per woman declined from 3.2 in the early 60s to 1.5 in the early 
80s and afterwards slightly increased to 1.8 in 2010.41 This decrease is most likely 
associated with use of OCs and therefore it is not expected to result in an increased 
risk of ovarian cancer. Increasing age at first childbirth may be also associated with 
use of OCs. However, after taking OCs use into account Adami et al.39 found an 
11% risk reduction for each 5-year increment in age at first childbirth. This risk 
reduction is probably only valid for uniparous and not for multiparous women,42 but 
there are only Dutch data for uniparous and multiparous women together. In the 
Netherlands, between the early 1970s and 2010 the average age at first childbirth 
increased with 5 years (from 24.3 to 29.4 years) which had a possible downward 
effect on the incidence trend.41 Another protective factor is breastfeeding and the 
percentage of babies breastfed at birth has increased from 67% in 1989-1991 to 
75% in 2007-2009 and at the age of 6 months this percentage increased from 26% to 
35% in the Netherlands, respectively.43 A recent case-control study showed a strong 
inverse association between breastfeeding and epithelial ovarian cancer of about 
1.4% reduction per month of lactation up to a maximum of 12 months, particularly 
for mucinous ovarian cancers, and independent of parity.44 However, not all studies 
found a significant inverse association.45 
 Recently, it was proposed that serous ovarian cancers originate in the distal 
fallopian tube or uterus,46,47 explaining why hysterectomies and tubal ligations are 
protective against ovarian cancer. The number of hysterectomies in the Netherlands 
increased during the 1960s and 1970s and started to decrease from the early 1980s 
from about 28,000 to 11,908 in 2009.48-50 Unfortunately, no information is available 
about the frequency of tubal ligation, but we expect that this intervention decreased 
over time, because a variety of alternative anticonceptive methods became available 
such as Mirena and OC use. As a result, it is expected that the incidence of serous 
carcinomas will increase in the future. Among the elderly (≥60 years) we observed 
an increase in serous carcinomas which could not only be explained by the shift 
from adenocarcinomas NOS to serous carcinomas and even the total ovarian 
cancer incidence seems to increase since 2005-2006, possibly due to the decrease in 
hysterectomies since the 1980s, despite the introduction of OC use. 
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A positive family history of epithelial ovarian cancers is another well-established 
risk factor. Carriers of BRCA1 or BRCA2 mutations have the highest cumulative life 
time risk of 30-60% and 5-20%, respectively.51-53 Both mutations are associated 
with serous carcinomas. For women with a BRCA1 or BRCA2 mutation prophylactic 
bilateral salpingo-oophorectomy is advised around the age of 40.54,55 While first the 
oophorectomy rates declined from 130 per 100,000 woman-years in the early 1980s 
to less than 85 in 199026 we expect this rate only to increase among BRCA-carriers. 
Since only about 5% of ovarian cancers are explained by family history we do not 
expect that this increase in oophorectomies will notably affect the ovarian cancer 
incidence trend. However, the decrease since the 1980s could be also one of the 
reasons of the possible incidence increase among the elderly. 
trends in survival
The overall 5-year survival rate of 39% during 1989-2009 found in this study is 
comparable with survival rates of other European countries, but lower than in 
the US.3, 56, 57 The higher survival rate in the US might be a result of difference in 
completeness of follow-up between the cancer registries. A high completeness of 
follow-up as in this study, affects survival outcome negatively.58 
 During the study period we found an improvement in 5-year survival from 36% 
in 1989-93 to 42% in 2004-09 which is probably due to improved diagnostics and 
treatment. In this study, we found that the survival improvement was partly explained 
by the histological shift from adenocarcinomas NOS to serous carcinomas. Serous 
carcinomas had 18% higher 5-year relative survival than adenocarcinomas NOS in 
2004-2009. This histological shift is probably not a real shift, but a result of improved 
diagnostics and more surgical procedures. Women with an adenocarcinoma NOS are 
often not diagnosed and treated optimally because of the high age and/or advanced 
stage of these women. In this study, we found that women with adenocarcinoma 
NOS were significantly older than other ovarian cancer patients and this age gap 
increased over time. In 2004-09, women with adenocarcinoma NOS were 71 years 
compared to other women who were 62 years. Women with adenocarcinoma NOS 
had also more often an advanced stage than other patients (81% vs 59%). 
  Another result of improved diagnostics is the stage migration, which also 
played a role in the improving survival. In this study, we observed a relative increase 
in advanced stage disease, but also a 2% increase of positive lymph nodes among 
women with a T1 or T2 tumour, whereas the percentage of women with a T3 tumour 
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increased with 3% during 1989-2009. However, if stage migration was the only cause 
for survival improvement we would not have observed any survival improvement 
for the total patient population.
  Survival improvement can be also explained by improved primary treatment 
(e.g. more often (neo)adjuvant chemotherapy and optimal debulking surgery)59 
and improved treatment strategies after relapsed disease. Another possible factor 
influencing the outcome of ovarian cancer is whether surgery is provided by a 
gynaecologic oncologist or a general  gynaecologist.60 Furthermore, it has been 
shown that women treated in specialized and semispecialized hospitals survive 
longer than women treated in general hospitals.61,62 The North Netherlands was one 
of the first regions that systematically provided assistance in treatment of ovarian 
cancer patients by sending gynaecologic oncologist to general hospitals since the 
1980s. During recent years much debate took place on centralisation of ovarian 
cancer treatment in the Netherlands, which led to the introduction of Managed 
Clinical Networks in most areas, centred around University Hospitals. 
CoNClusioN
In conclusion, ovarian cancer incidence and mortality markedly decreased since the 
last decades, most pronounced among young and middle aged women (<60 years) 
and particularly among women born after the 1920s. The incidence decrease is 
probably a result of the introduction of OC use and increased age of first childbirth. 
Five-year relative survival increased with 6-percent points between 1989 and 2009 
as a result of improved diagnostics causing a histological shift and stage migration, 
and treatment, which also partly explains the mortality decrease.
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ABstrACt
Background. Prostate cancer occurrence and stage distribution changed dramatically 
during the end of the 20th century. This study aimed to quantify and explain trends 
in incidence, stage distribution, survival and mortality in the Netherlands between 
1989 and 2006.
methods. Population-based data from the nationwide Netherlands Cancer Registry 
and Causes of Death Registry were used. Annual incidence and mortality rates were 
calculated and age-adjusted to the European Standard Population. Trends in rates 
were evaluated by age, clinical stage and differentiation grade.
results. 120,965 men were newly diagnosed with prostate cancer between 1989 
and 2006. Age-adjusted incidence rates increased from 63 to 104 per 100,000 
person-years in this period. Two periods of increasing incidence rates could be 
distinguished with increases of predominantly in cT2-tumours between 1989 and 
1995 and predominantly in cT1c-tumours since 2001. cT4/N+/M+-tumour incidence 
rates decreased from 23 in 1993 to 18 in 2006. The trend towards earlier detection 
was accompanied by a lower mean age at diagnosis (from 74 in 1989 to 70 in 2006), 
increased frequency of treatment with curative intent and improved 5-year relative 
survival. Mortality rates decreased from 34 in 1996 to 26 in 2007.
Conclusions. The increase of prostate cancer incidence in the early 1990s was 
probably caused by increased prostate cancer awareness combined with diagnostic 
improvements (transrectal ultrasound, (thin) needle biopsies), but not PSA testing. 
The subsequent peak since 2001 is probably attributable to PSA testing. The decline 
in prostate cancer mortality from 1996 onwards may be the consequence of increased 
detection of cT2-tumors between 1989 and 1995. Unfortunately, data on the use of 
PSA tests and other prostate cancer diagnostics to support these conclusions are 
lacking.
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iNtroDuCtioN
In the last decades of the 20th century, prostate cancer incidence increased in most 
high-income countries. It is generally accepted that a large part of this increase can 
be accounted for by earlier (and increased) detection due to more frequent digital 
rectal examination as a consequence of greater prostate cancer awareness, incidental 
diagnosis due to the increasing use of transurethral resection of the prostate (TURP) 
and developments in diagnostic techniques such as transrectal ultrasound (TRUS) 
imaging and thin needle biopsies.1-4
 The late 1980s, PSA testing became available.5 Particularly in the United States 
of America (USA), but also in other high-income countries, a further steep increase 
in prostate cancer incidence was observed after the introduction of PSA testing.6 
Welch et al. calculated that from 1986 to 2005 an excess of at least one million men 
were diagnosed with and treated for prostate cancer in the USA due to PSA testing.7 
Recently, the European Randomised study of Screening for Prostate Cancer (ERSPC) 
showed a 20% decrease in prostate cancer related mortality in study participants as 
an effect of programmed population-based PSA testing.8 However, PSA testing is 
not routine practice yet in the Netherlands.9 Consequently, whether PSA testing is 
responsible for the observed decrease in the incidence of metastasized tumours and 
mortality in the Netherlands over the past 16 years is questionable.
 New therapies or improvements in existing therapies can also cause trends 
or trend changes in prognosis. Radical surgery and radiotherapy (external-beam 
radiotherapy and brachytherapy) are available for the treatment of localised prostate 
cancer and, for advanced disease, these treatments are sometimes combined with 
hormonal therapy.10 It is not known whether changes in the application of these 
therapies have had an effect on trends in the prognosis of patients with prostate 
cancer in the Netherlands.
 Insight in incidence, disease stage and mortality patterns in the Netherlands 
may reveal a need for policy changes. Prostate cancer represents a large burden for 
society and with the ageing population the number of newly diagnosed patients 
in the Netherlands is expected to rise from 9500 patients in 2006 to an estimated 
15,000 in 2015.11 The number of prevalent patients for whom periodical check-ups 
will be necessary is expected to increase even more dramatically. The aim of this 
population-based study was to identify and explain temporal trends in prostate 
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cancer incidence, disease stage, survival and mortality in the Netherlands from 1989 
to 2006.
mAtEriAl AND mEtHoDs
The Association of Comprehensive Cancer Centres (CCCs) has registered data of all 
newly diagnosed neoplasms in the Netherlands since 1989. The resulting nationwide 
Netherlands Cancer Registry (NCR; www.ikcnet.nl) is considered to be of very high 
quality due to the standardised identification of new cases of cancer through the 
national automated pathology archive (PALGA), the national registry of hospital 
discharges (LMR), haematology departments and radiotherapy institutions, and 
because of the thorough training and testing of the registrars. After identification of 
new cases, these registrars abstract data from the medical files in all Dutch hospitals. 
Computerised consistency checks and re-abstraction and re-entry of data further 
improve the quality of the data. Completeness is estimated to be at least 95%.12 
Population-based data concerning prostate cancer diagnoses between 1989 and 
2006 were analysed for the purpose of this study.11 One of the eight CCCs (CCC South) 
began with cancer registration in the 1950s. Therefore, we were also able to make 
use of data from CCC South for the period 1970-1988 in order to investigate longer 
term trends in overall incidence.13 The data from the CCC South were used only for 
the long-term evaluation of overall incidence and mortality. For the calculation of 
survival, the NCR links its database with the population-based demography registry 
that keeps data on vital status of all Dutch citizens. This nationwide demography 
database was started in 1995. Four of the eight CCCs contributing data to the NCR 
have retrospectively collected vital status data of all patients diagnosed before 1995. 
Mortality data, obtained from Statistics Netherlands, were available from 1970 to 
2007.14
  Histology was coded according to the International Classification of Diseases 
for Oncology (ICD-O).15 Differentiation was graded using the World Health 
Organisation (WHO) grading system until 2003, after which it was replaced by the 
Gleason score.16 Histological grading was categorised as well differentiated (WHO 
grade 1 or Gleason score 2-6), moderately differentiated (WHO grade 2 or Gleason 
score 7) or poorly differentiated (WHO grade 3 or Gleason score 8-10). Patients with 
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undifferentiated (grade 4) tumours (<1%) were included in the category ‘poorly 
differentiated tumours’.
 Clinical stage was recorded strictly according to the formal TNM classification 
in use at the time of diagnosis and grouped into cT1a/b, cT1c (existing since 1993), 
cT2, cT3, cT4/N+/M+ or ‘unknown’ (cTx) if insufficient information was available for 
accurate staging.17 For patients who had undergone a radical prostatectomy, the 
clinical and post-surgical T-stage were crosstabulated to evaluate trends in clinical 
overstaging and understaging by period of diagnosis.
 The first-line treatment (or treatment combination) was recorded. Patients 
who were incidentally diagnosed with prostate cancer in TURP specimens and who 
received no further treatment, were categorized into the ‘no therapy’-group.
 The study period was divided into three 5-year episodes and one 3-year period: 
1989-1993, 1994-1998, 1999-2003, and 2004-2006. Patients were grouped into three 
age categories in order to identify age-specific trends in stage distribution and 
treatment (<65, 65-74 and ≥75 years) and into five age categories for incidence and 
mortality rates (45-54, 55-64, 65-74, 75-84 and ≥85 years).
statistical analysis
Annual incidence and mortality rates for the period 1989-2006 were calculated 
per 100,000 person-years, using the annual mid-year population size as obtained 
from Statistics Netherlands. Rates were age-standardised to the European standard 
population (European Standardised Rates (ESR)). Changes were evaluated by 
calculating the estimated annual percentage change (EAPC) and the corresponding 
95% confidence interval. To calculate this, a regression line was fitted to the natural 
logarithm of the rates, using the calendar year as regressor variable (i.e. y=ax + b 
where y = ln(rate) and x = calendar year; then EAPC = 100 * (ea – 1)). 18 Incidence 
rates were also calculated per age group, differentiation grade and clinical stage. 
Treatment administration was described as percentage per age group and calendar 
period.
 Follow-up of all patients was calculated as the time from diagnosis to death or 
to January 1st 2008. Five-year relative survival was used to estimate disease-specific 
survival. Relative survival was calculated as the absolute survival among cancer 
patients divided by the expected survival for the general male population with the 
same age.19 For the stage-stratified survival analysis, the pTNM classification was 
used. If pTNM was not available, cTNM was used. Traditional cohort-based relative 
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survival analysis was used for the period 1989-2003 which represents the survival 
of patients diagnosed during 1989-2003. Period-based relative survival analysis 
was used for the most recent period 2004-2006, in order to obtain a more up-to-
date estimate for this period.20 Survival trends were quantified as the mean annual 
percentage change (MAPC) from 1989 to 2006 as estimated by a linear regression 
model. This calculation assumes that the rates increased or decreased at a constant 
rate over the entire period. SAS software (SAS system 9.2, SAS Institute, Cary, NC) 
was used to perform the statistical analyses.
rEsults
Age-specific incidence
A total of 120,965 patients were diagnosed with prostate cancer between 1989 and 
2006. The annual number of diagnoses more than doubled from 4201 in 1989 to 
9516 in 2006. The mean age at diagnosis decreased from 74 years in 1989 to 70 in 
2006. 
 Prostate cancer incidence rates gradually increased in the CCC South catchment 
area between 1970 and 1989, with an EAPC of 1.9% (95% CI 1.1-2.7%). Thereafter, 
the incidence in the whole country increased steeply from 63 per 100,000 person-
years in 1989 to 90 in 1995, with an EAPC of 7.1% (95% CI 4.5-9.8%) (Figure 4.1.1). 
Incidence rates remained stable between 1995 and 2000 (EAPC -0.9%; 95% CI -5.9 
to 3.8%), but rose from 88 in 2000 to 104 in 2006 (EAPC 3.6%; 95% CI 1.1-6.1%). The 
CCC South data in the period 1989-2006 showed the same pattern as the nation-
wide data.
stage-specific incidence
Since the introduction of the cT1c-category in the TNM classification for PSA-
detected prostate cancer in 1993, cT1c-tumor incidence rose to 35 per 100,000 
person-years in 2006 (EAPC: 18.2%; 95% CI 16.0-20.5%) (Figure 4.1.3). The largest 
increase was observed from 2001 onwards. The incidence rate for cT1a/b-tumours 
dropped from 1992 to 1993 and decreased further until 2001. The incidence rate 
of cT2-tumours increased from 19 in 1989 to 37 in 1995 (EAPC 16.7%; 95% CI 13.5-
20.0%) and then decreased to 30 in 2006 (EAPC -1.6%; 95% CI -2.7 to -0.5%). After 
increasing from 1989 to 1994 (EAPC 12.4%; 95% CI 6.0-19.3%), the incidence rate of 
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cT3-tumours remained stable until the end of the study period (EAPC 1.4%; 95%CI 
-0.2 to 3.0). The incidence rate of cT4/N+/M+-tumours decreased from 1993 to 1999 
(EAPC -4.5%; 95%CI -6.6 to -2.2%), after which it remained stable. In absolute 
numbers, the annual number of diagnosed cT4/N+/M+-tumours increased gradually 
from 1,345 cases nationwide in 1989 to 1,614 in 2006.
Figure 4.1.1 | Age-standardised rates (European Standard Population) for incidence and 
mortality of prostate cancer in the Netherlands 1970-2006 (incidence rates 1970-1988: data 
Comprehensive Cancer Centre South; incidence rates 1989-2006: data Netherlands Cancer 
Registry - no differences between CCCS and NCR data in period 1989-2006 -; mortality rates 
1970-2006: Statistics Netherlands)
Age-stratified incidence rates increased over time for men under the age of 75 years 
(Figure 4.1.2). Incidence rates for men aged 65-74 years rose from 1989 until 1995 
(EAPC 8.9%; 95% CI 5.9-12.7%), were stable until 2000 (EAPC 0.7%; 95% CI -2.9 to 
4.4%) and then rose again until 2006 (EAPC 4.5%; 95% CI 0.8-8.4%). For men aged 
55-64 incidence rates increased throughout the study period: EAPC 17.7% (95% CI 
0.8-37.3%) from 1991 to 1994 and 5.8% (95% CI 4.9-6.8%) from 1994 to 2006. 
 For men over 75, incidence rates increased until 1994, but then decreased until 
2006 with EAPCs of -1.8% (95% CI -2.7 to -0.9%) for men aged 75-84 and -7.4% 
(95% CI -12.1 to -2.7%) for men over 85.
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Figure 4.1.2 | Age-standardised incidence rates per 100,000 person-years (European Standard 
Population) for prostate cancer in the Netherlands 1989-2006, stratified by age category
Figure 4.1.3 | Age-standardised incidence rates per 100,000 person-years (European Standard 
Population) for prostate cancer in the Netherlands 1989-2006, stratified by clinical stage
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Figure 4.1.4 | Age-standardised incidence rates per 100,000 person-years (European Standard 
Population) for prostate cancer in the Netherlands 1989-2006, stratified by clinical stage in 
three age categories: (a) < 65 years of age (b) 65-74 years of age and (c) > 74 years of age
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Age-stratified analysis of these data shows that the increase in cT1c-tumours was 
most markedly present in men under 75 years of age and that increase seemed to 
accelerate from 2001 onwards (Figure 4.1.4a-c). The incidence rate of cT2-tumours 
rose quickly until the mid-1990s for all age categories, after which it remained stable 
for men under 75 and decreased for men over 75. The incidence rate of cT3-tumours 
gradually increased for men under 75 and remained nearly constant for men over 
75. The decrease in cT4/N+/M+-tumour incidence from 1993 to 1999 was most clearly 
present for men over 75.
 The incidence rate of well-differentiated tumours increased from 1991 to 
1995 (EAPC 8.3%; 95% CI 5.5-11.2%) and then decreased until 2003 (EAPC -6.1%; 
95% CI -9.2% to -2.9%) (Figure 4.1.5). For moderately differentiated tumours, the 
EAPC was 5.5% (95% CI 4.2-6.9%) from 1989 to 2003. Since 2003, the incidence 
of well-differentiated tumours increased, while moderately differentiated tumours 
decreased.
Figure 4.1.5 | Age-standardised incidence rates per 100,000 person-years (European Standard 
Population) for prostate cancer in the Netherlands, stratified by grade of differentiation (until 
2003 the WHO grading system was used to determine differentiation; from 2004 onwards the 
Gleason scoring system was used: Gleason score 2-6 = well differentiated, Gleason score 7 = 
moderately differentiated, Gleason score 8-10 = poorly differentiated)
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Clinical understaging
17,117 patients underwent a radical prostatectomy. For these patients, both cTNM 
and pTNM were known. Approximately one third of these patients who were 
considered cT2 (n=8,868) were clinically understaged and had pT3 (n=2,675) or pT4 
(n=246). Patients classified as cT3 were overstaged in 27% of the cases with a known 
pT-classification (n=136/499). The amount of understaging of cT2- and cT3-tumors 
remained relatively constant during the last three periods of diagnosis. Clinical 
overstaging of cT3-tumors occurred more frequently over time, rising from 18% in 
1989-1993 to 37% in 2004-2006.
treatment
For 1,333 patients (1.1%) the primary treatment was not registered. These patients 
were excluded from this analysis. Over time, patients under 75 with cT1- and cT2-
tumours more frequently underwent radical prostatectomy. Patients aged 65-
74 with localised tumours underwent surgery less frequently than their younger 
counterparts. Still, the percentage of men undergoing radical prostatectomy almost 
doubled to 20% between 2004 and 2006. Radiotherapy as sole therapy increased 
mainly through increased application of brachytherapy. Active surveillance was 
chosen less often (from 38% of all cT1-tumours in 1989 to 9% in 2006). The latter 
group included patients with incidental prostate cancer found during TURP. 
 Patients under 75 with cT3-tumours received concurrent radiotherapy and 
hormonal therapy in more than 70% of cases since the late 1990s. Patients over 75 
with localised disease most often received either no therapy (60%, 30% and 20% of 
the patients with cT1-, cT2- and cT3-tumour, respectively) or hormonal therapy.
 For cT4/N+/M+ prostate cancer the only available therapy is hormonal therapy. 
This was given to 80% to 90% of the patients in all age categories. The combination 
of radiotherapy and hormonal therapy was chosen for approximately 10% of 
patients under 75 years of age (data not shown).
survival
Five-year survival significantly increased in all age categories under 85 and all stages 
(Figure 4.1.6). The age-stratified analysis showed that men aged 45-54 had the 
highest MAPC with 1.8% annual increase (95% CI 1.2-2.3%). This increase declined 
gradually with every higher age category to 1.3% (95% CI 1.0-1.6%) for men aged 
75-84 and no change for men over 85 years of age. The stage-specific increase in 
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survival was strongest for men with pT3/pT4-tumours with a MAPC of 1.6% (95% CI 
1.2-2.0%). Locally extended or metastatic cancer had the lowest MAPC with 0.4% 
annual increase in survival (95% CI 0.2-0.7%).
 A B
Figure 4.1.6 | (a) Five-year relative survival from prostate cancer by period of diagnosis, 
stratified by age category (*calculation by period analysis for period of diagnosis 2004-06); (b) 
5-year relative survival from prostate cancer by period of diagnosis, stratified by pathological 
stage (*calculation by period analysis for period of diagnosis 2004-06); † significant change (p 
< 0,05) in 5-year relative survival
mortality
Disease-specific mortality rates increased slightly from 1970 to 1995 (from 26 to 34 
per 100,000 person-years) (EAPC = 1.2; 95% CI 1.0-1.3%) and then decreased to 26 in 
2007 (EAPC = -2.5%; 95% CI -3.0 to -2.0%) (Figure 4.1.1). This pattern was observed 
for all men over 65 years of age (Figure 4.1.7) and was most evident in men over 85 
years of age, with an EAPC from 1996 to 2007 of -3.4% (95% CI -4.0 to -2.8%).
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Figure 4.1.7 | Age-standardised mortality rates per 100,000 person-years (European Standard 
Population) for prostate cancer in the Netherlands 1970-2006, stratified by age category: (a) 
45-54 years, 55-64 years and (b) 65-74 years, 75-84 years, 85+ years
DisCussioN
Age-specific incidence
Between 1989 and 2006, two periods with significant increases in prostate cancer 
incidence were observed. The increase in the first period, from 1989 to 1995, is 
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often explained as an effect of PSA testing.13,21,22 However, arguments exist against 
this explanation. In the Netherlands, PSA testing was introduced relatively slowly, 
although valid population-based data about the use of PSA tests throughout the 
study period are not available. An interim analysis of the Rotterdam section of the 
ERSPC found 8% effective contamination in the control arm between 1997 and 
2000.23 Also, according to a Statistics Netherlands survey, in 2001 only 14% of men 
over 45 years of age had a PSA measurement in the previous five years.9 Moreover, 
the increase in incidence from 1989 to 1995 was present in all age categories, while 
PSA testing in asymptomatic men would be expected to be used less frequently 
among elderly (over 75 years of age) because of reservations towards treatment 
for men with a relatively short life expectancy (less than 10 years). Although the 
percentage of men over 75 years of age who had a PSA test in the previous 5 years 
(40%) is approximately equal to the percentage of men between 55 and 75 years 
of age, 43% of all the men over the age of 70 who reported having had a PSA test, 
was between 70 and 74 years of age (Dr. Bruggink, Statistics Netherlands, personal 
communication). A difficulty with the interpretation of these percentages, though, 
is that with these numbers on cannot distinguish whether these PSA tests were the 
first to be undergone by the interviewed men. This is unfortunate as the first PSA 
test is the most important one when testing for prostate cancer. Very likely, men 
who have had PSA tests before, will remain to be tested at a later age by their GP 
or urologist.
stage-specific incidence
Unfortunately, there is no detailed information available about PSA-detected 
tumours before 1993, as the cT1c-category was only introduced in the cTNM 
classification (and the NCR registry protocol) in 1993. Therefore, the cT1a/b-category 
is heterogeneous until 1992, comprising both TURP-detected and PSA-detected 
prostate cancer. The stage-specific analyses from 1993 onwards reveal that cT1c-
tumour incidence continuously increased and was accompanied by a decrease in the 
incidence of cT1a/b-tumours until 2001. This increase, together with the increase in 
cT2-tumour incidence until 1995 and the decrease in cT4/N+/M+-tumour incidence 
from 1993 to 1999, results in the biphasic increase observed in the overall incidence. 
 From these data, it can be deduced that the rise of prostate cancer incidence 
in the early 1990s was mainly caused by an increase in cT2-tumours, probably due 
to more frequent digital rectal examinations (DRE) and technical improvements in 
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diagnostics, such as TRUS imaging and the use of (thin) needle biopsies. Because 
cT1c-tumour incidence continued to rise while the incidence of all other stages 
stabilized since 2000, PSA testing must have caused the subsequent peak from 2000 
to 2006. This is further supported by the fact that incidence rates increased only for 
patients under 75 years of age and by the results of the Statistics Netherlands survey, 
which showed that the percentage of men over 45 years of age who had their serum 
PSA measured in the previous five years rose from 14% in 2001 to 26% in 2008.9 
Direct population-based data to support this are not available, however.
 Incidence rates of locally extensive and metastatic (cT4/N+/M+) disease evidently 
decreased from 1993 to 1999, particularly in men over 65. As interventions directed 
at detection of cancer in an earlier stage need time to show their beneficial effect 
on metastasized disease or mortality, a delay between the rise in localized tumors 
and decrease in metastasized tumors is to be expected. Also, one might expect 
to see a rise of localised prostate cancer in a younger age category, followed by 
a decrease in more advanced disease in an older age category. This study found 
a difference in onset of the increase in localised prostate cancer (1989/1990) and 
decrease of metastasized cancer (1993) of approximately 4 years. This corresponds 
reasonably well to the effect of early detection of prostate cancer on mortality as 
observed in the ERSPC, which only became apparent after 7 to 8 years.8 Thus, some 
change must have occurred around 1990, most probably an increased use of DRE, 
TRUS imaging and (thin) needle biopsies, but not yet PSA testing. However, this 
conclusion is somewhat speculative. Other factors might also have contributed to 
a rise in localised prostate cancer and the subsequent decrease in metastasized 
disease.
 From 1995 to 2003, more moderately differentiated tumours were detected, 
whereas the incidence of well-differentiated tumours decreased. Knowing that the 
incidence of cT1c-tumours increased in the same period, this could indicate that 
PSA testing was effective in detecting moderately differentiated tumours. The 
trend continued until the registration protocol was changed from the WHO grading 
system to the Gleason scoring system in 2004. Unfortunately, these systems are not 
easily interchangeable, as the WHO grading system is based on cellular and nuclear 
characteristics and the Gleason scoring system on growth patterns. The sudden 
changes in well-differentiated and moderately differentiated tumours around 2004 
were most probably caused by this change in protocol.
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Other western countries have shown similar increases in prostate cancer incidence 
in the study period. The situation in the United Kingdom (UK) might resemble 
the Dutch situation. In the UK, similar trends were seen with regard to prostate 
cancer incidence and mortality.24 In the UK, as in the Netherlands, PSA uptake was 
considerably lower than in the USA, as illustrated by an overall annual rate of 6.0% 
for PSA testing in men aged 45-84 with no previous diagnosis of prostate cancer 
between 1999 and 2002.25 Consequently, it is possible that the rise in prostate cancer 
incidence in the UK in the early 1990s and the decrease in mortality since the mid-
1990s was also caused by an increased prostate cancer awareness. Without analyses 
of stage-specific data from the UK, however, this will remain unclear. 
 The overall prostate cancer incidence in the Netherlands is still considerably 
lower than in, e.g. Sweden and North America.26,27 Interestingly, however, prostate 
cancer incidence has been decreasing in the USA since 2001.28 This might indicate 
that the “prevalent pool” of prostate cancer cases in the USA is being exhausted. 
The following years will learn whether a similar trend will occur in the Netherlands 
and other western countries. 
treatment
Over time, patients under 65 with localised (cT1- and cT2-) tumours more often 
underwent surgery (radical prostatectomy). At the same time, the proportion 
of patients who received no therapy/TUR- only decreased. This might again be 
explained by PSA testing. Since PSA became available, patients who were otherwise 
eligible for TURP may now have had a PSA test with, if indicated, subsequent random 
prostate biopsies prior to the resection. This would result in an increasingly smaller 
proportion of prostate cancers detected at TURP.29
 Patients under 75 with cT3-tumors received radiotherapy in 50% of the cases 
in the early 1990s. Since 1999, the combination of radiotherapy and hormonal 
therapy was chosen for over 70% of cT3-patients. This reflects that this combination 
is considered the gold standard for cT3 prostate cancer, as proposed by Bolla and 
colleagues in 1997.30 In addition to this indication, our data showed that, with time, 
this combination was also given more often to patients under 75 with cT1- and cT2-
tumors.
 Men over 75 years have a life expectancy shorter than 10 years.31 As a result, 
according ot the guidelines, the majority of patients over 75 with a cT1-tumour 
did not receive therapy. Those who received treatment were most often treated 
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with hormonal therapy. As for the younger patients, combined radiotherapy and 
hormonal therapy for cT3-tumors were applied more frequently with time.
 Treatment options for cT4/N+/M+ prostate cancer are still very limited. Hormonal 
treatment remained the cornerstone of treating extensive disease, reflected by 
the fact that over 90% of these patients in all age categories received hormonal 
treatment. A small minority received radiotherapy in addition to the hormonal 
treatment.
survival
Survival from prostate cancer improved for all stages and age categories, except for 
patients over 85. Tumour stage and grade changes may have played a role in this. 
With the development of new imaging techniques, tumour staging became more 
precise. This could result in upstaging , for example, of what previously would have 
been recorded a large cT2-tumour to a minimal cT3-tumor, consequently increasing 
survival in both strata. Also, a grade shift could have been caused by the insight 
that Gleason scores lower than 6 should not be given on needle biopsy material, 
an advice stated by Epstein in 2000 and adopted by the ISUP in 2005.32-34 However, 
as a decrease in prostate cancer mortality was also observed, this suggests that a 
genuine improvement of prostate cancer specific survival is also present.
mortality
Prostate cancer mortality rates in the Netherlands have decreased since the mid-1990s. 
In most western European countries, a levelling-off of prostate cancer mortality rate 
has also been observed since the mid-1990s.35 Another study comparing 1985-1989 
with 1995-1998 found that prostate cancer mortality for males between 65 and 84 
years declined by 4% in the EU and 6% in the USA.36
 The decrease in prostate cancer mortality in the Netherlands might again be 
attributed to PSA testing. However, we have argued that PSA testing probably did 
not cause the decrease in incidence of metastasized cancer from 1993 to 1999. A 
similar argument can be put forward for the mortality rates although, again, we 
cannot support this with hard data. As the decrease in mortality started in 1996, the 
change most probably took place around 1990 (assuming approximately 7 years lag-
time before an intervention shows an effect on mortality rates)8 and was therefore 
most probably due to an increased use of DRE, TRUS and needle biopsy rather than 
to PSA testing. In addition to this, more precise staging and, subsequently, better 
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treatment might also have contributed to the decrease in prostate cancer mortality. 
Unfortunately, it is not possible to disentangle the extent to which these factors 
have played a role in the observed trends.
CoNClusioN
The NCR data presented here have shown that prostate cancer incidence increased 
between 1989 and 2006. This increase was most likely caused by an increased 
application of DRE in combination with technical improvements in diagnostics (TRUS, 
(thin) needle biopsies), whereas the subsequent peak in prostate cancer incidence 
from 2000 to 2006 can be attributed to PSA testing. The decline in prostate cancer 
mortality from 1996 onwards may be the consequence of the increased detection 
of cT2 prostate cancer from 1989 to 1995. Other unobserved factors may also have 
played a role in causing these trends.
Prostate cancer was more often detected in an early stage and treated with a 
curative intent, leading to a decreased incidence of metastatic prostate cancer, 
a lower mortality rate and increased survival. Thus, it can be said that significant 
progress has been made against prostate cancer in the Netherlands. However, this 
progress has come at the expense of considerable overdiagnosis. With the rising 
burden of prostate cancer due to the aging population, major improvements are 
still needed in the areas of biomarkers and detection, imaging and staging in order 
to avoid overdiagnosis.
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ABstrACt
Background. The aim of this study was to describe trends in survival and therapy in 
advanced stage epithelial ovarian cancer (EOC) in the Netherlands and to determine 
if changes in therapy affected survival. 
methods. All EOC patients diagnosed in the Netherlands during 1989-2009 were 
selected from the Netherlands Cancer Registry. Differences in treatment over time 
were tested by the Cochran-Armitage trend test. Multivariable relative survival 
analyses were performed to test whether changes in treatment are associated with 
survival. 
results. 23,399 patients were diagnosed with EOC, of whom 15,892 (67.9%) in 
advanced stage (stage ≥2b). In advanced stage patients, the proportion receiving 
(neo-)adjuvant chemotherapy and optimal debulking (residuals <1cm) increased 
over time in all age groups. In elderly patients (≥75 years) a stable proportion 
(approximately 28%) did not receive any treatment. Five-year relative survival 
in advanced stage patients increased from 18% in 1989-1993 to 28% in 2004-
2009. In the multivariable model survival improved over time (relative excess risk 
(RER) of 2004-2009 was 0.71, 95% CI 0.67-0.75 compared to 1989-1993). This RER 
attenuated to 0.85 (95% CI 0.80-0.90) and 0.91 (95% CI 0.83-0.99) with inclusion of 
treatment variables in the model (surgery with chemotherapy or optimal surgery 
with chemotherapy, respectively). This suggests that the improvement was mainly, 
although not entirely, caused by changes in treatment. 
Conclusions. Treatment in advanced stage EOC patients in the Netherlands improved 
over the last two decades; more patients received (neo)adjuvant chemotherapy 
and underwent an optimal debulking surgery. Changes in treatment led to partial 
improvement of survival in EOC patients. 
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iNtroDuCtioN
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy in the 
Western World. In the Netherlands, approximately 1200 new patients are diagnosed 
with ovarian cancer each year, with approximately 900 deaths annually.37 Due to the 
non-specific symptoms of this malignancy the majority of patients are diagnosed 
in an advanced stage of disease, i.e., stage 2b or higher. Since survival proportions 
drop significantly with increasing stage of disease patients with epithelial ovarian 
cancer in general face a very poor prognosis. 
 Management of epithelial ovarian cancer has changed during the last decades. 
Cisplatin was introduced in the USA in the mid 1970s and was later adopted as 
part of first line chemotherapy treatment. The use of paclitaxel-containing 
chemotherapy started in the early 1990s. In the late 1960s and early 1970s the concept 
of cytoreductive surgery (debulking) was introduced. A meta-analysis by Bristow 
showed that maximum cytoreduction is associated with an increase in survival.38 
The last decade, achieving an optimal debulking has become an important goal in 
therapy. Recently, the organization of EOC care has become an important issue. Both 
the surgeon performing the debulking surgery as well as the number of this type 
of surgeries performed per year and the type of hospital seem to affect survival of 
patients with EOC.39,40 In the Netherlands, where traditionally patients were staged 
and treated in the hospital of diagnosis, this knowledge has led to the introduction 
of so-called regionalized care for EOC patients. Although at present a gynaecologic 
oncologist nearly always assists in surgery of patients with EOC in general and semi-
specialized hospitals, still a minority of patients with EOC are indeed operated in 
referral hospitals.
 The main goal of all these therapeutical changes is of course improvement of 
survival. A previous population-based study in the Netherlands showed an improved 
prognosis in the period 1975 until 1985.41 International studies show an increased 
survival over the past decades. Generally this information is based on data obtained 
from trials and therefore not easily generalizable to the general population. In many 
studies details on therapy are lacking so the effect of changes in therapy on survival 
are unknown and often the population consists of ovarian cancer patients without 
respect for the subtypes of ovarian cancer which show very different survival rates. 
The aims of this nation-wide population-based study were to describe the trends in 
treatment and survival of advanced stage EOC patients during the period 1989 till 
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2009 and to study the possible effect of changes in therapy on the survival of EOC 
patients. 
mAtEriAl AND mEtHoDs
Data collection
Population-based data were used from the Netherlands Cancer Registry (NCR). 
The NCR, which reached full national coverage in 1989, is based on notification 
of all newly diagnosed malignancies in the Netherlands by the automated nation-
wide pathology archive (PALGA). An additional source is the national registry of 
hospital discharge diagnoses, which accounts for up to 8% of all cases. Information 
on patient characteristics like date of birth, and tumour characteristics such as date 
of diagnosis, topography (International Classification of Diseases for Oncology 
(ICD-O-3)42), histology, TNM stage (Tumour Lymph Node Metastasis classification43) 
and FIGO stage,44 grade, and primary treatment, are obtained from the medical 
records. The quality of the data is high, due to thorough training of the dedicated 
registrars and computerized consistency checks. Completeness is estimated to be 
at least 95%.45 The information on vital status and date of death before January 
1, 2010 was obtained from the municipal demography registries and from 1995 
onwards from the nationwide population registries network. These registries 
provide virtually complete coverage of all Dutch citizens.
 For the present study, all cases with epithelial ovarian cancer (C56, morphology 
code 8000, 8010-8013, 8020-8033, 8041-8231, 8255-8574 and 9000) diagnosed 
in the period 1989-2009 in the Netherlands were selected (n=23,399). This covers 
common histological types like serous, mucinous and endometrioid carcinoma, as 
well as adenocarcinoma not otherwise specified (NOS), mixed types, rare carcinomas 
(including clear cell carcinoma). All advanced stage patients, defined by FIGO stage 
2b or higher were included in the analyses of treatment and survival (n=15,892). The 
tumour stage was based on postoperative findings, except when no operation had 
been performed, in which case clinical stage was used. Patients were divided in two 
age groups for treatment analysis (<75 and ≥75 years) and in four age groups for 
survival analyses (<44, 45-59, 60-74, and ≥75 years). The study period was divided into 
four categories: 1989-1993, 1994-1998, 1999-2003, and 2004-2009. Debulking data 
were available from 1995 till 2009 for four of the eight regional cancer registries 
Trends in therapy and survival in ovarian cancer | 167
4.2
contributing to the NCR which are representative for the whole of the Netherlands. 
Optimal surgery was defined as a debulking surgery with residual tumour lesions 
smaller than 1 cm in maximum diameter. Patients younger than 15 years of age 
(n=4) and older than 95 years of age (n=28) were excluded from survival analyses, as 
well as all cases diagnosed by autopsy only (n=76).
statistical analyses
Treatment was described as percentages per age group and calendar period. 
Differences in treatment over time were tested by the Cochran-Armitage trend test. 
Follow-up of vital status of all patients was calculated as the time from diagnosis to 
death or to the censuring date of January 1, 2010. Relative survival was calculated 
as an estimation of disease-specific survival. It reflects survival of cancer patients, 
adjusted for survival in the general population with the same structure for age and 
gender. Relative survival is calculated as the ratio of the observed survival among 
cancer patients to the expected survival of the general population.19 For the period 
1989-2003 cohort-based survival analysis was used. For the period 2004-2009 period-
based survival analysis was conducted, in order to better capture recent survival 
experience.20 Survival trends were quantified as the mean annual percentage change 
within 1989-2009 estimated by a linear regression model. Survival trends were 
evaluated by a linear regression model and p<0.05 was considered as statistically 
significant.
 Multivariable relative survival analyses, using Poisson regression modeling,46 
were performed to estimate relative excess risk (RER) of dying for the periods of 
diagnosis. The variables period, age, stage and histology were included in the 
model. The two treatment variables were added to investigate the effect of therapy 
on the RER of period of diagnosis. The first variable was Surgery with chemotherapy 
(yes versus no) which was registered in all cancer registries. The second treatment 
variable, registered in four registries was (Optimal) Surgery with Chemotherapy 
and it was categorized in four groups: No surgery with chemotherapy, Yes but no 
optimal surgery, Yes but optimal surgery unknown and Yes and optimal surgery. 
Analyses were performed using SAS (SAS system 9.2, SAS Institute, Cary, NC).
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rEsults
A total of 23,399 patients were diagnosed with epithelial ovarian cancer in the 
Netherlands during the period 1989-2009. Median age at diagnosis of the patients 
was stable at 65 years during this period. The majority (68%) of the patients were 
diagnosed in an advanced stage (n=15,892) while 5,893 patients were diagnosed in 
early stages of disease (table 4.2.1). An increasing number of serous carcinomas was 
found with a simultaneously decreasing number of adenocarcinomas NOS. 
table 4.2.1 | Characteristics of all epithelial ovarian cancer patients diagnosed between 1989 
and 2009 in the Netherlands by period of diagnosis (n=23,399)
Period of diagnosis n (%)
1989-1993 1994-1998 1999-2003 2004-2009 total period
Age (years)
 <44 653 (11.4) 514 (8.8) 425 (7.9) 451 (7.1) 2,043 (8.7)
 45-59 1,567 (27.3) 1,626 (27.8) 1,642 (30.4) 1,870 (29.2) 6,706 (28.7)
 60-74 2,287 (39.8) 2,248 (38.4) 2,004 (37.1) 2,419 (37.8) 8,958 (38.3)
 ≥75 1,243 (21.6) 1,463 (25.0) 1,332 (24.6) 1,656 (25.9) 5,692 (24.3)
Figo stage
 I 1,415 (24.6) 1,430 (24.4) 1,302 (24.1) 1,403 (21.9) 5,550 (23.7)
 II A 84 (1.5) 96 (1.6) 68 (1.3) 95 (1.5) 343 (1.5)
 IIB/IIC 433 (7.5) 360 (6.2) 365 (6.8) 433 (6.8) 1,591 (6.8)
 III 2,470 (43.0) 2,591 (44.3) 2,431(45.0) 2,735 (42.8) 10,227 (43.7)
 IV 976 (17.0) 876 (15.0) 862 (16.0) 1,360 (21.3) 4,074 (17.4)
 unknown 372 (6.5) 498 (8.5) 374 (6.9) 370 (5.8) 1,614 (6.9)
Histology
 Serous 1,565 (27.2) 1844 (31.5) 2,061 (38.2) 2,966 (46.4) 8,436 (36.1)
 Mucinous 848 (14.7) 794 (13.6) 592 (11.0) 552 (8.6) 2,786 (11.9)
 Endometrioid 525 (9.1) 576 (9.8) 570 (10.6) 693 (10.8) 2,364 (10.1)
 Adeno NOS§ 2,415 (42.0) 2,078 (35.5) 1,609 (29.8) 1,478 (23.1) 7.580 (32.4)
 Other 397 (6.9) 559 (9.6) 570 (10.6) 707 (11.1) 2,233 (9.5)
total 5,750 5,851 5,402 6,396 23,399
§ Adenocarcinoma not otherwise specified 
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trends in treatment in advanced stage disease
For patients with advanced stage disease the optimal management consists of a 
combination of debulking surgery and chemotherapy. An increasing number of 
patients received this combination, both in the younger (<75 years) and in elderly 
group (>75 years), with percentages rising from 63% in 1989-1993 to 82% in 2004-
2009 and 23% to 34%, respectively (table 4.2.2). This increase in the proportion 
of patients receiving a combination of therapy occurred simultaneously with a 
decreasing proportion of patients receiving chemotherapy alone, from 22% to 10% 
in the group under the age of 75 and from 30% to 21% in the elderly group. Also the 
percentage of patients receiving only surgery (though occasionally combined with 
hormonal therapy) showed a small decrease in both age groups. The proportion of 
patients receiving radiotherapy was negligible. In the younger patient group the 
proportion of patients receiving no therapy decreased. The only group that showed 
no change over time was the group of elderly not receiving any treatment. Nearly 
one third of the patients of 75 years or over received no therapy. A change was seen 
towards more optimal debulking procedures. This was true for the group of patients 
under 75 where the proportion of optimal debulking surgeries increased from 43% 
to 66% as well as for the elderly patients where the proportion increased from 17% 
to 24%. 
trends in survival
Overall survival rates of EOC patients increased during the period 1989 and 2009 
but figures differ between early stage (Figure 4.21A) and advanced stage disease 
(Figure 4.2.1B). Women with stage I or IIa disease showed a stable 5-, and 10-year 
survival rate (table 4.2.3). In advanced stage disease 1-, 3-, 5- and 10-year relative 
survival showed a significant increase. The 5-year survival increased between the 
period 1989-1993 and 2004-2009 from 19% to 28% (Figure 4.2.1B). As for the age of 
the patients, 5-year survival increased in the age groups 45-59 and 60-74, while in 
the age group above 74 years survival remained stable (table 4.2.3).
multivariable relative excess risk 
The multivariable model for patients with an advanced stage of ovarian cancer 
without treatment included in the model showed improvements in survival over 
time, a lower survival for patients with more advanced stage of disease and a lower 
survival with increasing age (table 4.2.4). 
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table 4.2.2 | Treatment of advanced stage EOC patients by period of diagnosis and age at 
diagnosis (n=15,892)
treatment 
Age
1989-1993 n (%) 1994-1998 n (%) 1999-2003 n (%) 2004-2009 n (%) p-valuea
surgery and chemotherapy 
<75 
≥75
1881
203
(62.8)
(22.9)
1999
239
(70.4)
(24.2)
2162
284
(78.5)
(31.3)
2680
429
(81.7)
(34.4)
<.001
<.001
surgery alone
<75
≥75
220
116
(7.3)
(13.1)
208
186
(7.3)
(18.8)
149
146
(5.4)
(16.1)
127
116
(3.9)
(9.3)
<.001
<.001
Chemotherapy alone
<75
≥75
660
268
(22.0)
(30.3)
431
224
(15.2)
(22.7)
286
192
(10.4)
(21.2)
317
256
(9.7)
(20.5)
<.001
<.001
radiotherapy 
 <75 
≥75
42
12
(1.4)
(1.4)
13
3
(0.5)
(0.3)
12
3
(0.4)
(0.3)
12
2
(0.4)
(0.3)
<.001
.01
No therapy
<75 
≥75
165
244
(5.5)
(27.6)
159
273
(5.6)
(27.7)
121
224
(4.4)
(24.7)
122
374
(3.7)
(30.0)
<.001
.15
optimal Debulkingb
<75
≥75
-
-
-
-
417
51
(43.0)
(16.7)
558
94
(57.2)
(25.6)
779
118
(66.2)
(23.7)
<.001
.02
a Cochrane-Armitage trend test; b Definition of optimal debulking: tumour residuals after surgery smaller than 1 cm. 
Data on optimal debulking are available from 1995 from four regional cancer registries
Addition of the treatment variable Surgery with chemotherapy (yes versus no) to 
the model attenuated the relative excess risk during the study period, e.g. for 2004-
2009 the relative excess risks changed from 0.71 (95% CI 0.67-0.75) to 0.85 (95% CI 
0.80-0.90). This suggests that improvements in survival probabilities over time were 
partially due to changes in therapy. Patients who did receive surgery combined with 
chemotherapy had a better survival compared to patients who did not (RER 0.36; 
95% CI 0.34-0.37). 
 The multivariable model for advanced stage patients in four regional cancer 
registry areas which had information on debulking, including the variable (Optimal) 
Surgery with chemotherapy is shown in the last two columns of table 4.2.4. Addition 
of the variable showed a change in the RER for calendar period 2004-2009 from 0.78 
(95% CI 0.71- 0.85) to 0.91 (95% CI 0.83 - 0.99). Patients who underwent surgery and 
chemotherapy but with a non-optimal result had a better survival compared with 
patients who did not undergo surgery (RER 0.35; 95% CI 0.31-0.39) while patients 
with an optimal result of their debulking surgery had the best survival (RER 0.26; 
95% 0.23-0.28). 
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Figure 4.2.1 | Relative survival (1, 3, 5 and 10 years) for EOC patients in early stage of disease 
(A) and advanced stage of disease (B) by period of diagnosis. For the period 1989-2003 cohort 
analysis was used and for the period 2004-2009 period analysis was conducted. Survival trends 
were evaluated by a linear regression model.
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table 4.2.3 | The 5-year relative survival (SE) in EOC patients by period of diagnosis, age and 
stage of disease 
1989-1993 1994-1998 1999-2003 2004-2009a p Annual trend
stage
 I 82.9 (1.2) 82.6 (1.2) 82.6 (1.3) 84.1 (1.1) .89
 IIA 60.7 (5.9) 67.2 (5.6) 64.9 (6.4) 69.0 (5.8) .07
 IIB/C 43.4 (2.6) 51.0 (2.9) 56.7 (2.8) 63.3 (2.6) <.001
 III 17.9 (0.8) 20.7 (0.8) 26.8 (1.0) 28.6 (0.9) <.001
 IV 6.1 (0.8) 6.6 (0.9) 13.2 (1.2) 14.1 (1.1) <.001
Age at diagnosis
 <45 years 64.4 (1.9) 67.4 (2.1) 64.4 (2.3) 63.6 (2.3) .06
 45-59 44.4 (1.3) 48.0 (1.3) 52.3 (1.3) 53.6 (1.2) <.001
 60-74 27.7 (1.0) 32.4 (1.1) 37.0 (1.1) 39.1 (1.1) <.001
 ≥ 75 18.0 (1.4) 14.8 (1.2) 19.1 (1.3) 20.5 (1.3) .20
Histology
 Serous
 Mucinous
 Endometrioid
 Adeno NOS
 Other
37.3 (1.3)
58.1 (1.8)
52.8 (2.4)
19.3 (0.9)
43.0 (2.7)
36.8 (1.2)
56.7 (1.9)
59.7 (2.2)
20.8 (1.0)
34.8 (2.2)
37.6 (1.1)
62.4 (2.2)
67.7 (2.2)
24.6 (1.2)
39.4 (2.2)
38.5 (1.0)
64.1 (2.1)
69.9 (2.0)
21.4 (1.1)
42.2 (2.1)
.70
.02
<.001
.09
.84
total 34.7 (0.7) 36.0 (0.7) 40.0 (0.7) 41.1 (0.7) <.001
a The survival rates of this period were based on period analysis.
table 4.2.4 | Relative excess risk (RER) of dying for advanced stage EOC patients in the 
Netherlands including the treatment variable Surgery with chemotherapy and for patients 
in four cancer registry regions including the treatment variable (Optimal) Surgery with 
chemotherapya 
multivariate model for the  
Netherlands without treatment /  
with treatment variable
multivariate model for four regions
without treatment / with treatment 
variable
rEr 95%Ci rEr 95%Ci rEr 95%Ci rEr 95%Ci
Period
 1989-1993 1.00 Reference 1.00 Reference
 1994-1998 0.94 0.89-0.99 1.01 0.96-1.06 1.00 Reference 1.00 Reference
 1999-2003 0.75 0.71-0.80 0.88 0.83-0.92 0.77 0.71-0.84 0.89 0.82 – 0.98
 2004-2009 0.71 0.67-0.75 0.85 0.80-0.90 0.78 0.71-0.85 0.91 0.83 – 0.99
Age    
 <44 0.63 0.58-0.69 0.69 0.63-0.75 0.65 0.54-0.78 0.64 0.53 – 0.77
 45-59 0.71 0.67-0.74 0.80 0.76-0.84 0.69 0.63-0.76 0.81 0.74 – 0.89
 60-74 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
 ≥75 2.11 2.01-2.11 1.60 1.52-1.68 2.25 2.06-2.46 1.53 1.39 – 1.68
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table 4.2.4 | Continued
multivariate model for the  
Netherlands without treatment /  
with treatment variable
multivariate model for four regions
without treatment / with treatment 
variable
rEr 95%Ci rEr 95%Ci rEr 95%Ci rEr 95%Ci
stage
 IIB-C 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
 III 2.39 2.19-2.60 2.37 2.18-2.58 2.41 2.03-2.86 2.46 2.07 – 2.91
 IV 3.97 3.62-4.34 3.37 3.08-3.69 3.94 3.29-4.72 3.46 2.89 – 4.14
Histology
 Serous 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
 Mucinous 1.76 1.63-1.90 1.54 1.49-1.60 1.86 1.61-2.15 1.54 1.33 – 1.78
 Endometrioid 0.93 0.85-1.01 0.92 0.88-0.96 0.90 0.76-1.06 0.91 0.77 – 1.07
 Adenocarcinoma NOSb 1.62 1.55-1.69 1.32 1.27-1.37 1.74 1.61-1.90 1.40 1.29 – 1.53
 Other 1.76 1.61-1.93 1.58 1.51-1.66 1.94 1.63-2.31 1.62 1.36 – 1.93
surgery with chemotherapy
 No 1.00 Reference
 Yes 0.36 0.34-0.37
(optimal) surgery with Chemotherapy
 No 1.00 Reference
 Yes, suboptimal surgery 0.35 0.31-0.39
 Yes, optimal unknown 0.30 0.25-0.35
 Yes, optimal surgery 0.26 0.23-0.28
a Optimal surgery is defined as a debulking surgery with residual tumour lesions smaller than one cm in maximum 
diameter. b Adenocarcinoma not otherwise specified
DisCussioN
This nationwide study of therapy and survival in advanced stage epithelial ovarian 
cancer supports the notion that the cornerstone of treatment consists of surgery 
combined with (neo) adjuvant chemotherapy. This combination has been applied 
in an increasing proportion of the Dutch EOC patients. Treatment options other 
than surgery and/or chemotherapy are rarely applied in EOC patients. Also elderly 
patients are more often treated in accordance with the (internationally) advised 
regimen, though still about 30% of the older patients with advanced stage of 
disease receive no treatment at all. The multivariable analyses demonstrate that 
changes in treatment partially led to improvement of survival. However, 10-year 
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survival figures for all stages show a small increase only from 29 to 31% despite all 
the efforts made with respect to therapeutic improvements. 
 All published studies on survival of ovarian cancer patients show an improvement 
over time. In the Supplemental Table S1 an overview is provided of population-based 
studies presenting series diagnosed since 1990 in high incidence countries.26,47-58 
Within Europe survival figures are fairly similar.26 Differences in survival may be the 
result of different data sources used, e.g., in the study by Engel et al.51 a hospital-
based instead of population-based series was presented. Also the inclusion (as in 
most studies) or exclusion of non-epithelial ovarian cancer patients will influence 
survival. One Dutch population-based study on the prognosis of ovarian cancer 
patients was published before but it included non-epithelial cancer patients also.41 
Accordingly, survival data cannot be compared with our data. Both studies however 
show an improvement in 5-year survival figures. 
 Changes in chemotherapeutics over the years have improved survival. As early 
as the 1980s cisplatin-based combination therapy was found to be more effective 
than alkylating agents only.59,60 Later on cisplatin was replaced by carboplatin 
because of less toxicity and better quality of life in EOC patients.61 The introduction 
of taxanes again showed an improvement in survival in ovarian cancer patients.62 
The internationally recommended chemotherapy regimen as well as the first choice 
chemotherapy in the Dutch Guideline for EOC patients is now carboplatin plus 
paclitaxel.63 Unfortunately the National Cancer Registry has no detailed data on 
agents, number of courses, doses or if it was adjuvant or neoadjuvant chemotherapy 
that was given in order to verify compliance with this guideline. 
 Since 1995 detailed data on surgical therapy are registered in four regions of 
the NCR. The data on the debulking result show an increase in the proportion of 
optimal debulking surgeries with tumour residuals smaller than one cm in largest 
diameter. The multivariable analysis showed that survival improvement was 
partially explained by this increase in optimal debulking surgeries. Internationally, 
the emphasis with respect to debulking surgery is on complete debulking with 
no visible tumour residuals. Unfortunately, these data were not registered. An 
increasing number of interval debulkings may result in more optimal surgery results, 
but data on the type of surgery (primary or interval debulking surgery) were also 
not available. 
 In The Netherlands, the care of cancer patients is increasingly organized 
regionally. Regionalised care for EOC patients was introduced in the late 1990s in 
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most regions in the Netherlands and at present is adopted nation-wide. By now, 
most EOC patients are operated by a registrered gynaecologic oncologist, either 
in a central oncology centre or in the referral hospital. Surgical care provided by 
gynaecologic oncologists also leads to improvement of survival.39,64 
 Not only direct improvements in treatment such as complete debulking but 
also improvements in staging procedures can indirectly result in a better prognosis. 
Staging procedures were not registered in the NCR in the majority of cases but since 
both the 2004 and 2009 Dutch guideline emphasize the importance of a complete 
staging procedure this may probably have led to an improvement in staging. Also, 
in the nation-wide data an increasing number of lymph node and distant metastases 
were recorded over time in T1 and T2 tumours suggesting more extended application 
of staging procedures. Stage migration therefore, may play a role in improved 
survival estimates per stage, known as the Will Rogers phenomenon, but it cannot 
explain overall improvement of survival.65
 Besides improvements in therapy, there may be additional factors influencing 
the improved survival. Earlier diagnosis can lead to improvement of survival, both 
artificially (lead time bias) and through earlier effective intervention. To date, there 
is no reliable method of screening that can detect early stage ovarian cancer. So far 
studies demonstrated that both CA125 measurements66-68 as well as (a combination 
with) ultrasonography68,69 seem ineffective for detecting ovarian cancer at an 
earlier stage. Even in high risk populations screening appeared ineffective.70 Only 
prophylactic bilateral salpingo-oophorectomy (BSO) has shown to be effective in 
the prevention of ovarian cancer in high risk populations.71 Prophylactic surgery 
may have an effect on survival when prevalent (mostly early stage) but so far 
undiagnosed cases are operated. In the two decades that are covered by our study 
the number of prophylactic BSOs that were performed may have increased but the 
expected effect on survival is very small
 Changes in the histological pattern of EOC could explain changes in survival. 
During the study period a shift from adenocarcinomas NOS to serous carcinomas 
was found. Serous carcinomas had an 17 percent-point better 5-year survival than 
adenocarcinomas NOS in 2004-09. Patients with adenocarcinoma NOS are older and 
have more often an advanced stage of disease. This histological shift is probably the 
result of improved diagnostics and more surgical procedures in the elderly patient 
with advanced stage of disease. Furthermore, the proportion of endometrioid 
carcinomas increased and the proportion mucinous carcinomas decreased. Survival 
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increased in both histology groups and the shifts in these groups have probably not 
materially influenced overall survival.
 Other factors that may have an impact on survival are age, co-morbidity and 
performance status because these may influence the choice of treatment. Data on 
age as independent prognostic factor are conflicting.72,73 A retrospective population-
based study in the Netherlands showed that the majority of the EOC stage II and 
III patients with age above 70 years did not receive the standard treatment.74 
Moreover, both age and co-morbidity were independent predictors of receiving 
the advised treatment. Age also had a prognostic effect in multivariable analyses 
unlike co-morbidity. A trend was shown in prescribing the advised treatment more 
often. We demonstrate the same trend over the last 20 years in both age groups, 
but survival has mainly improved in the age group of 45-74 years. Unfortunately, 
information on co-morbidity and performance status is not available. Therefore, we 
are not able to explain why nearly one third of the patients above 75 years did not 
receive any treatment or what the relation is between these factors and survival. 
 The study was limited by the lack of information on chemotherapy schedules, 
comorbidity and interval debulking surgery. Another limitation of this study is the 
use of two different methods to calculate 5-year relative survival. Although the 
results from period-based analysis can differ slightly from cohort-based results, it 
has been repeatedly shown that the period based results come very close to the later 
obtained cohort-based results. A difference between two calendar periods based on 
the two different methods likely points to a change in prognosis.75 
CoNClusioN
Changes in therapy over the last 20 years in the Netherlands have contributed to 
the improved 5-year survival of advanced stage epithelial ovarian cancer patients. 
The poor 5-year survival of 41% in the last calendar period, however, urges further 
improvements of cancer care in EOC patients. 
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table s1. | Published population-based studies on survival in epithelial ovarian cancer (EOC) or 
ovarian cancer (OC) diagnosed since 1990 in high incidence areas
reference (Period) Number of 
patients
region tumor Change in 5-year 
relative survival
Bjorge et al.47 (1954-1993) 14,160 Norway EOC 0.30 to 0.35
Klint et al.48 (1964-2003) unknown Denmark
Finland
Iceland
Norway
Sweden
OC 0.20 to 0.33
0.25 to 0.44
0.18 to 0.34
0.31 to 0.41
0.28 to 0.43
Barnholtz-Sloan et al.49 (1973-1997) 32,845 SEER USAa EOC 0.37 to 0.43
Brenner et al.50 (1976-1995) 2,124 Germany (Saarland) OC 0.29 to 0.39
Engel et al.51 (1978-1997) 3,750 Germany (Munich area)b OC 0.43 to 0.49
Minelli et al.52 (1978-1982) unknown Italy (Umbria) OC 0.33 to 0.41
Hannibal et al.53 (1978-2002) 13,035 Denmark OC 0.22 to 0.33
Laurvick et al.54 (1978-2002) 1,336 Western Australia OC 0.32 to 0.36c
Chan et al.55 (1988-2001) 26,670 SEER USA EOCd 0.42 to 0.46c
Karim-Kos et al.26 (1990-2002) unknown Europe (10 countries) OC 0.37 to 0.42
Akhtar-Danesh et al.56 (1992-2005) 7,771 Canada EOC 0.49 to 0.53
Chirlaque et al.57 (1995-1999) 1,649 Spain (8 regions) OC 0.43
Coleman et al.58 (1995-2007) unknown Australian registries 
Canadian registries Norway
Denmark
UK registries
OC 0.36 to 0.38
0.38 to 0.42
0.37 to 0.40
0.32 to 0.36
0.33 to 0.36
Van Altena et al. (1989-2009) 23,399 Netherlands EOC 0.35 to 0.41
a SEER Surveillance Epidemiology and End Results; b Population gathered via hospital registry system; c from Kaplan-
Meier survival figure; d EOC without clear cell
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ABstrACt
Background. Consultant gynecologic oncologists from the regional Comprehensive 
Cancer Center assisted community gynecologists in the surgical treatment of 
patients with ovarian carcinoma when they were invited. For this report, the authors 
evaluated the effects of primary surgery by a gynecologic oncologist on treatment 
outcome.
methods. The hospital files from 680 patients with epithelial ovarian carcinoma who 
were diagnosed between 1994 and 1997 in the northern part of the Netherlands 
were abstracted. Treatment results were analyzed according to the operating 
physician’s education by using survival curves and univariate and multivariate Cox 
regression analyses.
results. Primary surgery was performed on 184 patients by gynecologic oncologists, 
and on 328 patients by general gynecologists. Gynecologic oncologists followed 
surgical guidelines more strictly compared with general gynecologists (patients with 
International Federation of Gynecology and Obstetrics (FIGO) Stage I–II disease, 
55% vs. 33% (P=0.01); patients with FIGO Stage III disease, 60% vs. 40% (P=0.003)) 
and more often removed all macroscopic tumor in patients with FIGO Stage III 
disease (24% vs. 12%; P=0.02). When patients were stratified according to FIGO 
stage, the 5-year overall survival rate was 86% versus 70% (P=0.03) for patients with 
Stage I-II disease and 21% versus 13% (P=0.02) for patients with Stage III-IV disease 
who underwent surgery by gynecologic oncologists and general gynecologists, 
respectively. The hazards ratio for patients who underwent surgery by gynecologic 
oncologists was 0.79 (95% confidence interval (95%CI), 0.61–1.03; adjusted for 
patient age, disease stage, type of hospital, and chemotherapy); when patients age 
75 years and older were excluded, the hazards ratio fell to 0.71 (95%CI, 0.54–0.94) 
in multivariate analysis.
Conclusions. The surgical treatment of patients with ovarian carcinoma by 
gynecologic oncologists occurred more often according to surgical guidelines, tumor 
removal more often was complete, and survival was improved.
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iNtroDuCtioN
Patients with ovarian carcinoma have the worst prognosis of all patients with 
gynecologic malignancies. Their overall 5-year survival rate approximates 40%, 
mainly due to the large proportion of patients who present with advanced disease. 
The life-time risk of developing ovarian carcinoma is 1 in 75.76 In the Netherlands, 
with a population of 17 million, there are 1100 newly diagnosed patients each 
year, for an average of 1-2 new patients per year for every gynecologist. The 
treatment of ovarian carcinoma is multidisciplinary in nature. Chemotherapy has 
had a major impact on survival and, currently, most patients receive platinum-
containing combinations.77 Over a decade ago, when not all patients received 
platinum-containing chemotherapy, the effect of cytoreductive surgery on survival 
was considered minor compared with the impact of platinum.78 Currently, however, 
with virtually all patients with advanced stage disease receiving platinum, optimal 
cytoreduction is considered an important tool to improve survival.38
 Surgery is important to determine the correct disease stage and to remove as 
much tumor as possible in patients.79-82 Several studies have shown that patients 
with ovarian carcinoma who underwent surgery by a gynecologist had better 
survival compared with patients who underwent surgery by a general surgeon.83-86 
Subsequently, it was suggested that surgery by a gynecologic oncologist would 
improve survival further.87,88 However, that hypothesis could not be confirmed in 
a large population-based study on differences in patterns of care of patients with 
ovarian carcinoma.84 In a more recent population-based study on the impact of 
surgery by a gynecologic oncologist compared with a general gynecologist, a survival 
benefit was found for patients with International Federation of Gynecology and 
Obstetrics (FIGO) Stage III disease.89 The results of that study cannot be generalized 
because patients with nonepithelial tumors also were included in the study 
population, and the effect of treatment in teaching hospitals was not addressed. 
However, because it also was found that gynecologic oncologists attained optimal 
cytoreduction more often compared with general gynecologists,90 it is expected that 
survival will be improved when surgery is performed by gynecologic oncologists.
 The Comprehensive Cancer Center North covers the northern part of the 
Netherlands, a mainly rural area with a population of approximately 2.1 million. 
Within our region, guidelines regarding the diagnosis and treatment for most 
malignancies have been developed and revised since the middle 1970s. The Working 
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Party on Gynecological Tumors, which includes gynecologists, medical oncologists, 
pathologists, and radiotherapists, believed that, especially in the smaller hospitals, 
which treated <10 patients with ovarian carcinoma per year, treatment results needed 
improvement. Since 1980, gynecologic oncologists at our regional university hospital 
regularly have assisted their fellow gynecologists in the community hospitals when 
performing surgery on patients with suspected ovarian carcinoma. The difference in 
patterns of care offered to patients with ovarian carcinoma in our region provides a 
perfect, natural, population-based experiment for studying the effect of surgery by 
a gynecologic oncologist on the quality of surgery and the outcome of patients. The 
results of this natural experiment are presented herein.
mAtEriAl AND mEtHoDs
The medical charts of 680 consecutive patients who were diagnosed with epithelial 
ovarian carcinoma between January 1994 and January 1998 in the northern part 
of the Netherlands were reviewed. Patients were identified from the Regional 
Cancer Registry of the Comprehensive Cancer Center North. Data were collected 
on a specifically designed case-report form by registry clerks of the Cancer Center. 
The case-report forms were monitored by one of the authors (M.J.A.E.). The data 
gathered from the inpatient and outpatient hospital files included comorbidity, 
for which an adapted Charlson score91 was used, the results from diagnostic tests, 
the surgery reports, the pathology reports, information on additional treatments 
(including chemotherapy and radiotherapy), and follow-up. Most attention was 
paid to the surgical procedures undertaken. Findings at inspection and palpation 
were noted along with which tissues and organs were removed, whether there was 
spill, residual tumor (size and location), the amount of blood loss, and complications.
regional guidelines
Guidelines on the diagnostic work-up, surgical and medical treatment, and follow-
up of patients with ovarian carcinoma are made and revised regularly by the 
regional Working Party on Gynecological Tumors. The surgical guidelines largely 
resemble FIGO guidelines.92 For statistical analysis in the current study, treatment 
according to surgical guidelines was defined as total abdominal hysterectomy and 
bilateral salpingo-oophorectomy,(partial) omentectomy, at least one lymph node 
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removed, and at least one peritoneal biopsy taken for patients with early-stage 
disease; and as total abdominal hysterectomy and bilateral salpingo-oophorectomy 
and (partial) omentectomy for patients with Stage III disease. When the uterus or 
one ovary already had been removed before the current procedure, removal of the 
remaining organs was considered guideline treatment. Patients with FIGO Stage IV 
disease were left out of the analyses concerning correct surgical staging because 
uniform surgical guidelines were lacking for Stage IV disease.
 The regional guidelines also advise on adjuvant treatment. In the first half 
of the study period, adjuvant chemotherapy (the first choice was six cycles of 
cyclophosphamide and carboplatin) was advised for all stages and grades of disease 
except for Stage IA, IB, and IIA well differentiated tumors in patients without 
residual tumor. Age older than 70 years and a creatinine clearance <60 mL/minute 
were regarded as contraindications, and the second choice (melphalan) was advised 
for those patients. In the second half of the study period, these contraindications 
were regarded as relative, and chemotherapy was advised for all stages except Stage 
IA and IB well differentiated tumors in patients without residual tumor. The first 
choice remained cyclophosphamide with carboplatin, and paclitaxel was introduced 
as second-line treatment.
statistical analysis
Differences between patients who underwent surgery by general gynecologists and 
patients who underwent surgery by gynecologic oncologists were assessed using 
the Kruskal-Wallis test for continuous variables and the chi-square test for categoric 
variables. The survival of patients who underwent surgery was calculated as the 
difference between date of first surgical procedure and either the date of death 
or the date of last patient contact for patients who did not die during follow-up. 
Because the exact dates of disease progression or recurrence were not scored in 
a standard manner, we choose overall survival as the only endpoint. Observed 
survival rates were estimated by using the Kaplan-Meier method. The log-rank test 
was used to assess differences in survival between patients who underwent surgery 
by a gynecologic oncologist and patients who underwent surgery by a general 
gynecologist, with the patients stratified into a group with early-stage disease (FIGO 
Stage I-II) and a group with late-stage disease (FIGO Stage III-IV). In multivariate 
analyses, a Cox proportional hazards model was used to assess the effect of the type 
of surgeon (gynecologic oncologist or general gynecologist) on survival adjusted 
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for prognostic variables, hospital of surgery, and chemotherapy. Variables entered 
the model as a confounder when β estimates of the type of surgeon changed by 
>10%. The proportional hazards assumption was confirmed by inspection of log 
(-log[survival]) curves and by examination of time-dependent covariates. P values 
<0.05 were considered significant. All analyses were conducted using SPSS software 
(version 11.0; SPSS Inc., Chicago. IL).
rEsults
Patients
Apart from the University Hospital, our region is comprised of 13 general hospitals 
and 3 teaching hospitals that participate in the training of medical specialists. The 
annual number of new patients with ovarian carcinoma in the different hospitals 
varies from 2 patients to 24 patients. The largest numbers (20-24 new patients per 
hospital annually) were treated in the 3 teaching hospitals. Gynecologists in these 
hospitals only incidentally will call for the assistance of their academic colleagues 
(8% of first procedures). The smaller nonteaching hospitals, which treat 2-11 new 
patients annually, used this service for 42% of first surgical procedures (range, 
0-76% of first procedures).
 The current study population consisted of all 680 patients who were diagnosed 
with epithelial ovarian carcinoma between January 1994 and January 1998 in the 
northern part of the Netherlands. Forty-eight patients were excluded; no data could 
be retraced in 9 patients, 9 patients were diagnosed at autopsy, 5 patients were 
treated outside of our region, the original diagnosis of primary ovarian carcinoma 
had changed in 11 patients (2 patients had borderline ovarian tumors, 2 patients 
had nonepithelial ovarian tumors, and 7 patients had tumors located in other 
primary sites), 12 patients were diagnosed concurrently with a second malignancy 
other than carcinoma of the endometrium or skin, and 2 patients were included 
twice in the database. Having a prior malignancy was no reason for exclusion from 
the study. Therefore, the study population was comprised of 632 patients.
 Thirty-four patients who had incomplete surgical staging procedures underwent 
a second surgical staging. In these patients, findings from the first surgery and the 
restaging procedure were combined and analyzed statistically as a single procedure. 
Those who underwent surgery by general surgeons (n=25 patients) for the most part 
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were patients with suspected colon carcinoma. In general, these patients were older 
and had a higher disease stage (FIGO Stage IV, 32%) compared with patients who 
underwent surgery by gynecologists. On univariate survival analysis, the patients 
who underwent surgery by a general surgeon had a hazards ratio of 3.70 (95% 
confidence interval (95% CI) 2.33-5.89) compared with patients who underwent 
surgery by a gynecologic oncologist. Because the patients who underwent surgery 
by a general surgeon were not comparable to the patients who underwent surgery 
by a gynecologist, and because we were interested in possible (dis)advantages of 
surgery by gynecologic oncologists compared with surgery by general gynecologists, 
the patients who underwent surgery by a general surgeon were excluded from 
further analyses along with two patients for whom the type of operating surgeon 
was unknown.
 Ninety-three of 632 patients (14.7%) did not undergo primary surgery. Six 
patients underwent intervention surgery after they received primary chemotherapy. 
The remaining 87 patients, who did not undergo surgery, had a median age of 81 
years (range, 42-93 yrs). Thirteen percent of patients were staged clinically with at 
least FIGO Stage I-II disease, 16% of patients had Stage III disease, 48% of patients 
had Stage IV disease, and the stage of disease was unknown in 23% of patients. 
No treatment was instituted in 56 patients. Reasons for withholding treatment 
were patient wishes, age, comorbidity, or a combination thereof in 39 patients; 
noneligible performance status in 12 patients; and unknown reasons in 5 patients. 
 The characteristics of 512 patients who underwent primary surgery by a 
gynecologist are summarized in table 4.3.1, which shows that patients who 
underwent surgery by a gynecologic oncologist were younger and more often 
underwent surgery in a nonteaching hospital (by a visiting gynecologic oncologist) 
compared with patients who underwent surgery by a general gynecologist. 
Among the patients who were treated by a gynecologic oncologist, 85% received 
chemotherapy, when indicated, which contained a platinum compound in 91% of 
patients. In the patients who were treated by a general gynecologist, 75% of patients 
received chemotherapy, if indicated, which contained a platinum compound in 81% 
of patients. The percentages of patients who received chemotherapy if indicated 
and the percentages of patients who received a platinum compound differed 
(P=0.01) between gynecologic oncologists and general gynecologists. In only 5% 
of 512 patients, chemotherapy was not indicated, because those patients were 
diagnosed with well differentiated Stage IA or IB disease.
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table 4.3.1 | Characteristics of patients with ovarian carcinoma who underwent primary 
surgical procedures
general gynecologist gynecologic oncologist
No. of patients % No. of patients % P value
Age
 Median (yrs) 65 60 0.002
 Range (yrs) 16-92 25-87
 <40 14 4.2 14 7.6 0.01
 40-49 53 16.2 33 17.9
 50-59 70 21.3 41 22.3
 60-69 73 22.3 55 29.9
 70-79 85 25.9 36 19.6
 ≥ 80 33 10.1 5 2.7
Figo stage 
 I 97 29.6 48 26.1 0.17
 II 38 11.6 17 9.2
 III 142 43.3 98 53.3
 IV 51 15.5 21 11.4
tumor grade 
 1 53 16.2 31 16.8 0.93
 2 81 24.7 44 23.9
 3-4 132 40.2 78 42.2
 Unknown 62 18.9 31 16.8
Histology
 Serous 179 54.6 84 45.7 0.003
 Mucinous 31 9.5 33 17.9
 Endometroid 21 6.4 23 12.5
 Clear cell 20 6.1 13 7.1
 Adenocarcinoma NOS / 
 unclassified
77 23.5 31 16.8
Preoperative CA 125
 ≤35 U/mL 50 15.2 27 14.7 0.02
 >35 U/mL 234 71.3 147 79.9
 Unknown 44 13.4 16 5.4
Comorbidity
 No 228 69.5 135 73.4 0.36
 Yes 100 30.5 49 26.6
Ascites
 Absent 97 29.6 48 26.1 0.21
 Present 211 64.3 130 70.7
 Unknown 20 6.1 6 3.3
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table 4.3.1 Continued
general gynecologist gynecologic oncologist
No. of patients % No. of patients % P value
Hospital of surgery
 Teaching 184 56.1 64 34.8 <0.001
 Nonteaching 144 43.9 120 65.2
Chemotherapy 
 No 95 29.0 33 17.9 <0.001
 Yes, platina 188 57.3 138 75.0
 Yes, no platina 45 13.7 13 7.1
total no. patients 328 184 
FIGO International Federation of Gynecology and Obstetrics; NOS not otherwise specified.
surgery
In table 4.3.2, the details of the surgical staging and debulking procedures are 
shown for patients with FIGO Stage I-III ovarian carcinoma. In patients with Stage 
I/II disease, (partial) omentectomy and lymph node sampling or lymphadenectomy 
were performed more often by gynecologic oncologists compared with general 
gynecologists (P<0.001 for both). In patients with FIGO Stage III disease, more 
patients underwent complete debulking surgery by gynecologic oncologists (24% 
vs. 12%; P=0.02). Furthermore, 62% of patients with FIGO Stage III disease who 
underwent surgery by a gynecologic oncologist were left with residual tumor masses 
that measured <2 cm in greatest dimension compared with 45% of patients who 
underwent surgery by general gynecologists (P=0.05). The amount of residual tumor 
in patients with FIGO Stage III disease had a major impact on survival, with 5-year 
survival rates of 54% for patients with no residual disease, 15% for patients who 
had residual disease masses that measured < 2cm in greatest dimension, and 6% 
for patients who had more residual disease (P<0.001). In all disease stages, patients 
more often received surgical treatment according to prevailing surgical guidelines 
when they underwent surgery by a gynecologic oncologist (patients with FIGO Stage 
I-II disease, P=0.01; patients with FIGO Stage III disease, P=0.003; chi-square test). 
The risk of dying for patients who did not undergo surgery according to surgical 
guidelines was almost twice the risk for patients who underwent surgery according 
to the guidelines. For patients with FIGO Stage I-II disease, the 5-year survival rate 
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was 84% when guidelines were followed and 73% when guidelines were not 
followed (hazards ratio 1.95; 95% CI 0.82-4.63 (P=0.13)); for patients with FIGO 
Stage III disease, the 5-year survival rates were 32% and 11%, respectively (hazards 
ratio 1.97; 95% CI 1.45-2.68 (P<0.001)). The survival advantage for patients who 
underwent surgery according to the guidelines remained nearly unchanged in an 
exploratory multivariate analysis that compared the survival of these patients with 
the survival of patients in whom surgical guidelines were not followed (adjusted for 
patient age, disease stage, and chemotherapy; hazards ratio 1.79; 95% CI 1.33-2.41 
(P<0.001)).
table 4.3.2 | Surgical procedures undergone by 440 patients with International FIGO Stage I, 
II, and III ovarian carcinoma
Figo stage i-ii Figo stage iii
general 
gynecologist
gynecologic 
oncologist
general
gynecologist
gynecologic
oncologist
surgical procedure No. % No. % P value No. % No. % P value
salpingo-oophorectomy
 No 1 0.7 - - 0.45 32 22.5 13 13.3 0.13
 Unilateral 20 14.8 4 6.2 16 11.3 6 6.1
 Bilateral 16 11.9 9 13.8 28 19.7 18 18.4
 Bilateral with hysterectomy 96 71.1 51 78.5 61 43.0 56 57.1
 Unknown 2 1.5 1 1.5
omentectomy 
 No 46 34.1 5 7.7 <0.001 23 16.2 2 2.0 0.002
 Total/partial 89 65.9 58 89.2 116 81.7 93 94.9
 Unknown - - 2 3.1 3 2.1 3 3.1
Biopsy
 None 33 24.4 3 4.6 <0.001
 ≥1 59 43.7 48 73.8
 Unknown 43 31.9 14 21.5
Pelvic and/or paraaortic lymph node 
sampling/lymphadenectomy
 No 90 66.7 25 38.5 <0.001
 Yes 41 30.4 40 61.5
 Unknown 4 3.0 - -
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table 4.3.2 | Continued
Figo stage i-ii Figo stage iii
general 
gynecologist
gynecologic 
oncologist
general
gynecologist
gynecologic
oncologist
surgical procedure No. % No. % P value No. % No. % P value
Postoperative residual tumor
 No macroscopic 113 83.7 60 92.3 0.50 15 10.6 22 22.4 0.09a
 <2 cm 6 4.4 2 3.1 22 15.5 18 18.4
 >2 cm 2 1.5 - - 45 31.7 25 25.5
 Size unknown 3 2.2 1 1.5 43 30.3 26 26.5
 Unknown 11 8.1 2 3.1 17 12.0 7 7.1
Postoperative complications
 None 125 92.6 54 83.1 0.04 114 80.3 82 83.7 0.61
 ≥1 10 7.4 11 16.9 28 19.7 16 16.3
Peri-operative death
 No 135 100.0 65 100.0 - 137 96.5 97 99.0 0.41
 Yes - - - - 5 3.5 1 1.0
surgical guidelines
 Not followed 61 45.2 23 35.4 0.01b 81 57.0 36 36.7 0.01b
 Followed 30 22.2 28 43.1 53 37.3 55 56.1
 Unknown 44 32.6 14 21.5 8 5.6 7 7.1
total no. of patients 135 65 142 98
FIGO International Federation of Gynecology and Obstetrics; a P =0.02, residual tumor mass versus no residual tumor 
mass (unknown not included); P =0.05, residual tumor mass <2 cm versus residual tumor mass >2 cm (unknown size not 
included); b P=0.01 for International Federation of Gynecology and Obstetrics (FIGO) Stage I–II ovarian carcinoma and 
P=0.003 for FIGO Stage III ovarian carcinoma (unknown not included).
survival 
Figure 4.3.1 shows that the 5-year survival rate for patients who had FIGO Stage 
I-II ovarian carcinoma was 86% when surgery was performed by a gynecologic 
oncologist and 70% when surgery was performed by a general gynecologist (P-=0.03). 
For patients who had FIGO Stage III–IV disease, the 5-year survival rates were 21% 
(median survival, 23 mos) and 13% (median survival, 15 mos) (P=0.02), respectively 
(Figure 4.3.2). In univariate analysis, age, FIGO stage, tumor grade, mucinous or 
endometrioid histotype, the presence of ascites, an elevated serum CA 125 level, 
comorbidity, and residual tumor all were found to be significant prognostic factors 
in the study population, as shown in table 4.3.3.
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Figure 4.3.1 | Crude overall 5-year survival in patients with International Federation of 
Gynecology and Obstetrics Stage I-II ovarian carcinoma who underwent surgery performed by 
gynecologic oncologists and surgery performed by general gynecologists.
Figure 4.3.2 | Crude overall 5-year survival in patients with International Federation of 
Gynecology and Obstetrics Stage III-IV ovarian carcinoma who underwent surgery performed 
by gynecologic oncologists and surgery performed by general gynecologists.
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table 4.3.3 | Univariate Cox Proportional Hazards analysis of patients who underwent a 
primary surgical procedures 
Variable No. of patients No. of deaths Hr 95% Ci P value
surgeon
 General gynecologist 183 194 1.00 0.11
 Gynecologic oncologist 326 98 0.82 0.64-1.05
Patient age
 <50 114 39 1.00 <0.001
 50-59 109 61 1.81 1.21-2.70
 60-69 128 69 1.86 1.26-2.76
 ≥70 158 123 3.87 2.70-5.56
Figo stage
 Stage I 144 24 1.00 <0.001
 Stage II 55 20 2.46 1.35-4.46
 Stage III 238 183 7.80 5.09-11.96
 Stage IV 72 65 15.98 9.93-25.71
tumor grade
 Grade 1 84 26 1.00 <0.001
 Grade 2 124 67 2.15 1.37-3.38
 Grade 3-4 209 147 3.34 2.20-5.08
 Unknown 92 52 2.16 1.35-3.46
Histology
 Serous 262 169 1.00 <0.001
 Mucinous 64 23 0.46
 Endometroid 43 12 0.32
 Clear cell 33 16 0.69
 Adenocarcinoma NOS 107 72 1.18
Preoperative CA 125
 ≤35 U/mL 76 20 1.00 <0.001
 >35 U/mL 380 241 3.31 2.10-5.22
 Unknown 53 31 2.79 1.59-4.90
Comorbidity
 No 360 188 1.00 <0.001
 Yes 149 104 1.69 1.33-2.15
Ascites
 Absent 143 50 1.00 <0.001
 Present 340 230 2.63 1.98-3.51
 Unknown 26 12 1.53 0.87-2.71
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table 4.3.3 | Continued
Variable No. of patients No. of deaths Hr 95% Ci P value
residual tumor
 No macroscopic 217 53 1.00 <0.001
 < 2 cm 59 44 4.37 2.93-6.53
 > 2 cm 96 87 8.14 5.76-11.52
 Unknown 137 108 5.52 3.97-7.69
Hospital of surgery
 Teaching 246 136 1.00 0.29
 Nonteaching 263 156 1.13 0.90-1.43
HR hazards ratio; 95% CI 95% confidence interval; FIGO International Federation of Gynecology and Obstetrics; NOS 
not otherwise specified.
multivariate Analysis 
In a Cox proportional hazards analysis, the crude hazards ratio (risk of dying) was 
0.82 (95% CI 0.64-1.05) for patients who underwent surgery by a gynecologic 
oncologist versus a general gynecologist. The presence of ascites, preoperative CA 
125 level, and comorbidity did not appear to affect the correlation between type 
of gynecologist and survival. However, patient age, disease stage, and the type of 
hospital (teaching or nonteaching) were found to affect this relation and therefore 
required adjustment. When we adjusted for age, stage, and type of hospital, the 
hazards ratio of surgery by a gynecologic oncologist was 0.77 (95% CI 0.60–1.00) 
(table 4.3.4). When chemotherapy was included in the model, because platinum-
based chemotherapy in particular was prescribed more often to patients who 
underwent surgery by a gynecologic oncologist, the hazards ratio became 0.79 
(95% CI 0.61-1.03). Younger patients especially appeared to benefit from specialized 
surgical treatment, because, after correcting for age, stage, type of hospital, and 
chemotherapy, the hazards ratio fell to 0.71 (95% CI 0.54-0.94) when patients older 
than age 75 years were excluded (leaving 431 patients for analysis).
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table 4.3.4 | Cox Multivariate Model Adjusted for the Impact of Covariates on the Difference 
in Risk of Dying (HR) for Patients with Ovarian Carcinoma who Underwent Surgery Performed 
by Gynecologic Oncologists Compared with Patients who Underwent Surgery Performed by 
General Gynecologists
Crude survival difference, all stages Hr 95% Ci P value
univariate
 General gynecologist 1.00 0.11
 Gynecologic oncologist 0.82 0.64-1.05
Adjusted for age, stage and type of hospital
 General gynecologist 1.00 0.05
 Gynecologic oncologist 0.77 0.60-1.00
Adjusted for age, stage, type of hospital and chemotherapy
 General gynecologist 1.00 0.08
 Gynecologic oncologist 0.79 0.61-1.03
Adjusted for age, stage, type of hospital, chemotherapy and age <76 yrs
 General gynecologist 1.00 0.02
 Gynecologic oncologist 0.71 0.54-0.94
HR hazards ratio; 95% CI 95% confidence interval
DisCussioN
The phenomenon of traveling gynecologic oncologists assisting general 
gynecologists in community hospitals in the northern region of the Netherlands 
gave us the unique opportunity to explore the impact of surgery by gynecologic 
oncologists on patients with ovarian carcinoma. In the current, population-based 
study, we were able to correct for all kinds of possible confounding factors, such 
as patient selection and hospital type, which often was not possible in previously 
published studies concerning the impact of surgery by gynecologic oncologists on 
survival in patients with ovarian carcinoma. The results of the current study indicate 
clearly that surgery by a gynecologic oncologist indeed improves survival, because 
the multivariate analysis demonstrated a 23% reduction in the risk of dying for 
patients who underwent surgery by gynecologic oncologists after adjusting for 
patient age, disease stage, and the type of hospital. After an additional adjustment 
for chemotherapy, the reduction in the risk of dying became 21% (no longer 
significant; P=0.08), most likely due to the relatively small numbers. However, when 
patients older than age 75 years were excluded from the analysis, the reduction in 
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risk of dying became 29% (P=0.02), suggesting that younger patients in particular 
benefit from surgery by gynecologic oncologists.
 The overall survival of patients with late-stage ovarian carcinoma, as presented 
in the current study, may appear to be low on first sight, with 5-year survival rates 
of 21% and 13% for patients who underwent surgery by gynecologic oncologists 
and general gynecologists, respectively. However, our rates are comparable to those 
reported from other population-based studies. A Scottish group (Junor et al.89) 
reported 3-year survival rates of 20% for patients with FIGO Stage III disease and 
6% for patients with FIGO Stage IV disease and reported a median survival of 18 
months and 13 months for patients with Stage III disease who underwent surgery by 
gynecologic oncologists and general gynecologists, respectively (in our population, 
the median survival was 23 mos and 15 mos, respectively). In Utah, a median survival 
of 26 months versus 16 months was observed for patients with ovarian carcinoma 
who had late-stage disease treated by gynecologic oncologists versus general 
gynecologists, respectively.89 In addition, a Norwegian group (Tingulstad et al.93), 
reporting results from a case-control study regarding the centralization of treatment 
for ovarian carcinoma, observed 5-year survival rates of 26% and 4% for patients 
with advanced stage ovarian carcinoma who underwent surgery by gynecologic 
oncologists and general gynecologists, respectively.88,89,93
 It has been postulated before that patients with ovarian carcinoma should be 
treated by gynecologic oncologists, because this may improve their survival.94,95 In 
ovarian carcinoma, residual tumor mass after first surgery has a major impact on 
survival, and the current results showed that complete cytoreduction was attained 
more often by gynecologic oncologists than by general gynecologists in patients with 
FIGO Stage III disease. Moreover, 62% of patients with FIGO Stage III disease who 
underwent surgery by a gynecologic oncologist were left with residual tumor masses 
that measured <2 cm in greatest dimension compared with 45% of patients who 
underwent surgery by general gynecologists. In their meta-analysis on cytoreductive 
surgery for ovarian carcinoma, Bristow et al. reported a weighted mean percentage 
of optimal debulking (defined as the greatest dimension of residual disease <1-2 cm 
in 95% of selected studies) of 42% for a mix of operating physicians.38 Eisenkop and 
Spirtos published a survey among gynecologic oncologists on optimal debulking 
rates and reported optimal debulking in 70% of patients with FIGO Stage IIIC 
disease.96
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Apart from residual tumor mass, another major issue that may influence patient 
survival is treatment according to prevailing guidelines. Guidelines for the treatment 
of ovarian carcinoma have been published by regional, national, and international 
organizations.97 We observed greater compliance with surgical guidelines among 
gynecologic oncologists than among general gynecologists. Furthermore, patients 
with Stage I-II and Stage III ovarian carcinoma who underwent surgery according to 
the guidelines had a better survival.
 Stage migration, which means that, through adequate staging, patients are 
assessed correctly with a more advanced stage of disease, cannot be excluded to 
account in part for the survival benefit of patients who undergo surgery performed 
by gynecologic oncologists when comparing survival figures in the different stages. 
However, in the current study, this survival benefit was found consistently in all 
patient subgroups.
 Data that lead to findings comparable to those in the current study have been 
presented previously in other studies. However, the interpretation of many of those 
(older) studies is hampered by their association with important flaws. Such flaws 
also have prevented the gynecologic community as a whole from accepting and 
implementing the conclusions from those studies in the daily practice for patients 
with suspected ovarian carcinoma. A first example of a major flaw in many previous 
population-based studies is that survival analyses of patients who underwent surgery 
by general gynecologists often were mixed with survival analyses of patients who 
underwent surgery by general surgeons.87,88 Our current results show that survival 
was especially poor for patients with ovarian carcinoma who underwent surgery 
by general surgeons, which also has been reported in other studies;83-86 however, 
our results also showed that patients who underwent surgery by general surgeons 
differed from patients who underwent surgery by gynecologists. The majority of 
those patients already had gastrointestinal complaints and underwent surgery 
because of suspected colon carcinoma. Moreover, those patients were older and 
had higher FIGO stage disease. Differences in age, stage, or histotype of patients 
treated by general surgeons compared with gynecologists also have been noted 
previously; however, previous investigators did not report on the most important 
characteristic, namely, the presumptive preoperative diagnosis that indicated 
advanced-stage disease, that we present in the current study.83,85,86 Because of this 
clear patient selection bias, patients who undergo surgery by general surgeons 
should be excluded from comparative analyses between patients who do or do not 
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undergo surgery by gynecologic oncologists in population-based studies in ovarian 
carcinoma.
 Another important flaw in comparative survival analyses of patients with 
ovarian carcinoma is the possible beneficial influence of treatment in a teaching 
hospital.98 The advantage of undergoing surgery in a teaching hospital, which 
also was found in our multivariate analysis, is not understood easily. In subgroup 
analyses, the variables of patient age, disease stage, and type of first-course 
chemotherapy were excluded as explanations. Surgeon’s patient volume also was 
found to have no significant influence on survival. Possibly, the explanation may 
be sought in more subtle issues, such as the dose of chemotherapy given, the 
treatment of recurrent disease, the type and dosage of second-line chemotherapy, 
etc. Because the teaching hospitals also had much larger caseloads per hospital, 
hospital volume may be the more correct term for the effect found.99 The issue of 
beneficial influence of treatment in a teaching hospital was not addressed in the 
one population-based study that is most comparable to our current work89 or in the 
Norwegian case–control study regarding the centralization of primary surgery in 
patients with ovarian carcinoma.93 
 Finally, the third major issue that, in many population-based studies, may bias 
patient survival analyses in favor of gynecologic oncologists, is patient selection. 
In our multivariate analysis, however, we were able to correct for patient selection 
by adjusting for disease stage, patient age, teaching hospital, and chemotherapy, 
thereby excluding patient selection as a possible explanation for the observed better 
survival of patients who underwent surgery by gynecologic oncologists.
 When implementing the conclusion from the current study that patients with 
ovarian carcinoma optimally should undergo surgery by gynecologic oncologists, 
two important topics should be addressed. First, the referral of every patient who 
has a pelvic mass to cancer centers will prove to be hard because of problems with 
logistics and manpower. In this respect, a triage system may be applied to allow 
the identification of patients who have a low likelihood of ovarian carcinoma,100 
or the referral guidelines of the Society of Gynecologic Oncologists and the 
American College of Obstetricians and Gynecologists can be followed.101 Second, 
in patients who have a nonsuspected ovarian carcinoma removed suboptimally by 
a general gynecologist, a relaparotomy should be considered.102 Disease restaging 
is worthwhile, especially in patients with apparently early-stage ovarian carcinoma, 
because adjuvant chemotherapy does not appear to improve survival in optimally 
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staged patients with early stage disease.103 In patients with apparently advanced 
stage disease that was not debulked optimally by a general gynecologist, either 
direct relaparotomy by a gynecologic oncologist or intervention surgery after 
response to three cycles of chemotherapy may be considered.104,105
 The results of the current study demonstrate clearly that surgery by a 
gynecologic oncologist has a positive effect on survival, reducing the risk of dying 
by >20% for patients with ovarian carcinoma. Specific surgical training appeared 
to be important, because a surgeon’s patient volume alone had no effect on 
survival. Receiving treatment in a teaching hospital also improved survival. These 
results imply that every patient who has suspected ovarian carcinoma deserves 
to undergo surgery performed by a gynecologic oncologist. For the short term, a 
traveling gynecologic oncologist may be an acceptable alternative to the referral 
of all patients with ovarian carcinoma to a center with gynecologic oncologists. 
However, care should be taken that correct surgical treatment is followed by 
the right additional chemotherapy, particularly in smaller hospitals, in which the 
caseload for the medical oncologist is as low as that for the gynecologist. In the 
future, our objective should be to concentrate the treatment of patients who have 
ovarian carcinoma in teaching hospitals with gynecologic oncologists.
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ABstrACt
Background. The volume-outcome relationship for complex surgical procedures has 
been extensively studied. Most studies are based on administrative data and use in-
hospital mortality as the sole outcome measure. It is still unknown if concentration 
of these procedures leads to improvement of clinical outcome. The aim of our study 
was to audit the process and effect of centralizing esophageal resections for cancer 
by using detailed clinical data.
methods. From January 1990 until December 2004, 555 esophagectomies for cancer 
were performed in 11 hospitals in the region of the Comprehensive Cancer Center 
West (CCCW); 342 patients were operated on before and 213 patients after the 
introduction of a centralization project. In this project patients were referred to the 
hospitals which showed superior outcomes in a regional audit. In this audit patient, 
tumor, and operative details as well as clinical outcome were compared between 
hospitals. The outcome of both cohorts, patients operated on before and after the 
start of the project, were evaluated.
results. Despite the more severe comorbidity of the patient group, outcome 
improved after centralizing esophageal resections. Along with a reduction in 
postoperative morbidity and length of stay, mortality fell from 12% to 4% and 
survival improved significantly (P=0.001). The hospitals with the highest procedural 
volume showed the biggest improvement in outcome. 
Conclusions. Volume is an important determinant of quality of care in esophageal 
cancer surgery. Referral of patients with esophageal cancer to surgical units with 
adequate experience and superior outcomes (outcome-based referral) improves 
quality of care.
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iNtroDuCtioN
The number of publications that report on the relationship between the volume 
of high-risk surgical procedures and patient outcome continues to grow.106 Most 
studies show better outcome with increasing number of operations performed by 
a specialized center or surgeon. However, there is still a debate about the level of 
evidence of these studies and the appropriateness of minimum volume thresholds 
for high-risk surgical procedures.107-109 For example, there are no randomized 
controlled trials that have compared outcome for complex surgical procedures 
between high- and low-volume hospitals. Despite this apparent lack of evidence, 
authors claim that many surgical deaths could be saved by centralizing these 
high-risk procedures.110 However, studies that have analyzed the actual effect of 
centralization (or regionalization) on hospital volumes and outcomes are rare.111 
 It has been widely acknowledged that esophagectomy for cancer is a complex 
surgical procedure and that concentration in high-volume centers could lead to 
improved outcome.112,113 However, translation of the conclusions of observational 
series to clinical practice is difficult. Cutoff values between high- and low-volume 
esophageal surgery vary greatly between studies. In The Netherlands, van Lanschot 
et al. investigated the volume-mortality relationship for esophageal resections, 
analyzing data from the Dutch National Medical Registry.114 The results of their study 
where in favour of patients treated in the high volume hospitals in our country, 
suggesting that referring patients to hospitals with higher case-volumes could 
reduce postoperative mortality. The purpose of our study was to analyze whether 
centralization of esophageal cancer surgery truly improves clinical outcome. Besides 
mortality, we were also interested in a more extensive set of outcome measures, 
including overall survival. As case mix has also been shown to be an important 
predictor for treatment outcomes, we included detailed clinical data of individual 
patient and tumor characteristics.115
mAtEriAl AND mEtHoDs
Comprehensive Cancer Center leiden
Eleven hospitals in the mid-western part of The Netherlands are affiliated to the 
Comprehensive Cancer Center West (CCCW). In this urbanized area travelling 
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distances between hospitals are not more than 45 km (30 miles). In 1997, a 
Professional Network of Surgical Oncologists (PNSO) involving all affiliated hospitals 
was established, with the objective of improving the effectiveness and efficiency 
of surgical care for patients with cancer. In the light of the increasing number of 
reports on a volume-outcome relationship for esophagectomies, the network 
decided to evaluate surgical care for patients with esophageal cancer treated in the 
CCCW region since the year 1990.
retrospective registration
All surgically treated esophageal carcinomas from 1990 to 1999 were identified 
through the cancer registry of the CCCW, in which all cancer patients diagnosed 
and treated in the mid-western part of The Netherlands (1.7 million inhabitants) 
are registered. All 11 hospitals formally gave their consent to participate in this 
audit and were subsequently visited by two investigators who retrieved the original 
patient files. Patient demographics, pathological notes, data on surgical and (neo)
adjuvant treatments, comorbidity as well as postoperative morbidity, mortality, 
length of stay, and survival were extracted from the patients’ files. Pathological 
notes were reviewed in detail by two independent researchers and all cancers 
were staged according to the tumor-node-metastasis (TNM) staging system of the 
International Union against Cancer (UICC) 1997. The obtained pTNM stages were 
then cross-checked with the tumor stages in the cancer registry. Discrepancies in 
tumor stage were discussed between the researchers and a trained data manager 
from the CCCW/cancer registry database. If consensus could not be reached, the 
tumor stage was classified as ‘‘unknown.’’
intervention
In January 2000 the results of this retrospective analysis were presented at the PNSO 
meeting.115 Differences in volume and outcome between hospitals were discussed 
and all surgeons agreed to participate in a prospective registration. Also, all surgeons 
agreed upon the scenario of having to refer esophageal cancer patients to centers 
with a better outcome if their own results proved to be unfavorable (outcome-
based referral). These referrals were on a voluntary basis, however, for both the 
patient and surgeon.
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Prospective registration
From January 2000 until December 2004 the same data were prospectively collected 
from the original patient files, and again all affiliated hospitals took part in this 
exercise. Completeness of the data was cross-checked with the independently 
collected information from the cancer registry. Each year, interim results were 
presented and discussed within the group of surgeons at the meeting of the PNSO. 
Control group
To put the data of the CCCW in national perspective, we compared the outcome of 
the CCCW region with the results of the nearest referral center for esophagectomy 
outside the CCCW region. In this high-volume university hospital, information of 
patients operated on for an esophageal carcinoma is prospectively collected from 
original patient files by a data manager.
statistics
Differences in patient, tumor, and treatment characteristics, as well as in outcome 
measurements were assessed using the Kruskal-Wallis test for continuous variables 
and the chi-square test for categorical variables. Patients with an ‘‘unknown’’ 
status for a given variable were excluded for the analyses. Duration of survival was 
calculated as the difference between date of surgery and either date of death or 
date of last patient contact. To prevent the problem of differential follow-up, for all 
groups follow-up was cut-off at 2 years after surgery. Observed survival rates were 
estimated by using the Kaplan-Meier method. The logrank test was used to assess 
differences in survival between patients who were operated in different time periods 
and in low- versus high-volume hospitals. The Cox proportional hazard model was 
used to calculate hazard ratios, adjusting for possible confounding variables. All 
analyses were conducted using SPSS software (version 12.0; SPSS Inc.,Chicago, IL).
rEsults
Hospital volume
Between 1990 and 2004, evaluation and treatment of patients with esophageal 
cancer was performed in 11 hospitals in the region of the CCCW (one university 
hospital, five teaching hospitals, and five general hospitals). In 555 consecutive 
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patients, an esophageal tumor was resected with curative intent. Figure 4.4.1a 
illustrates the distribution of surgical procedures within the studied time period 
for the 11 hospitals, and Figure 4.4.1b shows the resection rates for esophageal 
carcinomas diagnosed in the CCCW region in three different time periods. 
 A B
Figure 4.4.1 | A Number of esophageal resections in hospitals in region of CCCW per 5-year 
period (1990-1994, 1995-1999, 2000-2004). *Hospitals that abandoned esophageal resections 
during 2000-2004 period. Hospital 4 abandoned esophageal resections after 1st January 2005. 
B Resection rates of newly diagnosed patients with esophagus carcinoma in hospitals in CCCW 
region per 5-year period (1990-1994, 1995-1999, 2000-2004).
From 1990 to 1999, none of the hospitals performed more than seven esophageal 
resections per year (low-volume hospitals; LVH). From the year 2000 onwards, a 
gradual concentration of esophageal resections occurred, and in two hospitals (I 
and II) procedural volumes increased to more than ten resections per year (high-
volume hospitals; HVH). In the same period of time, a mean annual number of 56 
esophageal resections was performed in the nearest high-volume center.
Patient, tumor, and treatment Characteristics
table 4.4.1 shows the patient, tumor, and procedural characteristics of esophageal 
resections performed in three consecutive time periods. There was no significant 
difference in age, gender, histological type or location of the tumors. However, the 
number of patients with comorbidities increased during the study period. Stage 
I tumors were more frequently seen in the later time periods, and an increasing 
number of transhiatal resections were performed. The number of nodes evaluated 
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by the pathologist changed in time, with a mean number of 6.3, 7.5, and 13.5 
nodes reported for the different time periods. In the 2000-2004 time period more 
neoadjuvant chemotherapy was used, especially in patients with a tumor in the 
lower esophagus, included in a trial on perioperative epirubicin, cisplatin, and 
fluorouracil (ECF).116
table 4.4.1 | Characteristics of patients who underwent esophageal resection by period of 
surgery
1990-1994 1995-1999 2000-2004
Characteristics No. of patients % No. of patients % No. of patients % P value
Age (years) 0.19
 Median 66 65 64
 Range 37-87 33-85 33-86
gender 0.70
 Male 109 70.8 139 74.3 159 74.3
 Female 45 29.2 48 25.7 55 25.7
Co-morbidity 0.25a,b
 No 68 44.2 74 39.6 83 38.8
 1 organ system 51 33.1 61 32.6 85 39.7
 2 organ systems 19 12.3 30 16.0 41 19.2
 ≥ 3 organ systems 4 2.6 7 3.7 4 1.9
 Unknown 12 7.8 15 8.0 1 0.5
Histology 0.93a,c
 Adenocarc. 107 69.5 130 69.5 144 67.3
 Squamous carc. 45 29.2 51 27.3 52 24.5
 Barrett’s dysplasia 1 0.6 3 1.6 6 2.8
 Other - - 2 1.1 5 2.3
 Unknown 1 0.6 1 0.5 7 3.3
tumour localisation 0.97a,d
 Cervical esoph. 4 2.6 3 1.6 4 1.9
 Mid esoph. 23 14.9 30 16.0 32 15.0
 Distal esoph. / GE junction 127 82.5 152 81.3 177 82.7
 Unknown - - 2 1.1 1 0.5
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table 4.4.1 | Continued
1990-1994 1995-1999 2000-2004
Characteristics No. of patients % No. of patients % No. of patients % P value
stage (pTNM) 0.65a
 0 2 1.3 5 2.7 6 2.8
 I 10 6.5 26 13.9 31 14.5
 II 80 51.9 80 42.8 82 38.3
 III 52 33.8 60 32.1 74 34.6
 IV 9 5.8 12 6.4 15 7.0
 Unknown 1 0.6 4 2.1 6 2.8
Neo-adjuvant treatment <0.001a,e
 No 150 97.4 165 88.2 160 74.8
 Chemo ±  radiotherapy 2 1.3 19 10.1 54 25.2
 Unknown 2 1.3 3 1.6 - -
surgical approach <0.001a,f
 Abdomino-cervical 53 34.4 97 51.9 156 72.9
 Thoraco-abdominal 62 40.3 34 18.2 11 5.1
 Abd-thor-cervical 16 10.4 27 14.4 27 12.6
 Abdominal 23 14.9 29 15.5 15 7.0
 Unknown - - - - 5 2.3
Anastomoses <0.001g
 Cervical 69 44.8 126 67.4 187 87.4
 Thoracic 60 39.0 30 16.0 12 5.6
 Abdominal 25 16.2 31 16.6 15 7.0
total no. of patients 154 187 214
GE gastro-esophageal; a ‘‘Unknown’’ category was excluded; b Linear trend analysis; c Squamous versus adenocarcinoma 
plus Barrett’s dysplasia; d Distal esophagus/GE-junction versus others; e No neoadjuvant therapy versus others; f 
Abdomino-cervical versus others; g Cervical versus thoracic plus.
outcome
The outcome of esophagectomies in the CCCW region improved with time (table 
4.4.2). The percentage of patients with a microscopic radical resection (R0) improved 
from 69% to 73%. The number of patients who left the hospital without adverse 
events was highest in the 2000-2004 period. Hospital stay was shortened significantly 
and inhospital mortality was reduced almost threefold. As shown in Figure 4.4.2, 
significantly better 2-year survival is seen for the last time period (P=0.001). After 
exclusion of in-hospital mortality, this difference is still significant (P=0.045). 
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table 4.4.3 shows the results of a multivariate analysis for the risk of dying after 
surgery in the three time periods with adjustments for the impact of the covariates: 
stage, comorbidity, surgical approach, and neoadjuvant treatments. Somewhat 
higher stages of the disease and more patients with multiple comorbidities were 
operated in the last time period. Although there are significant differences in 
surgical approach and the use of neoadjuvant chemotherapy between time periods, 
the survival benefit in the 2000-2004 period remains significant in multivariate 
analysis (hazard ratio (HR) 0.61). An analysis of the data after exclusion of patients 
who received (neo)adjuvant treatment showed similar improvements in mortality 
rates and survival after 2000. Also, a multivariate analysis was performed after 
exclusion of the patients who died during hospital stay (table 4.4.4). Improvements 
in survival stayed (borderline) significant after adjustments for differences in stage, 
age, gender, and comorbidities (P=0.05), but after introducing surgical approach in 
the model, significance was lost (P=0.25). 
Figure 4.4.2 | Two-year survival after resection for all stages of esophageal carcinoma in three 
time periods (p1: 1990–1994, p2: 1995–1999, p3: 2000–2004), including hospital mortality
In table 4.4.5 patient, tumor, and treatment characteristics of patients operated 
on in hospitals with fewer than ten resections a year (low-volume hospitals LVH) 
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and with more than nine resections a year (high-volume hospitals HVH) are shown. 
Only patients operated in a year in which the procedural volume of the hospital 
concerned exceeded nine resections were included in the HVH group. In this group 
more patients with more comorbidity were operated, and the transhiatal approach 
was used more often than the transthoracic approach. Significantly more adverse 
events occurred in the LVH group, with a mortality rate of 6.3% in the LVH group 
and 2.9% in the HVH group (table 4.4.6). After exclusion of the patients who died 
in hospital, median hospital stay was 8 days shorter in the HVH group. Survival 
analysis did not show a difference in 2-year survival between the LVH and HVH 
group (P=0.63). 
table 4.4.2 | Outcome after esophageal resections in region of CCCW (1990-994, 1995-1999, 
2000-2004)
1990-1994 1995-1999 2000-2004
outcome No. of patients % No. of patients % No. of patients % P value
margins 0.57a,c
 R0 107 69.5 140 74.9 156 72.9
 R1 34 22.1 21 11.2 39 18.2
 R2 10 6.5 25 13.4 12 5.6
 Unknown 3 1.9 1 0.5 7 3.3
Complications 0.20a
 No 43 27.9 46 24.6 70 32.7
 Yes 106 68.8 140 74.9 143 66.8
 Unknown 5 3.2 1 0.5 1 0.5
re-intervention 0.27a,d
 None 115 74.4 155 82.9 163 76.2
 1 27 17.5 21 11.2 32 15.0
 2 5 3.2 7 3.7 12 5.6
 ≥ 3 2 1.3 3 1.6 3 1.4
 Unknown 5 3.2 1 0.5 4 1.9
Hospital stay (days)b 0.002
 Median 20 21 17
 Range (9-92) (9-125) (8-273)
in-hospital mortality 0.003a
 No 131 85.1 160 85.6 204 95.3
 Yes 22 14.3 23 12.3 10 4.7
 Unknown 1 0.6 4 2.1 - -
total no. of patients 154 168 214
a ‘‘Unknown’’ category excluded; b Patients who died during hospital stay were not included; c R0 versus R1 plus R2; d 
No reintervention versus others.
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table 4.4.3 | Cox multivariate model adjusted for the impact of covariates on the risk of dying 
(HR) for patients who underwent esophageal resection for cancer by period of surgery
Hr 95% Ci
univariate
 1990-1994 1.00
 1995-1999 0.89 0.69–1.14
 2000-2004 0.66 0.50–0.86
Adjusted for stagea and co-morbiditya
 1990-1994 1.00
 1995-1999 0.82 0.61–1.11
 2000-2004 0.57 0.42–0.77
Adjusted for stagea, co-morbiditya and surgical approacha
 1990-1994 1.00
 1995-1999 0.85 0.62–1.15
 2000-2004 0.60 0.43–0.84
Adjusted for stagea, co-morbiditya, surgical approacha and neo-adjuvant treatmenta
 1990-1994 1.00
 1995-1999 0.85 0.63–1.16
 2000-2004 0.61 0.44–0.86
HR hazards ratio, CI Confidence Interval; a “Unknown” categories excluded
table 4.4.4 | Cox multivariate model adjusted for the impact of covariates on the risk of 
dying (HR) for patients who underwent esophageal resection for cancer by period of surgery 
(patients who died in hospital excluded)
Hr 95% Ci
univariate
 1990-1994 1.00
 1995-1999 0.87 0.64-1.20
 2000-2004 0.67 0.48-0.91
Adjusted for stagea
 1990-1994 1.00
 1995-1999 0.90 0.65-1.24
 2000-2004 0.67 0.48-0.93
Adjusted for stagea, age and gender
 1990-1994 1.00
 1995-1999 0.88 0.64-1.22
 2000-2004 0.67 0.48-0.93
Adjusted for stagea, age, gender and co-morbiditya
 1990-1994 1.00
 1995-1999 0.88 0.64-1.22
 2000-2004 0.67 0.48-0.93
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table 4.4.4 | Continued
Hr 95% Ci
Adjusted for stagea, age, gender, co-morbiditya and surgical approacha
 1990-1994 1.00
 1995-1999 0.92 0.66–1.29
 2000-2004 0.75 0.52–1.07
HR hazards ratio, CI Confidence Interval; a “Unknown” categories excluded
table 4.4.5 | Characteristics of patients who underwent esophageal resection by hospital 
volume in the 2000-2004 time period
lVHs HVHs
Characteristics No. of patients % No. of patients % P value
Age 0.24
 median (yrs) 64 63
 range (yrs) 33-86 43-80
gender 0.53
 Male 80 72.1 79 76.7
 Female 31 27.9 24 23.3
Co-morbidity 0.001a
 no 56 50.5 27 26.2
 1 organ system 35 31.5 50 48.5
 2 organ systems 18 16.2 23 22.3
 ≥ 3 organ systems 1 0.9 3 2.9
 Unknown 1 0.9 - -
Histology 0.98a,b
 Adenocarc. 73 65.8 71 68.9
 Squamous carc. 27 24.3 25 24.3
 Barrett’s dysplasia 3 2.7 3 2.9
 Other 2 1.8 3 2.9
 Unknown 6 5.4 1 1.0
tumour localisation 0.61a,c
 Cervical oesoph. 2 1.8 2 1.9
 Mid oesoph. 18 16.2 14 13.6
 Distal oesoph. / GE-junction 90 81.1 87 84.5
 Unknown 1 0.9 - -
stage (pTNM) 0.90
 0 3 2.7 3 2.9
 I 15 13.5 16 15.5
 II 43 38.7 39 37.9
 III 39 35.1 35 34.0
 IV 6 5.4 9 8.7
 Unknown 5 4.5 1 1.0
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table 4.4.5 | Continued
lVHs HVHs
Characteristics No. of patients % No. of patients % P value
Neo-adj. treatment 0.27
 No 90 81.1 70 68.0
 Chemo ± radiotherapy 21 18.9 33 32.0
surgical approach <0.001a,d
 Abdomino-cervical 66 59.5 90 87.4
 Thoraco-abdominal 10 9.0 1 1.0
 Abd-thor-cervical 17 15.3 10 9.7
 Abdominal 14 12.6 1 1.0
 Unknown 4 3.6 1 1.0
Anastomoses <0.001e
 Cervical 86 77.5 101 98.1
 Thoracic 12 10.8 - -
 Abdominal 13 11.7 2 1.9
total no. of patients 111 103
LVHs low-volume hospitals (<10 resections/year), HVHs high-volume hospitals (≥10 resections/year), GE gastroesophageal; 
a ‘‘Unknown’’ category excluded; bAdenocarcinoma/Barrett’s dysplasia versus squamous and others; cDistal esophagus/
GE junction versus cervical/mid esophagus; dAbdomino-cervical versus others; eCervical anastomoses versus others.
table 4.4.6 | Outcome after esophageal resection by hospital volume in the 2000-2004 time 
period
lVHs HVHs
outcome No. of patients % No. of patients % P value
margins 0.35b,c
 R0 77 69.4 79 76.7
 R1 19 17.1 20 19.4
 R2 10 9.0 2 1.9
 Unknown 5 4.5 2 1.9
Complications
 No 24 21.6 46 44.7 0.001b
 Yes 86 77.5 57 55.3
 Unknown 1 0.9 - -
surgical complications 0.05b
 No 54 48.6 64 62.1
 Yes 56 50.5 39 37.9
 Unknown 1 0.9 - -
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table 4.4.6 | Continued
lVHs HVHs
outcome No. of patients % No. of patients % P value
general complications 0.001b
 No 44 39.6 65 63.1
 Yes 66 59.5 38 36.9
 Unknown 1 0.9 - -
reintervention 0.39b,d
 None 82 73.9 81 78.6
 1 19 17.1 13 12.6
 2 7 6.3 5 4.9
 ≥ 3 1 0.9 2 1.9
 Unknown 2 1.8 2 1.9
Hospital stay (days)a <0.001
 Median 22 14
 Range (10-273) (8-104)
in-hospital mortality 0.24
 No 104 93.7 100 97.1
 Yes 7 6.3 3 2.9
total no. of patients 111 103
LVHs low-volume hospitals (<10 resections/year), HVHs high-volume hospitals (≥10 resections/year); aPatients who died 
during hospital stay were not included; b ‘‘Unknown’’ category excluded; cR0 versus R1 plus R2; dNo reintervention 
versus others.
DisCussioN
In the last decade, many studies have been published that have addressed the 
volume-outcome relationship for complex surgical procedures.106,117 The results of 
these studies focus on the rather high difference in mortality rates between high- 
and low-volume providers for esophageal resections for cancer.112 As a consequence, 
these authors speculate that concentration of these high-risk surgical procedures in 
centers with adequate experience could avoid thousands of preventable deaths.110,118 
However, the present study is the first that shows an actual improvement in outcome 
after the process of centralization of esophageal resections for cancer.
 Chowdhury et al. reviewed 163 studies that looked at the volume-outcome 
relationship for complex surgical procedures.106 Seventy-three percent of these 
studies showed significant better outcomes in high-volume hospitals and for high-
volume surgeons. However, most studies are registry-based and omit important 
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case-mix adjustments from clinical data. Moreover, hospital mortality is often 
presented as the sole outcome measure, without presenting other dimensions of 
quality of care. Therefore, there is solid criticism on the methodological issues, 
which hampers centralization initiatives for complex surgical procedures, especially 
in The Netherlands. Despite the expected benefits of centralizing complex surgical 
procedures at high-volume providers, there are few studies that show an actual 
improvement in clinical outcome after centralization of a specific procedure.119 As 
a part of a broader initiative, the Leapfrog Group, a large coalition of private and 
public purchasers of health insurance in the USA, has been referring their patients 
to high-volume providers of esophagectomies since 2000. Although expectations 
about the beneficial effects of this intervention were high, no results have been 
published yet.110,118
 Our study adds clinical proof to the effectiveness of concentrating complex 
surgical procedures: not only was hospital mortality reduced to a third of the 
original value, but also other outcome indicators, such as the number and severity 
of adverse events, showed improvement after centralization of esophagectomies 
in the CCCW region in The Netherlands. This was also reflected in a lower number 
of reinterventions and shorter length of stay. Remarkable is the significant 
improvement in survival that is already demonstrated after a limited concentration 
of esophageal resections (Figure 4.4.2). In our opinion, overall survival, adjusted for 
differences in tumor stages, should be the most important performance indicator in 
surgical oncology, being even more valuable than operative mortality.
 In an earlier article from our group we showed that case mix is an important 
determinant of outcome and should be part of every study comparing outcome 
between providers.115 Therefore we tried to study the effect of differences in 
case-mix between the hospitals. The identification of more patients with multiple 
comorbid diseases and more patients with stage IV disease in the last time period 
(table 4.4.1) supports our conclusion that outcome improved with centralization of 
esophageal resections.
 However, our study has several limitations. First, the accuracy of the registry 
database should be confirmed. This was done by comparing the results with the 
data of the independently retrieved information in the cancer registry of the CCCW. 
Only 3% of the patients operated on for esophageal cancer in our region were 
missing from our prospective database. The treatment and outcome characteristics 
of this small group of patients did not differ significantly from those of the original 
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group. An earlier report on a detailed medical audit confirms the accuracy of clinical 
outcomes databases on major fields such as operative mortality, major complications, 
and significant factors in risk stratification.120
 Secondly, our dataset is still limited, though more (co)variables were included 
than in most volume-outcome studies. In contrast to the available data on case-
mix variations, no information on structural changes in perioperative care was 
available. To our knowledge no important improvements in the treatment of 
esophageal cancer are known from the literature, nor within the region of the 
CCCW. Nevertheless, progress in anesthesiological techniques and postoperative 
care within the study period could have interfered with our findings. In addition, 
limited data were available on the survival of patients in the later time period (2-
year survival). This could be insufficient to evaluate differences in disease control 
obtained by transthoracic and transhiatal procedures. Recently, the 5-year survival 
data of the Dutch randomized controlled trial comparing these surgical approaches 
were published.121 No survival benefit was shown for either approach. Nevertheless, 
after introducing surgical approach in our multivariate analyses (table 4.4.4), the 
statistical difference in survival between the time periods was lost, suggesting an 
important role for the choice of operative approach. In our opinion, the choice 
for a transhiatal or transthoracic procedure is made in a decision-making process 
in which careful interpretation of diagnostic images and surgical experience are 
combined. The increase in hospital volumes, as a result of the concentration of 
esophagectomies in our study, might have led to better surgical decision-making, 
especially in the choice of operative approaches.
 The beneficial effects of the centralization process conducted in the last time 
period are further supported by the comparison of outcome between LVHs and 
the hospitals that acquired the status of HVH (C10 resections/year) in the last time 
period (table 4.4.6). Although differences in operative mortality are not significant, 
they strongly suggest that the most important improvement in outcome is made 
in the HVHs, which now parallel the outcome in the nearest high-volume referral 
center (data not shown). Differences in case mix, especially comorbidities, are also 
in favor of the HVHs (table 4.4.5). Continuation of the centralization process and 
the outcome registration in our region will lucidate the mechanisms behind these 
improvements in patient outcome. From 1st January 2005 esophagus resections 
in the region of the CCCW are concentrated in three hospitals with mean annual 
volume of more than 15 esophagus resections.
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Finally, the feedback we gave to individual surgeons and hospital organizations 
on their performance (mirror information) could in itself have influenced practice 
patterns and dedication of the professionals. When outcomes data are used for 
internal peer review within institutions, changes in the process of care can be 
initiated by surgeons or hospitals themselves. A good example is the Veterans 
Affairs National Surgical Quality Improvement Program (NSQIP) in which feedback 
to providers and managers led to a decrease in the relative risk for postoperative 
mortality of 27% and a 45% decrease in postoperative morbidity.122 However, 
this program was more detailed, consisting of outcome-based annual reports, 
periodic assessment of performance, self-assessment tools, structured site visits, 
and dissemination of best practices. Nevertheless, the observed improvements in 
outcome in our study could be not only a result of the concentration of services 
but also of the introduced feedback on surgical performance. This could explain 
the improved outcome that was also demonstrated in the LVHs, being of a lesser 
magnitude than the improvements in HVHs (table 4.4.6).
 Some authors believe that procedural volume, as a proxy for quality, is preferable 
above direct outcomes measurement.123,124 The availability and easy access of these 
data and the avoidance of the statistical problem of small sample size are mentioned 
as important advantages.125 However, in a study from our own country, van Heek et 
al. showed that, despite a 10-year-long ‘‘evidence- based’’ plea for centralization of 
pancreatic surgery, no reduction of mortality or change in referral pattern was seen 
in The Netherlands.126 The problem is that provider volume as a quality measure only 
holds true on average, and is a poor predictor of quality in individual hospitals or 
surgeons.127,128
 In our opinion, continuous monitoring of clinical outcomes not only has the 
ability to assess quality of care but can actually improve surgical performance. A 
number of methods for surgical monitoring, which take into account different 
levels of prior risk, have been described in the literature.129,130 A routinely conducted 
medical audit, providing hospitals and surgeons with individualized and pooled 
outcome information, can be a stimulus for the introduction of a range of 
improvements in hospital and surgical care.131-133 In addition, a national or regional 
approach, such as the example for esophageal cancer surgery in our study, clarifies 
important differences in quality of care. In a peer-review environment or when 
reliable, hospital-specific outcome information is made available to the public, 
actual changes in referral patterns can be made (outcome-based referral).
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ABstrACt
Progress against cancer through prevention and treatment is often measured 
by survival statistics only instead of analyzing trends in incidence, survival and 
mortality simultaneously because of interactive influences. This study combines 
these parameters of major cancers to provide an overview of the progress achieved 
in the Netherlands since 1989 and to establish in which areas action is needed. The 
population-based Netherlands Cancer Registry and Statistics Netherlands provided 
incidence, 5-year relative survival and mortality of 23 major cancer types. Incidence, 
survival and mortality changes were calculated as the estimated annual percentage 
change. Optimal progress was defined as decreasing incidence and/or improving 
survival accompanied by declining mortality, and deterioration as increasing 
incidence and/or deteriorating survival accompanied by increasing mortality rates. 
Optimal progress was observed in 12 of 19 cancer types among males: laryngeal, 
lung, stomach, gallbladder, colon, rectal, bladder, prostate and thyroid cancer, 
leukemia, Hodgkin and non-Hodgkin lymphoma. Among females, optimal progress 
was observed in 12 of 21 cancers: stomach, gallbladder, colon, rectal, breast, cervical, 
uterus, ovarian and thyroid cancer, leukemia, Hodgkin and non-Hodgkin lymphoma. 
Deterioration occurred in three cancer types among males: skin melanoma, 
esophageal and kidney cancer, and among females six cancer types: skin melanoma, 
oral cavity, pharyngeal, esophageal, pancreatic and lung cancer. Our conceptual 
framework limits misinterpretations from separate trends and generates a more 
balanced discussion on progress.
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iNtroDuCtioN
A question frequently asked by professionals, policymakers and the public is whether 
or not we are making progress in combating cancer. Are there improvements or is 
there even deterioration? It seems that the war on cancer is far from won,1,2 despite 
the investments since President R. Nixon declared the ‘war on cancer’ in 1971 in the 
United States and since the start of the ‘Europe against Cancer’ program in 1986.3 
 Cancer survival statistics are often used to measure progress against cancer 
achieved by early detection/screening and therapy, whereby comparisons between 
countries and regions receive special attention.4-6 However, improved survival from 
cancer at the population level does not always imply progress in absolute terms 
of less suffering and fewer deaths due to cancer. This ‘artificial’ progress is often 
due to early detection and screening practices which result in length bias (increased 
survival time by more frequent diagnoses of indolent cancers) or lead-time bias 
(earlier diagnosis causing an increased survival time without postponing time of 
death) or incomplete incidence or follow-up data.7-9
 Many parameters may indicate progress, such as less false positive and false 
negative screening exams, more effective therapies with fewer associated side 
effects, better quality of life, and improved organization of palliative care. All 
of these are difficult to measure and monitor through the standard surveillance 
instruments, mainly cancer registries. However, several of these parameters will 
influence incidence, survival and/or mortality of cancer, which can be monitored 
over time. We chose to focus on these three measures of cancer burden (i.e., 
incidence, survival, and mortality) combined in order to achieve a more objective 
assessment of progress against cancer, while avoiding over-interpreting findings 
from one of these measures only.7,9,10 Based on these three measures, two key 
situations of progress can be distinguished: (i) a decreasing incidence as a result of 
preceding lower risk factor prevalence or screening of pre-malignant lesions (e.g., of 
cervical and colorectal cancer), and (ii) an improving survival as a result of changes 
in incidence (i.e., shifts in cancer subsite/morphology distribution caused by changes 
in risk factor prevalence, and more favorable stage distribution due to earlier 
diagnosis and improved detection) and changes in therapy regimens. Both changes 
in incidence and survival had to ultimately affect mortality. Optimal progress should 
thus be reflected in a decreasing incidence and/or improving survival accompanied 
by decreasing mortality.
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On the contrary, increasing incidence due to preceding increased risk factor 
prevalence, and/or a worsening survival as a result of unfavorable changes in 
incidence (i.e., shifts towards certain subtypes or morphologies with a poor 
prognosis) or deterioration of (access to) care leading to worsening survival will 
result in increasing mortality.11
 Recently, American, European and worldwide data on incidence, mortality, 
and survival were published,12-14 but none of these studies combined these three 
measures to assess progress. The present study shows the trends in incidence, survival 
and mortality to assess to what extent progress against cancer has been made in 
the Netherlands since 1989 and to establish where action needs to be taken. This 
approach can be used as a framework by others using routinely collected cancer 
registry data for (inter)national comparisons over time.
mAtEriAl AND mEtHoDs
Data on the following 23 cancer types were collected: oral cavity (ICD-10 code: C01-
06), pharynx (C09-14), larynx (C32), esophagus (C15), stomach (C16), colon (C18), 
rectum (C19-20), gallbladder (C23), pancreas (C25), lung (C33-34), skin melanoma 
(C43), female breast (C50), cervix (C53), corpus uteri (C54-55), ovary (C56), prostate 
(C61), testis (C62), bladder (C65, invasive only), kidney (C64-66, C68), thyroid (C73), 
Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-88), and leukemia (C91-95).
 Incidence data from 1989 to 2009 were obtained from the population-based 
Netherlands Cancer Registry (NCR), which has complete national coverage and 
registers about 90,000 cases annually.15 Mortality data from 1989 to 2009 were 
derived from Statistics Netherlands.16 Information on the vital status of diagnosed 
cancer patients (necessary to calculate survival time) was initially obtained from 
municipal registries and from 1995 onward from the nationwide database of all 
municipal population registries. These registries provide virtually complete coverage 
of all deceased Dutch citizens. Follow-up was complete until 1 January 2010. 
 Trends in incidence, survival and mortality were categorized by all possible 
combinations of incidence and survival trends (either improving, stable or 
deteriorating) and were further classified by the mortality trend, which is a result 
of the incidence-survival combination. table 5.1.1 gives all the possible incidence-
survival-mortality combinations and their outcome on progress against cancer. 
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table 5.1.1 | Categories of trends in incidence, survival and mortality, and the progress 
classification
Category trends in Progress classification
incidence survival mortality
A-1 ↓ ↑ ↓ Pr-Opt
↓ ↑ = Pr-Inc/Pr-Surv
↓ ↑ ↑ Pr-Inc/Pr-Surv
A-2 ↓ = ↓ Pr-Opt
↓ = = Pr-Inc
↓ = ↑ Pr-Inc
A-3 ↓ ↓ ↓ Pr-Opt/Non-Imp
↓ ↓ = Pr-Inc/Non-Imp
↓ ↓ ↑ Pr-Inc/Det
B-1 = ↑ ↓ Pr-Opt
= ↑ = Pr-Surv
= ↑ ↑ Pr-Surv
B-2 = = ↓ Oth
= = = Oth
= = ↑ Oth
B-3 = ↓ ↓ Non-Imp
= ↓ = Non-Imp
= ↓ ↑ Det
C-1 ↑ ↑ ↓ Pr-Opt /Non-Imp
↑ ↑ = Pr-Surv/Non-Imp
↑ ↑ ↑ Pr-Surv/Det
C-2 ↑ = ↓ Non-Imp
↑ = = Non-Imp
↑ = ↑ Det
C-3 ↑ ↓ ↓ Non-Imp
↑ ↓ = Non-Imp
↑ ↓ ↑ Det
Abbreviations: Pr-Inc: progress by decreasing incidence; Pr-Surv: progress by improved survival; Pr-Opt: optimal 
progress by decreasing incidence and/or improved survival accompanied by decreasing mortality; Det: deterioration by 
increasing incidence and/or worsening survival accompanied by increasing mortality; Non-Imp: non improvers because 
of an increasing incidence and/or worsening survival; Oth: other situations.
Optimal progress was defined as a decreasing incidence and/or improving survival 
accompanied by decreasing mortality (Pr-Opt). Decreasing incidence and/or 
improving survival without decreasing mortality were also seen as progress (Pr-
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Inc and Pr-Surv). Deterioration (Det) was defined as increasing incidence and/or 
deteriorating survival accompanied by increasing mortality. Increasing incidence 
and/or deteriorating survival without increasing mortality were classified as ‘non 
improvers’ (Non-Imp). All other situations were classified as ‘other’ (Oth). We 
considered a trend as increasing or decreasing when the trend showed a statistically 
significant change; in other cases we considered a trend as stable. 
statistical analysis
Incidence and mortality rates were standardized to the European standard 
population. Changes in these rates were evaluated by calculating the estimated 
annual percentage change (EAPC) and the corresponding 95% confidence interval 
(CI). A regression line was fitted to the natural logarithm of the rates, using the 
calendar year as regressor variable [i.e., y = mx + b where y = ln(rate) and x = calendar 
year, then EAPC = 100 * (em – 1)].
 Five-year relative survival was used to estimate disease-specific survival. It 
reflects survival of cancer patients, adjusted for competing causes of death in the 
general population with the same age and gender distribution. Traditional cohort-
based relative survival analysis was used for the period 1989-1991. Since follow-up 
was available until January 2010, period-based relative survival analysis was used 
for the most recent period 2007-2009, which gives the most up-to-date estimates 
for this period.17 Survival trends were quantified as the mean annual percentage 
change within 1989-2009 estimated by a linear regression model. A positive value 
of the mean annual change reflects an upward trend in survival (i.e., improving) 
and a negative value implies a negative trend (i.e., deterioration). p-Values are two-
sided, and p<0.05 was considered statistically significant. All statistical analyses were 
performed using SAS (version 9.2).
rEsults
tables 5.1.2 and 5.1.3 present data on tumor-specific incidence, survival and 
mortality for Dutch males and females separately. The tumor-specific relationship 
between incidence-mortality and survival-mortality is shown in Figure 5.1.1. The 
most important results are described below.
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Progress against cancer among males
Optimal progress (Pr-Opt) was observed for 12 out of 19 studied male cancers: 
laryngeal, stomach, colon, rectal, gallbladder, lung, prostate, bladder and thyroid 
cancer, leukemia, Hodgkin and non-Hodgkin lymphoma. For oral cavity, pharyngeal, 
esophageal, pancreatic, testicular and kidney cancer, and skin melanoma progress 
was made through significant survival improvement (Pr-Surv) only. Progress made 
by significant decreasing incidence (Pr-Inc) only was not observed for any studied 
male cancer.
 Deterioration (Det) was seen for 3 out of 19 studied male cancers: esophageal 
and kidney cancer and skin melanoma. However, the mortality increases were smaller 
than the incidence increases probably as a result of the above mentioned survival 
improvements. Oral cavity, pharyngeal, colon, rectal, prostate, testis and thyroid 
cancer, non-Hodgkin lymphoma and leukemia (9 out of 19 studied male cancers) 
were classified into the group non improvers (Non-Imp) because of a significantly 
increasing incidence. None of the studied male cancers showed a deteriorating 
survival trend. 
Progress against cancer among females
Optimal progress (Pr-Opt) became manifest for 12 out of 21 studied female cancers: 
stomach, colon, rectal, gallbladder, breast, uterus, cervical, ovarian and thyroid 
cancer, leukemia, Hodgkin and non-Hodgkin lymphoma. For skin melanoma, oral 
cavity, esophageal, lung and kidney cancer progress was made by significant survival 
improvement (Pr-Surv) only. Progress made by significant decreasing incidence (Pr-
Inc) only was not observed for any studied female cancer. Stable incidence, survival 
and mortality trends were seen for laryngeal cancer.
 Deterioration (Det) was seen for 6 out of 21 studied female cancers: skin 
melanoma, oral cavity, pharyngeal, esophageal, pancreatic and lung cancer. For skin 
melanoma, oral cavity and esophageal cancer the mortality increases were smaller 
than the incidence increases probably as a result of the above mentioned survival 
improvements. Colon, rectal, breast, uterus, kidney, bladder and thyroid cancer, 
leukemia, Hodgkin and non-Hodgkin lymphoma (10 out of 21 studied female 
cancers) were classified as non improvers (Non-Imp) because of a significantly 
increasing incidence. None of the studied female cancers showed a deteriorating 
survival trend. 
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Figure 5.1.1 | Trends in incidence and mortality (a, b), and 5-year survival and mortality (c, 
d) for cancer in males and females, the Netherlands 1989–2009 (dots with a circle: mortality 
trend is not statistically significant; for 95% CIs of the point estimates, see Tables 2 and 3). See 
page 318 for color figure.
DisCussioN
A largely positive pattern of progress against cancer was observed for the 
Netherlands in the last 20 years. Out of the 19 male and 21 female cancer types 
included in our study, optimal progress (Pr-Opt) was observed for 12 male and female 
cancers, and deterioration (Det) for three male and six female cancers only. Marked 
incidence increases were observed for nine male and ten female cancers without 
being accompanied by increasing mortality rates. These cancers and deteriorating 
cancers need our attention as well as cancers with a poor prognosis for which 5-year 
survival remained below 20% (e.g., cancers of the esophagus, stomach, gallbladder, 
pancreas and lung). 
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gender differences in progress against cancer
Out of the 17 studied cancers which occur in both sexes, all cancers showed progress 
(Pr-Opt or Pr-Surv) among males, while among women progress was seen for 13 
of these cancers. This gender difference in progress is due to opposite trends in 
incidence of laryngeal, pancreatic and bladder cancer and a lack of progress in terms 
of survival for pharyngeal and pancreatic cancer among females. The opposite trends 
in incidence are most likely a result of opposing trends in smoking prevalence, as 
was already observed for lung cancer. While the smoking prevalence among adult 
males decreased from 90% in the late 1950s to 30% in 2009, it increased among 
females until the 1970s (about 40%) and slowly decreased to 26% in 2009.18 This 
gender difference in smoking trends combined with alcohol intake is probably also 
the main cause of gender differences in deterioration that we have observed in this 
study: marked incidence and mortality increases were observed for cancers of the 
oral cavity, pharynx, pancreas and lung among females only.19,20 
 For pharyngeal cancer, males had a somewhat lower survival than females 
in 1989-1991 (survival gap of 8%), indicating more opportunity for improvement 
among males. However, large survival gaps of about 10% remained for skin 
melanoma, oral cavity and bladder cancer, where males had a worse survival, except 
for bladder cancer. Such gender differences have been reported before and it is 
known that (generally) males have a worse cancer survival than females, which was 
more pronounced in the past.21 The survival benefit for women is generally thought 
to be due to earlier detection because of increased awareness, but for melanomas 
the survival benefit has been shown to be independent of stage and other tumor 
characteristics.22,23
Dutch progress against cancer in an international perspective
Observed cancer trends in this study resembled those in other developed countries.13 
Within Europe, the Netherlands has one of the strongest increases of esophageal 
cancer incidence, probably partly due to the marked increase of obesity prevalence 
although this prevalence is still one of the lowest in Europe.24-26 Increases in prostate 
cancer incidence were more modest than in other European countries probably 
due to the lower frequency of PSA testing in the Netherlands.24 This also explains 
why prostate cancer incidence in the US is much higher than in the Netherlands. 
Dutch ovarian cancer incidence showed one of the strongest declines within Europe 
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and is at a lower level than in the US, probably due to very common use of oral 
contraceptives in the Netherlands.24, 27 
 Survival improvements for the Netherlands are comparable with findings for the 
US, except for bladder cancer where only US data showed improvements. Survival 
for patients with laryngeal cancer deteriorated in the US, while it remained stable 
in the Netherlands.14 Overall the 5-year survival rates were higher in the US than 
in the Netherlands, particularly for colorectal, thyroid, prostate and kidney cancer 
concurring with a comparison of European cancer survival results (EUROCARE) with 
US SEER data.4 The higher frequency of screening of colorectal and prostate cancer 
in the US is largely responsible for these higher survival rates. However, there might 
also be a difference in completeness of follow-up in the cancer registries, being high 
in the Netherlands and which effects survival outcome negatively.11 
influence of prevention on progress
Prevention programs aimed to reduce exposure to risk factors (e.g., smoking, obesity 
and excessive sun exposure) and thereby to reduce cancer incidence. In this study, 
we observed marked incidence decreases for stomach, gallbladder, laryngeal (only 
males), lung (only males), bladder (only males), cervical and ovarian cancer. The 
decreases of laryngeal and lung cancer among males are good examples of the effect 
of decreasing smoking prevalence among males. The national screening program 
for cervical cancer successfully reduced cervical cancer incidence by detecting pre-
malignancies.28 
 Prevention programs against smoking, obesity and excessive sun exposure 
remain important because of the enormous incidence increases of esophageal, 
oral cavity (only females), pharyngeal and lung cancer (only females), and skin 
melanoma.
influence of shifts in stage distribution on progress
A shift in stage distribution can be an important cause of improving or deteriorating 
survival, although these shifts do not always become visible in overall incidence 
trends. They can be caused by changes in diagnostics, early detection (e.g., screening 
programs) and increased awareness among clinicians and the population. Among 
cancer types with improved survival, we observed a statistically significant rise in 
the occurrence of early stages (T1/2 N0 M0) for esophageal, rectal, skin melanoma, 
female breast, uterus, prostate, testis, kidney and thyroid cancer (Supporting 
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Information Figure). In case of skin melanoma this rise is probably also due to 
increased awareness in the population, although advanced stage melanomas also 
increased during the last decades.29,30 The national breast cancer screening program 
in the Netherlands would explain the shift towards early breast cancer stages 
among women aged 50-75 years and probably part of the survival improvement,31,32 
to some extent also explained by increased use of adjuvant treatment.32,33 Increasing 
use of PSA tests in the Netherlands partly explain the shift towards early stage and 
even latent prostate cancers, leading to artificially high survival rates.34  
 Improvements in diagnostics (e.g., improved imaging techniques and increased 
number of examined lymph nodes) may also have led to a decrease in the occurrence 
of early stages resulting in the so-called stage migration. This is probably valid for 
laryngeal, stomach, lung, pancreatic, ovarian and bladder cancer for which a decrease 
in the occurrence of early stages was observed in the present study (Supporting 
Information Figure).
influence of shifts in subsite/morphology distribution on progress
Shifts in the prognostic profile as determined by the subsite or morphology 
distribution can cause a deteriorating survival, which can be compensated by new 
therapies that improve survival at the same time. So, a stable survival does not 
always reflect a lack of progress. Shifts in subsite/morphology reflect changes in 
risk factor prevalence and are not necessarily visible in overall incidence trends. An 
example is the subsite shift from noncardia to cardia stomach cancers (cardia shifted 
from 26% to 32% for males and 13% to 18% for females in 1989-1991 and 2007-
2009, respectively). Relative 5-year survival for patients with cardia tumors was only 
15% compared to 24% of those with noncardia tumors despite ample attention for 
earlier detection due to more endoscopy and better surgery.35
Changes in therapy regimens and progress
In the Netherlands, progress was more often made in terms of survival than 
in terms of incidence, indicating a large role for changes in therapy. Changes in 
survival may be influenced by improved treatment but also by preceding changes 
in incidence. Unraveling and elucidating changes in incidence and therapy is often 
difficult, even when incidence remains stable, because there might be underlying 
proportional changes in age, subsite, morphology and stage distribution, whether 
or not following risk factor prevalence changes or early detection. Multivariable 
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relative survival analyses have been shown to be useful in unraveling the underlying 
mechanisms of improved survival, e.g., a study on colon carcinomas showed a 
marked improvement in survival for patients with stage III disease to be due to more 
adjuvant chemotherapy.36
remarks on measuring progress 
Because of the interdependence between survival and incidence, it has been 
suggested to define progress against cancer merely as decreasing mortality.9,37,38 
Using this definition, our results indicate progress in 12 of 19 male cancers and 
12 of 21 female cancers. However, declining cancer mortality does not necessarily 
reflect recent progress, because mortality rates for a given year reflect the risk of 
cancer death among patients diagnosed over the preceding years depending on 
the prognosis of a certain cancer (e.g,. breast cancer mortality rates reflects deaths 
from the preceding 15-20 years).10 Improvements in survival can also slow down 
an increase of mortality following the incidence trend. In this study, e.g., EAPCs 
for mortality from skin melanoma, oral cavity and esophageal cancer were lower 
than those for incidence, most likely due to improved survival. Interestingly, certain 
cancers (melanoma and esophageal cancer for both sexes, oral cavity and lung 
cancer for females and kidney cancer for males) fall both into the Pr-Surv group 
and into the deterioration group which illustrates there can be progress in survival 
while incidence and mortality continue to rise. Therefore, it is important to consider 
information on incidence, survival and mortality simultaneously. Another reason 
not to use cancer mortality data only is that changes in mortality can also follow 
changes in coding practice of underlying cause–of-death. Therefore, we feel it is 
necessary to interpret mortality changes in combination with incidence and survival.
 Welch et al.8 attempted to measure progress against cancer in the USA by 
correlating both changes in incidence and changes in mortality with changes in 5-year 
survival. They concluded that the effectiveness of cancer care is tenuous, because 
of the small effect of survival changes on mortality, but much more influenced by 
changes in incidence. We did not focus on the strength of the association between 
incidence, survival and mortality, because of the difficulty of unraveling changes in 
incidence and therapy. 
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limitations of this study
Using the progress model proposed in this study, one should realize that taking 
the same observation periods for incidence, survival and mortality it is not possible 
to observe the final effect of the incidence-survival combination on mortality: as 
it takes some time before changes in incidence and survival are reflected in the 
mortality statistics. An alternative could be taking a gap of x years between the 
observation periods of incidence/survival and mortality. However, this gap of x years 
would be different for different cancer types and it would mean not using the most 
recent trend information on incidence and survival, which would be a pity. Another 
important thing to realize is that studying a certain time period does not take into 
account the progress made before that period. For example, before 1990, much 
progress was made in the treatment of testicular cancer resulting in a decreasing 
and very low mortality rates.39 In fact, mortality has become so low that there is 
hardly any room left for progress made by improved survival. In these situations 
progress made by improved survival only is the best progress one can expect.
 In this study, changes in incidence and mortality were evaluated by EAPCs 
calculated over the whole study period. However, during a longer period, temporary 
trends in opposing directions are not taken into account. For example, in the 
Netherlands the incidence of cervical cancer decreased from 9.1 per 100,000 to 6.5 
in 2001, but from 2001 it started to increase to 7.6 per 100,000 in 2009, but over the 
whole period there is still an overall decreasing incidence trend.40 When studying 
longer time periods, one might have to use joinpoint analysis in order to take such 
effects more precisely into account.
 To calculate 5-year relative survival we used two different methods, i.e., cohort 
and period-based survival analyses. Although period-based results can differ slightly 
from the traditional cohort-based results, it has been repeatedly shown that they 
come very close to the later obtained cohort-based results. A difference between 
the two calendar periods based on the two different methods likely points to a 
change in prognosis.41 
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CoNClusioN
In conclusion, our conceptual framework limits misinterpretations from separate 
trends and generates a more balanced discussion on progress. The observed 
progress against cancer in the Netherlands is the result of successful prevention 
resulting in e.g., decreasing smoking prevalence (particularly among males, e.g., 
lung, laryngeal and bladder cancer), adequate screening of breast and cervical 
cancer (national coverage), other early detection (e.g., melanoma and PSA testing 
for prostate cancer), better staging by improved imaging techniques (e.g., lung and 
kidney cancer), improved staging and treatment (e.g., rectal cancer). Although, 
there is still much room left for improvement, smoking prevalence and incidence 
of smoking related cancers are still on the increase in women, incidence of obesity 
related cancers and melanomas continues increasing and survival of esophageal, 
lung, gallbladder, pancreatic and stomach cancer remains still poor.
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APPENDix: suPPortiNg iNFormAtioN FigurE 
Percentage of low stages of studied cancer types among males and females
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ABstrACt
If cancer survival is reported to be worsening over time or inferior compared to 
other countries, politicians and health-care workers may get blamed because 
suboptimal care is presumed to be the cause. Yet, a variety of reasons exist for 
cancer survival statistics to change for the worse, of which deterioration of care 
is only one. Another explanation is that the improved diagnosis of premalignant 
lesions causes survival statistics to reflect only the most aggressive cancers – those 
with the poorest prognosis. In addition, deleterious changes in the distribution of 
prognostic factors and in the distribution of sociodemographic characteristics may 
negatively affect survival proportions. In this article, we identify the pitfalls that 
might be encountered in comparisons of published, population-based survival data 
from different time periods or populations.
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iNtroDuCtioN
Cancer survival statistics attract a lot of attention, particularly when comparisons 
between calendar periods or countries show that survival has decreased over time 
or is lower than expected based on the average found in surrounding countries. 
Population-based cancer survival tends to remain stable or increase over time in 
most industrialized countries and for most cancer types.24,42 Such increases in survival, 
however, do not necessarily reflect true improvements in cancer treatment. For 
example, early detection and screening practices have artificial effects on survival 
statistics because of the presence of a lead time or length bias (Box 1).7, 8 
 Decreasing survival proportions are sometimes observed over time and can result 
from of a variety of causes, even after adjustment for age and all-cause mortality.24, 
43 Here, we briefly explain the principles underlying cancer survival calculations and 
illustrate that a decrease in survival can be attributed to four factors: deterioration 
of care or of access to it; improved diagnosis of premalignant lesions; deleterious 
changes in the distribution of prognostic factors; and changes in the distribution 
of socio-demographic characteristics. We identify possible pitfalls that might be 
encountered when published survival data from different time periods or different 
populations are compared.
Box 1. Lead time and length bias
Early detection or screening aims to diagnose a disease at an earlier stage than 
would happen without screening. When the moment of death is not postponed 
by screening and, therefore, no additional lifetime has been gained, the survival 
time since diagnosis is longer for a screened person than for an unscreened person. 
In this case, screening seems to increase survival time, and this gain is called ‘lead 
time’.
Slow-growing tumors often have a better prognosis than rapidly growing ones. 
Early detection or screening is more likely to detect slow-growing tumors than 
fast-growing tumors, as slow-growing tumors exist for an extended time without 
causing symptoms, and some of these tumors might actually never cause clinical 
disease. In such cases, screen-detected tumors seem to be associated with improved 
survival because they represent a group of tumors that already had an inherently 
favorable prognosis. This effect is called ‘length bias’.
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DEtErmiNAtioN oF CANCEr surViVAl 
Cancer survival is estimated for cohorts of newly diagnosed patients, based on 
cytological or histological criteria and sometimes clinical criteria of patients when 
entered into a cohort study. Survival is measured as the time from cancer diagnosis 
until death; a 5-year follow-up period is most frequently used as an indicator of 
outcome, although survival at 10 years would be more suitable for many cancer 
types, such as those amenable to screening (for example, breast and prostate 
cancer). End points for calculating survival can vary. Death due to any cause is used 
to calculate all-cause survival, that is, the proportion of patients with cancer who are 
alive at a certain point in time after diagnosis. Death due to the cancer under study 
or its treatment is reflected by disease-specific survival. 
 Many practical problems are encountered in correctly determining and 
registering cause of death. For example, determining the correct underlying cause 
of death can be difficult.3 Relative survival circumvents the need to determine the 
cause of death because it represents the ratio of the overall survival for a cohort 
of cancer patients and the expected overall survival for the general population 
with the same sex and age distribution as the cancer patient cohort. Relative 
survival measures the excess mortality associated directly and/or indirectly with the 
diagnosis of a cancer and, thus, includes deaths due to complications of cancer or its 
treatment. For relative survival to be interpreted as a measure of excess mortality 
individuals with cancer, an accurate estimation of the expected mortality for the 
general population is important and requires mortality data stratified by sex, 
age, and calendar year.7 Cancer mortality and non-cancer mortality are assumed 
to be independent. Moreover, in theory, relative survival is dependent on trends 
in other causes of death in the general population. These assumptions, however, 
should sometimes be questioned. For example, a markedly decreased incidence 
and mortality from cardiovascular diseases (which would result in an increase in 
the expected overall survival for the general population) would lead to a decrease 
in the relative survival ratio of cancer, even when the observed disease-specific 
survival remains stable. In addition, patients with cancer are assumed to have had 
an average life expectancy if they had not been diagnosed with cancer. This is, of 
course, an arbitrary assumption for some types of cancer. For example, patients with 
lung cancer may have a lower life expectancy because the cause of their cancer 
(smoking) is also a strong risk factor for mortality from other diseases. 
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Relative survival ratios can be compared over time or between geographical regions, 
despite the ageing of populations, but the results are meaningful only when they 
are adjusted for age. In instances of differential period of observation, the most 
reliable survival comparisons are based on age-specific risks.44 Relative survival ratios 
are very useful for specific cancer subsites, but this measure is not suitable for all 
cancers combined because the deaths due to all cancers represent a considerable 
proportion of deaths due to all causes. The ‘expected’ survival figures for relative 
survival calculations in this scenario are based on mortality data for the general 
population that are substantially influenced by cancer mortality, causing the 
‘expected’ mortality figures to be overestimated. This causes the relative survival 
estimates to become less valid. Moreover, survival statistics for all cancer sites 
combined should not be compared directly because the various types of cancer and 
their distributions can differ greatly between distinct populations and time periods. 
To judge the quality of survival estimates given by a registry, the inclusion and 
exclusion rules of the registry database should be clear. If these rules of such criteria 
change, for example, in coding systems such as the ICD-O international classification 
of diseases or TNM staging system, survival estimates might change rapidly. When 
neoplasms that were previously considered noninvasive are reclassified as ‘new’ 
cancers (as happened, for example, with the change in classification of bladder 
papillomas into papillocarcinomas in 1978), survival estimates increase markedly.45 
Moreover, completeness of study follow-up is essential for accurate survival 
estimates. Unfortunately, administrative completeness can vary with time across and 
between countries. Survival proportions tend to decrease when the completeness 
of follow-up improves because many patients who were initially lost to follow-up 
are actually found to have died. The number of death-certificate only (DCO) cases 
in cancer registries depends on the quality of the registry and on access to death 
certificates. These cases are often excluded in survival analysis because the date of 
diagnosis (and hence survival time) of DCO cases is unknown.46 Registries with a high 
proportion of DCO cases will overestimate survival; therefore, if the proportion of 
DCO cases decreases over time, survival estimates may seem to worsen.47
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DEtEriorAtioN oF ACCEss to CArE 
The most obvious reason for decreasing survival proportions is less-aggressive or 
substandard care that results in lack of early detection or less-effective treatment of 
cancer, although this situation is uncommon. For example, decreased relative survival 
ratios for patients with laryngeal cancer were observed in the mid-1990s in the US 
compared with the 1980s.48 During the mid-1990s, many clinicians preferred to treat 
these patients with irradiation rather than laryngectomy. Detailed analyses over time 
revealed shorter survival for patients with laryngeal squamous-cell carcinoma who 
underwent nonsurgical treatment, compared with those who underwent surgery.49 
 Likewise, among patients with high-grade T1 bladder cancer who underwent 
radical surgery in the US, 5-year disease-free survival before 1998 was 70%, 
versus only 40% after 1998. During the 1990s, intravesical therapy (for example, 
immunotherapy and/or chemotherapy) facilitated bladder-sparing strategies for 
these patients. Before 1998, 74% of patients with high-grade T1 bladder cancer 
underwent radical surgery without prior intravesical therapy, while only 43% of such 
patients did so after 1998. The observed decrease in survival was attributed to the 
delay in scheduling radical surgery that resulted from increased use of intravesical 
therapy.50
 The economic collapse of the former socialistic countries of Central Europe 
coincided with decreased cancer survival during the transition period; the survival 
of patients with ovarian, cervical and uterine cancer, childhood soft-tissue sarcomas, 
and hepatic and germ-cell tumours temporarily decreased between 1988–1992 
and 1993-1997.51,52 These temporary decreases were probably related to the 
disintegration of health-care systems and infrastructures. 
 When cancers are detected at a later stage or are mistakenly classified as low-
stage disease because of deterioration in screening availability (for example, poor 
imaging capacity) treatment will be less effective and survival will decrease. Adjusting 
the survival calculations for stage at diagnosis is possible,53 although improvements 
in staging methods and changes in stage-coding could still be problematic when 
stage-adjusted survival estimates are compared over time. 
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imProVED DiAgNosis oF PrECANCErs
Survival proportions can decrease while therapeutic options remain stable or 
improve over time and/or early detection remains unchanged or improves. This 
pattern occurred for cervical cancer in many European countries, where large-
scale and high-quality population-based programs for cervical screening gradually 
became available (table 5.2.1).24 The same phenomenon might be observed in the 
future for colorectal cancer. 
 The aim of screening for cervical and colorectal cancers is not only the 
detection of cancers at an early stage but also the detection of premalignant lesions, 
which can be treated to prevent the development of ‘invasive’ cancer. However, 
the cancers that occur despite screening may consist of a select group of rapidly 
growing, aggressive tumors that are probably difficult to treat and, thus, might 
result in decreased survival proportions, preceded by a decreased cancer incidence. 
 Screening for most other types of cancer (for example, breast or prostate) 
detects early stages of cancer rather than premalignant lesions. For these cancers, 
survival proportions will increase as a result of screening because of lead time 
bias and even length bias (Box 1), and possibly as a result of improved efficacy of 
treatment. Survival proportions may decrease again, however, when individuals’ 
awareness or willingness to participate in screening programs decreases, which 
can potentially lead to increased disease stage at diagnosis. If the date of death is 
not postponed by treatment, then the survival proportions worsen, leading to an 
inverse ‘lead time’ effect. 
 New and improved methods for cancer diagnosis frequently result in improved 
survival proportions because these methods are more precise and/or detect the 
cancers earlier than previous techniques, which is hoped to result in improved 
therapeutic options. Conversely, the introduction of a new diagnostic technique 
may temporarily decrease cancer survival proportions. Pancreatic cancer is difficult 
to diagnose and treat and is associated with a poor prognosis. New diagnostic 
technologies have resulted in more diagnoses of this cancer occurring during the 
patients’ lifetimes, whereas previously the diagnosis would have been made at 
autopsy and recorded as a DCO. These tumors with a very bad prognosis will now be 
included in the survival statistics resulting in lower survival estimates.7
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table 5.2.1 | Relative survival proportions for cervical cancer in Europe
region start of screening 
program (year)
type of screening 
invitation
5-year relative survival ratios trends in survival
1990-199454 2000-20024,55,56 
Austria (Tirol) 1970 PB/OP (regional) 63.6 64.2 Increased
Iceland 1964 NRS 68.6 70.6 Increased 
Finland 1963 PB 66 65.8 No change
Italy 1982–1998 PB/OP (regional) 66.6 67 No change 
Netherlands 
(three regions)
1980 PB 69.4 69.2 No change
Scotland 1988 NRS 60.6 61 No change 
Norway 1995, pilot 1992 NRS 69 67.5 Decreased
Sweden 1967–1977 NRS 69.6 66.7 Decreased 
Switzerland No data OP 68.7 66.8 Decreased 
Czech republic 1966 OP 65.2 59.8 Large decrease
England 1988 NRS 63.8 58.6 Large decrease 
Germany 
(Saarland)
1971 OP 63.5 55.5 Large decrease 
Malta No data No data 64.4 46.5 Large decrease 
Poland No data No data 48.2 56 Large increase 
Slovenia 2003 (1995 
opportunistic)
NRS 59.9 65.2 Large increase 
Spain 1986 (regional) PB/OP 68.7 60.4 Large decrease 
Wales 1988 NRS 58.7 52.6 Large decrease 
Abbreviations: NRS, invitation only, to women who did not recently have an opportunistic smear; OP, opportunistic 
only; PB, population-based, invitational program.
CHANgEs iN ProgNostiC FACtors
subtypes and subsites 
Changes in risk-factor exposure may lead to shifts in the distribution of cancer 
subtypes. In the Netherlands, relative survival ratios for adenocarcinomas of the 
lung decreased during the 1980s despite increased application of improved 
endoscopic techniques by lung physicians, which was accompanied by improved 
access to specialized care. This decrease in relative survival ratios was partly 
attributed to the termination of mass screening for tuberculosis in the early 1980s, 
which sometimes detected slow-growing peripheral adenocarcinomas. In addition, 
the higher concentration of carcinogens in the peripheral lung zone as a result of 
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the increased use of filter cigarettes and deep inhalation may have caused tumors 
to more metastasize rapidly.57 Similar decreases in overall lung cancer survival from 
1992 to 2005 were observed in Malta, where a stable overall incidence of and 
mortality from lung cancer was accompanied by a relative rise in the incidence rate 
of adenocarcinomas (R. Micallef, personal communication).
 Shifts in cancer subtype and subsite distribution may need to be studied over 
time as a determinant of survival. This requirement is illustrated by a study of 
changes in incidence of and survival from gastric cancer in the southeastern part of 
the Netherlands. Despite marked improvements in the endoscopic early detection, 
staging, surgery, and perioperative mortality of gastric cancer, no improvement 
in gastric cancer survival occurred during the period 1982-1995 because the 
proportion of cardiac and diffuse cancers with a poor prognosis had increased.58 
Laryngeal cancers represent another example of the negative influence of shifts in 
cancer subsite on survival.46 Laryngeal cancers of the glottis exhibit a 5-year relative 
survival of around 60-80%, and for supraglottal cancers this rate is at around 40%.59 
Cancers of the glottis are usually detected at early stages. Alcohol consumption 
and tobacco smoking have different etiological effects on tumor subsite, with 
alcohol consumption being more relevant for supraglottal tumors and smoking for 
glottal cancers. With the decreasing prevalence of smoking and the stable alcohol 
consumption rates in many European countries, the proportion of cancers of the 
poor prognostic subsite (supraglottal tumors) will increase and negatively affect the 
relative survival ratios of laryngeal cancer over time.
Comorbidity
Changes in the prevalence of risk factors can also affect overall survival because 
of the presence of concomitant diseases (comorbidity). If a concomitant condition 
becomes prevalent in the population as a whole, the relative survival ratio is 
corrected for this change. However, relative survival ratios are likely to be affected 
when the comorbid condition is strongly associated with the tumor (for example, 
chronic obstructive pulmonary disease in patients with lung or laryngeal cancer) 
or when the comorbid condition is not only life-threatening, but also influences 
the eligibility of patients to receive aggressive cancer treatments such as surgery or 
chemotherapy, as is the case for diabetes.60
 Changes in behavioural risk factors, such as an increase in alcohol consumption, 
cause rises in alcohol-related cancer incidence, mortality and comorbidities, such as 
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ischemic heart disease, stroke, hypertension, diabetes, liver cirrhosis, and depression. 
An increased prevalence of such comorbid conditions will lead to decreased survival 
proportions.61 Since alcohol consumption is an important risk factor for cancer, 
particularly for squamous-cell cancer of the esophagus and supraglottal cancer of the 
larynx, the above-mentioned comorbid conditions are likely to be prevalent among 
patients with esophageal and laryngeal cancer, and result in suboptimal treatment 
and increased complications. This phenomenon may also have contributed to the 
observed declines in survival of these cancers during the transition period in the 
former socialist countries in Central Europe.24,62,63 
 In a similar manner, the increased prevalence of infectious diseases related 
to cancer (including HIV and hepatitis B and C viruses)64 may not only increase 
the incidence of tumors such as lymphomas and liver cancer, but may also have a 
negative effect on the survival of patients with these cancers.
soCioDEmogrAPHiC CHArACtEristiCs 
When patient populations change rapidly, survival can also be affected; for 
example, when certain subgroups comprise a larger part of the cancer burden due 
to changes in the distribution of socio-economic status. Cancer survival among 
people of low socioeconomic status is generally lower than it is in those of mid or 
high socioeconomic status; the relative risk of death within 5 years of diagnosis in 
the most deprived groups is 1.3-1.5-fold higher than in the most affluent group.65,66 
Underlying causes of this worse prognosis are related to decreased awareness and 
unfavorable tumor characteristics (for example, later stage at diagnosis because of 
diagnostic delay); personal characteristics such as ethnicity, screening participation 
rates, psychosocial factors and comorbidity; and health-care factors including 
treatment, screening, and quality of medical care.66 Changes in the distribution of 
socio-economic groups (for example, as a consequence of selective emigration of 
healthy and enterprising individuals) may lead to decreased survival proportions.
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CoNClusioNs
In conclusion, a variety of factors can lead to decreased cancer survival proportions, 
most of which do not represent deteriorating in care. Unfavorable changes in 
underlying risk factors and early detection or screening practices that lead to 
the identification of relatively less-aggressive lesions are often the cause of this 
phenomenon, as are the changing demographic profiles of populations of patients. 
Worsening survival proportions merit an in-depth investigation that takes into 
account preceding trends in incidence, particularly for tumor subtype or subsite. 
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For the first time it was possible to study long term trends in incidence and prognosis 
of and mortality from the diversity of cancer nationwide in the Netherlands because 
of recent availability of nationwide prognosis data in the Netherlands Cancer 
Registry. Combined analysis and presentation of incidence, prognosis and mortality 
potentially results in a more objective assessment of progress against cancer 
achieved in the Netherlands, while avoiding over-interpreting findings from one of 
these measures only. 
 First we described these cancer trends from 21 European countries, exploring 
the progress against cancer achieved in the Netherlands compared to other European 
countries. Secondly, we described cancer trends in more detail for oesophageal, 
lung, ovarian and prostate cancer in order to get an answer on our first research 
question: ‘what was the impact of changes in risk factor prevalence, primary and 
secondary prevention, and cancer management on cancer trends?’ Because of the 
diversity of incidence, prognosis and mortality trends (e.g. incidence increases faster 
than mortality) we developed a quantitative framework of measuring progress 
against cancer to get a comprehensive overview of all cancer trends. Besides, we 
discussed the merits of this approach versus using only trends in survival or mortality 
as outcome and answered our second research question: ‘How can we optimize the 
assessment of progress against cancer and what are the pitfalls?’
In this final chapter results are summarized and discussed, followed by an overall 
conclusion on our main question: ‘How much progress did we make against cancer 
in the Netherlands since the late 1980s?’.
DutCH CANCEr trENDs iN A EuroPEAN CoNtExt
The main conclusions from Chapter 2 were that cancer rates among Dutch males 
were mostly equal or even lower than the European average, particularly for 
cancers of the oral cavity and pharynx, stomach, pancreas, testis and prostate. Dutch 
females showed to have more often higher cancer rates than the European average, 
particularly for skin melanoma and cancers of the oral cavity and pharynx, larynx, 
lung, oesophagus, colorectum and breast. table 6.1 gives an overview of incidence, 
survival and mortality rates of the Netherlands compared to European average rates 
in the mid-1990s and early 2000s. 
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Cancers that were more common among Dutch males and females than among 
other European males and females are those which are strongly associated with 
smoking, overweight and excessive sun exposure. The smoking prevalence among 
Dutch females became high during the 1970s and continues to be high compared 
to Europe in general.1 This would explain the high incidence rates of cancers of 
the oral cavity and pharynx, larynx and lung among Dutch females. Remarkable 
is the enormous increase in the occurrence of oesophageal cancer since the mid-
1990s among Dutch males compared to other European males, while the incidence 
rate was average in the mid-1990s. This incidence increase is due to the increase 
in adenocarcinomas, which are associated with reflux caused by obesity.2 The 
prevalence of obesity among Dutch males tripled since the 1980s, although the 
prevalence remains relatively low compared to other European males.1, 3 Increases 
in skin melanomas have been described for many developed countries, and are 
speculated to be largely due to overdiagnosis.4 However, unlike the situation in 
many other countries, melanoma incidence rates of both thin and thick melanomas 
increased and mortality also increased since 1989. This makes clear that the incidence 
increases in the Netherlands are not merely due to overdiagnosis, but seems to be 
real, at least partly.5 Compared to the European average, skin melanoma incidence 
was high, particularly among females. This is most likely due to high excessive sun 
exposure possibly as a result of less awareness about the risks of sunburn and use 
of sunbeds or a low risk perception of the seriousness of skin cancer in a population 
with predominantly sun-sensitive skin types. 
 The high breast cancer incidence among females is on the one hand possibly 
related to the gradual introduction of our successful national screening program 
in 1989 with an attendance rate of 82%, one of the highest worldwide.6-8 On the 
other hand, it is plausible that the high incidence is related to changes in risk factors 
prevalence, like younger age at menarche, older age at menopause, increased age 
at first childbirth, lower parity and shorter lactation. The increased prevalence of 
obesity, diminishing physical activity and increased alcohol consumption are likely to 
have had a negative impact as well on the incidence of breast cancer.6,9,10 However, 
the breast cancer incidence started to stabilize since 2007,11 possibly as a result of 
levelling off of the screening effect and the decrease in hormone-replacement 
therapy since the early 2000s.12 
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imPACt oF CHANgEs iN risK FACtor PrEVAlENCE, PrimAry 
AND sECoNDAry PrEVENtioN AND CANCEr mANAgEmENt oN 
CANCEr trENDs
Many efforts have been made to lower cancer incidence and mortality and improve 
cancer prognosis by primary and secondary prevention programs and changes 
in cancer management (e.g. changes in diagnostics and therapies) as described 
in Chapter 1. table 6.2 gives an overview of changes in incidence, prognosis and 
mortality trends from all cancer types studied in the project ‘Progress against cancer 
in the Netherlands since the 1970s’ and the main cause(s) for these changes. From 
this table 6.2 we can conclude that changes in risk factor prevalence are one of the 
most important causes of changes in cancer trends. In Chapter 3.2 we showed that 
the ovarian cancer mortality rate decreased since the 1970s with a reduction of 36%, 
particularly among women born after the 1920s. The ovarian cancer incidence rate 
reduced by 30% between 1989 and 2009, which was one of the largest reductions 
observed within Europe.13 Both changes were mainly caused by the introduction of 
oral contraceptives in the mid-1960s, which showed to be protective against ovarian 
cancer.14 Another example of a change in cancer risk upon spontaneous changes in 
risk factor prevalence is stomach cancer. Due to changes in dietary patterns, improved 
food preservation techniques (e.g. refrigerator) and a decline in Helicobacter pylori 
infections incidence of and mortality from stomach cancer declined dramatically.15, 16
 These two examples of successes in lowering cancer incidence and mortality 
were reached without prevention campaigns, but show the potential room for 
primary prevention. From different studies it appeared that 25-50% of cancer is 
avoidable in the long run through lifestyle changes.17, 18 In Chapter 3.1 we showed 
the effect of lowering smoking prevalence rates on lung cancer incidence and 
mortality trends among females, as had already been seen for men in the past.19 The 
total lung cancer incidence among females is not yet decreasing and neither are the 
other smoking related cancers, but we are expecting a levelling off or decrease soon. 
These developments as a result of decreasing smoking prevalence among the Dutch 
population illustrate that primary prevention against smoking can be considered as 
a success. However, much less has been achieved than in neighbouring countries, as 
illustrated by the relatively high levels of smoking related cancers compared to the 
European average.
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For lung cancer we know that on average 57% is avoidable by reducing smoking 
to the lowest prevalence levels observed in Europe.17 For most cancer types, the 
association with a risk factor is much less strong than for smoking and lung cancer, 
hence potential effects of primary interventions are expected to be less clear-cut. 
From a public health perspective it is however important to keep in mind that 
primary prevention against a risk factor often affecting multiple chronic or non-
communicable diseases simultaneously, including certain cancer types (for instance, 
anti-smoking campaigns are also affecting trends of head and neck, oesophageal 
and bladder cancer, vascular diseases and COPD). Another example of primary 
prevention activities is the information campaigns on the risk of excessive sunbathing 
and sunburns especially for younger people by the Dutch Cancer Society. However, 
the incidence of skin melanomas is still rising, not only thin melanomas, but also 
thick melanomas, which results in a modest, but continuing increasing mortality.48 
But we have to keep in mind that it takes a long time before positive effects of 
primary prevention campaigns are visible in terms of cancer rates because of long 
latency times, e.g. for lung cancer it is about 30 years.49 The time between scientific 
evidence for a risk factor and governmental action can take even longer (lag 
time).50 Despite such long latency times it remains important to invest in primary 
prevention, especially when we consider the increasing prevalence of obesity 
and the increased use of alcohol during the 1970s and early 1980s. The increase 
in overweight/obesity is likely to be partly responsible for the observed incidence 
increases of non-Hodgkin lymphoma, leukaemia, oesophageal, colorectal, female 
breast (postmenopausal), corpus uteri, kidney and thyroid cancer between 1989 and 
2009.20,51 The observed increases in incidence of cancer of the oral cavity, pharynx, 
female breast and colorectal cancer are partly due to the increased use of alcohol.20,52 
While costs of primary prevention are lower than developments of new treatments, 
only 2% of all cancer research funding of the European Commission was spent on 
cancer prevention in 2002-2006.53 Especially in this time of the financial crisis with 
lower health budgets, we should focus more on primary prevention.54 Besides, it is 
important that governments become faster in taking action against upcoming risk 
factors and not waiting so long as they did against smoking and asbestos in the past.
 Two examples of secondary prevention in the Netherlands are the national 
screening programmes for breast and cervical cancer. Because of the different 
nature of the lesions detected (early stage invasive cancer and premalignant 
lesions), these two screening programmes had different effects on cancer trends. 
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While breast cancer screening caused at first an increasing incidence until 2007, 
particularly an increase in early stages and a decline in advanced stages,55,56 cervical 
cancer screening caused a decreasing incidence during 1989-2001.33
 Before the introduction of the nationwide mass-screening program for breast 
cancer in the 1990s, increasing trends were already found in the Southeastern 
Netherlands and breast cancer mortality started to decrease since the early 1990s, 
particularly for women younger than 70. A decrease in mortality as a result of 
population screening would not be expected to become visible within such a short 
time-frame.6 However, a recent case-control study showed that early detection by 
mammography screening might reduce breast cancer mortality by 50%.57 On the 
other hand, improvements in adjuvant treatment of breast cancer patients played 
also a role in the mortality decrease by improving survival of these patients.58-60
 The incidence of cervical cancer decreased during 1989-1998, followed by a 
more rapid fall in the period 1998-2001, although the incidence started to increase 
afterwards. The observed incidence trend followed the trend in age group 35-54 
years (the invited screening group before 1996) suggesting that screening was likely 
to underlie the observed incidence trends. Since 1996, the screening program was 
restructured and during the conversion period 1996-1998 several extra birth cohorts 
were invited followed by a period with normal, but less intensive screening (screening 
interval was lengthened from 3 to 5 years and age group was broadened to 30-60 
years). This conversion period of intensive screening is probably the reason for the 
rapid incidence decrease in 1998-2001 followed by a compensating modest increase 
in incidence. Besides changes in the screening program, other underlying causes, 
such as an increase in HPV infections in young people, might also be responsible for 
the increasing incidence.33 
 The Dutch Minister of Health decided in 2011 to start colorectal cancer screening 
from 2013 using the immunochemical faecal occult blood test (iFOBT).61 All persons 
aged 55-75 will be invited every 2 years for this national screening program. As 
this screening program, like the one for cervical cancer, is detecting pre-malignant 
polyps it is expected that the incidence trend will decrease on the long-term, while 
during the first 4-5 years the incidence will slightly increase. Furthermore, it was 
calculated that every year 1,428 deaths from colorectal cancer will be prevented 
during the first 30 years of screening with an attendance rate of 60%.62 In 2010, 
about 5,000 patients died from colorectal cancer in the Netherlands.11 With the 
increase in therapy costs for advanced colorectal cancer, screening is not only a 
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good approach to lower the incidence and mortality, but also to control the costs of 
colorectal cancer treatment.63 As a result of detecting pre-malignant polyps survival 
will not improve or even deteriorate if nothing changed.
 A negative effect of screening is overdiagnosis and overtreatment. In Chapter 
4.1 we gave an example of this negative screening effect by studying the prostate 
cancer trends and increased use of testing serum prostate-specific antigen level 
(PSA). Prostate cancer incidence increased and survival improved enormously by 
mainly detecting of indolent cancers which increased especially since 2000. 
 If a certain cancer type is a huge public health problem and there is a valid 
screening test which can detect pre-malignancies or early stages of cancer with 
better treatment options than would be available if the cancer was diagnosed later, 
and good prognosis, screening is a definitely good option to prevent (late stage) 
cancer and also saving treatment costs.
 Improvements in diagnostics and treatment can result in improved cancer 
survival as we illustrated in Chapter 4.2 for ovarian cancer. Five-year relative survival 
in advanced stage ovarian cancer patients increased from 18% in 1989-1993 to 
28% in 2004-2009. Part of this improvement was caused by changes in treatment: 
more patients received (neo)adjuvant chemotherapy and underwent an optimal 
debulking surgery over time. Other examples of (new) effective therapies that we 
could relate to improvements in survival are the total mesorectal excision (TME) 
surgery, increased use of pre-operative radiotherapy and adjuvant chemotherapy 
for patients with rectal cancer since the mid 1990s. Five-year relative survival of 
rectal cancer, stage II and III were recently about 70% and 55%, and increased for 
male patients with 9 and 12 percent-points between 1989 and 2006, and for female 
patients with 12 and 16 percent-points, respectively. This marked improvement in 
prognosis is largely due to the improvements in therapy besides earlier detection 
by increased use of endoscopy since the 1980s.26 For small cell lung cancer, we 
observed some first modest survival improvements since the early 1990s, particularly 
at age 45-59. This survival improvement is probably due to the increased use of 
chemoradiation for limited disease and the introduction of prophylactic cranial 
irradiation (PCI) since the early 2000s besides improved staging.31 
 In Chapter 4.3 we showed that ovarian cancer surgery (including staging) in 
the North Netherlands during the period 1994-1997 was better performed by an 
oncological gynaecologist than by a general gynaecologist. For oesophageal cancer, 
we found a reduction in postoperative morbidity, length of hospital stay, in-hospital 
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mortality which declined from 14% to 4.7% and 2-year survival improved from 
38% to 54% after centralisation of oesophageal resections in the mid-western part 
of the Netherlands (Chapter 4.4). These findings were confirmed by other studies 
performed in the Netherlands.24, 64 Discussions regarding the need for centralisation 
of treatment, particularly surgery, are also ongoing for cancers of the stomach, liver, 
pancreas, prostate, bladder and lung.65 
 Changes in cancer management can improve cancer survival. However, the costs 
to develop new diagnostics and therapies are likely to become very high which is 
visible in the increasing national health budget during the last years. For the future, 
it is important to study the cost-effectiveness of these new (targeted) therapies and 
to look for opportunities to improve existing therapies (e.g. improving effectiveness 
of systemic therapies). 
tHE NEw ProPosED FrAmEworK AND PitFAlls oF mEAsur-
iNg ProgrEss AgAiNst CANCEr 
Measuring progress against cancer is important to evaluate progress in clinical 
management and public health programs as often mentioned in (national) cancer 
programs. There are many parameters which can indicate progress, such as less 
false-positive and false-negative screening exams, more effective therapies with 
fewer associated side effects, better quality of life and improved organization of 
palliative care. These parameters are difficult to measure and monitor through the 
standard surveillance instruments, mainly cancer registries. However, several of 
these parameters influence cancer incidence, survival and mortality, which can be 
monitored over time. 
 In this thesis, we proposed a conceptual framework to measure progress 
against cancer where we combined incidence, survival and mortality to achieve an 
objective assessment of progress against cancer in the Netherlands, while avoiding 
misinterpreting findings from one of these measures (Chapter 5.1). However, it 
remains a challenge to unravel and elucidate coinciding changes in incidence and 
therapy, because changes in survival can be influenced by combinations of changes 
in treatment and incidence. Multivariable relative survival analyses showed to be 
useful in unravelling the relative importance of the potential underlying reasons of 
improved survival of rectal cancer.25 
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So far, progress against cancer on a population level has usually been expressed by 
trends in mortality or survival of cancer. As mortality is influenced by both incidence 
and survival, there are strong advocates of expressing progress in terms of changes 
in mortality rates.66,67 However, changes in mortality rates do not necessarily reflect 
recent progress, as mortality in a given year reflects the risk of cancer death among 
patients diagnosed over the preceding years depending on the prognosis of a certain 
cancer (e.g. breast cancer mortality rate in a given year reflects deaths from the 
preceding 15-20 years).68 Secondly, trends in competing risks of death, particularly 
among the elderly, may complicate the interpretation of cancer mortality trends.69 
Thirdly, mortality statistics are usually based on cause-of-death statistics, which have 
their problems in terms of reliability, such as correct coding of underlying cause of 
death and changing coding practices in time. Fortunately, in the Netherlands, the 
reliability of coding the underlying cause of death turned out to be high (>90%) for 
major causes of death such as cancer.70 Finally, not all cancer patients die from cancer 
and changes in cancer mortality often does not reflect the possible progress made 
for these patients at all. 
 Others advocate using cancer survival only as a measure of progress over time 
and between countries. Indeed, survival is often used and interpreted as a measure 
of progress made by changes in cancer management. However, survival is also 
influenced by stage at diagnosis that may differ over time and between countries.71 
This makes that survival is not a good measure either to evaluate screening 
programs because of the increased detection of (indolent) low-stage cancer (e.g. 
PSA screening) or premalignant lesions (e.g. cervical cancer screening). In Chapter 
5.2 we listed more phenomena which can influence survival and even can cause 
deteriorations in survival, such as changes in risk factor exposures which can lead to 
shifts in the distribution of cancer subtypes with different prognosis, changes in the 
prevalence of concomitant diseases (comorbidity) in the population and changes 
in the sociodemographic characteristics of a population. Inclusion of patients with 
multiple tumours in survival analyses can also lower survival.72
 Trends in cancer mortality and survival are sometimes contrasting and if studied 
separately, can cause a lot of debate about data quality and how to interpret cancer 
trends. Recently, this was the case in the United Kingdom where breast cancer 
mortality showed one of the strongest declines within Europe, but survival remained 
worse than elsewhere in Western Europe.73-75 Another example is that survival is 
improving, while mortality keeps on rising. For the Netherlands, we observed this 
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for skin melanoma, oral cavity and oesophageal cancer. These examples show 
that expressing progress in terms of either mortality or survival only gives a very 
limited impression of progress and show the need of including cancer incidence and 
combine them all three to avoid misinterpreting findings from one of these cancer 
trends.68,76,77 To add to current possibilities of assessing progress against cancer, it 
would be useful to have information on causes of death, in order to know if cancer 
patients are dying from their cancer or from other diseases/causes. This information 
will be extremely useful for getting more insight on long-term side effects of cancer 
treatment among long-term survivors of cancer.78,79 Unfortunately, the information 
on death causes are currently not routinely linked to the NCR. 
CoNClusioNs
 – The proposed conceptual framework for measuring progress against cancer can 
be useful to evaluate (national) cancer programs and to prioritize and monitor 
activities in the field of prevention and clinical research.
 – A largely positive, but mixed pattern of progress against cancer was observed for 
the Netherlands since the late 1980s: 
 – Optimal progress (defined as decreasing incidence and/or improving survival 
accompanied by declining mortality) was observed in 12 of 19 cancer types 
among males: laryngeal, lung, stomach, gallbladder, colon, rectal, bladder, 
prostate and thyroid cancer, leukaemia, Hodgkin and non-Hodgkin lymphoma. 
Among females, optimal progress was observed in 12 of 21 cancers: stomach, 
gallbladder, colon, rectal, breast, cervical, uterus, ovarian and thyroid cancer, 
leukaemia, Hodgkin and non-Hodgkin lymphoma. 
 – Deterioration (defined as increasing incidence and/or deteriorating survival 
accompanied by increasing mortality rates) occurred in three cancer 
types among males: skin melanoma, oesophageal and kidney cancer, and 
among females in six cancer types: skin melanoma, oral cavity, pharyngeal, 
oesophageal, pancreatic and lung cancer.
 – Primary and secondary prevention showed to have bigger impact on cancer 
trends than new diagnostics and treatment.
 – Anti-smoking campaigns can be considered as a success of primary prevention 
resulting in decreasing incidence and mortality of smoking related cancers. 
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However smoking prevalence rates are still high, particularly among Dutch 
women who showed to have higher rates of smoking related cancers than the 
average rates among European women. 
 – Screening for cancer can have different effects on cancer trends depending 
on detection of pre-malignancies (decreasing incidence and sometimes even 
deteriorating survival) or early stages of disease (increasing incidence and 
improving survival). It is not certain what will happen to colorectal cancer 
incidence after introduction of screening.
 – New effective diagnostics or treatment showed to improve cancer survival often 
coinciding with subspecialisation of clinicians and regionalisation of cancer care 
showed to be effective to improve survival (for instance ovarian and oesophageal 
cancer). 
rECommENDAtioNs For PoliCy AND FurtHEr rEsEArCH
 – The proposed conceptual framework for measuring progress against cancer 
should be used to monitor cancer trends as a basis for future scenarios which can 
be useful to determine clinical capacity and to prioritize activities in the field of 
prevention and clinical research.
 – Cancer epidemiologists should make sure that policy makers are well informed 
on newly occurring trends in occurrence, mortality or prognosis from cancer, 
and should also inform them on (new/emerging) risk factors, in order to try and 
minimize delays in taking action when new risk factors are detected.
 – Primary prevention needs to be back on the governmental agenda, e.g. campaigns 
against smoking, obesity and excessive sun exposure remain important to lower 
future cancer incidence. Particularly, the incidence of obesity related cancers 
such as oesophageal and colorectal cancer is high compared to other European 
countries.
 – Cancers of the oesophagus, stomach, gallbladder, pancreas and lung need our 
attention because of their stable poor prognosis (5-year relative survival below 
25%). What are the possibilities to lower the risk factor prevalence, increase earlier 
detection and improve treatment? And would centralisation/regionalisation of 
cancer care help? Scenario calculations could be useful to get more insight in the 
possibilities of prevention, early detection and improved cancer management.
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 – In the future it is important to evaluate the colorectal cancer screening by 
monitoring incidence and prognosis of and mortality from colorectal cancer, 
over time and also by birth cohort. The same is valid for evaluating the effects of 
using HPV DNA test as primary screen test in the cervical screening program and 
HPV vaccination among 12-year old girls since 2009 to prevent cervical cancer.
 – The cost-effectiveness of new targeted (often expensive) therapies should be 
studied and their effect on the overall cancer prognosis and mortality.
 – To give possible new directions for development of new therapies we should 
study also potential gender differences in incidence, prognosis and mortality in 
more detail.
 – It is important to assess progress against cancer by age (e.g., <20, 20-35, 35-49, 
50-69, 70-79, ≥80) to see whether special attention is needed for certain age 
groups. It is particularly interesting to know how much progress we are making 
among the elderly, because the age group of 75 and older is estimated to double 
until 2040.80 Birth cohort approaches will also be interesting when lifestyle risk 
factors play a role.
 – Assessing progress against cancer by socioeconomic status (SES) should be also 
interesting to monitor the gap between SES groups. Recently, it was found 
that those with low SES had highest incidence rates of common cancers, less 
favourable stage of disease, less likely to receive curative treatment and invasive 
therapies and had lower survival rates compared to those with high SES.77 
 – To make the assessment of progress against cancer more complete it will be 
interesting to incorporate disease-specific mortality (especially for the long-
term side effects of cancer treatment and therefore linking death causes with 
the NCR is highly recommended), quality of life (e.g. differs between stage of 
disease, cancer treatments)78,79 and/or costs invested in prevention programs 
and spent on (new) diagnostics and therapies. Recently, it was found that the 
US cancer mortality rates fall faster than cancer mortality rates in Europe and 
that US survival rates were on a higher level than European ones, possibly as 
consequence of higher health care spending.80
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summAry
During the second part of the 20th century, cancer has become an important health 
problem worldwide. In the Netherlands, cancer incidence increased with 50% since 
the 1970s. Fortunately, mortality from cancer started to decrease from the 1980s 
onwards. Impressive improvements in cancer survival started to occur since the 1970s, 
first for the younger patients and later on also for the elderly. To evaluate progress 
against cancer, incidence and prognosis of and mortality from cancer are useful 
outcome measures. The work in this thesis shows which progress has been achieved 
against cancer in the Netherlands since the late 1980s, also in comparison with 
other European countries. It shows the impact of changes in risk factor prevalence, 
primary and secondary prevention and cancer management on cancer trends and 
how we can optimize assessment of progress against cancer
Dutch cancer trends in a European context
In Chapter 2 we describe the main cancer trends within Europe from the mid 1990s 
to early 2000. The cancer incidence trends were generally favourable in the more 
prosperous countries from Northern and Western Europe, except for obesity related 
cancers, which showed increases in incidence. Whereas incidence of and mortality 
from tobacco-related cancers decreased for males in Northern, Western and 
Southern Europe, they increased for both sexes in Central Europe and for females 
nearly everywhere in Europe. Survival rates generally improved, probably due to 
better access to specialized diagnostics, staging and treatment. Marked effects 
of more early detection, organized or opportunistic screening became visible for 
breast, prostate and melanoma in the wealthier countries. Mortality trends were 
generally favourable, except for smoking related cancers.
 Dutch males had comparable cancer rates, while Dutch females had more often 
higher cancer rates compared to the European average. In the beginning of this 
century, the incidence rates of cancer of the oral cavity and pharynx, larynx, stomach, 
pancreas, prostate and testis were lower among Dutch males than the European 
average. Whereas incidence rate of male lung cancer was higher than the European 
average during the mid 1990s, it is now on the European average. More common 
among Dutch males than the European average were oesophageal cancer and 
Hodgkin lymphoma. During the early 2000, the incidence of cancer of the stomach, 
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pancreas, cervix, corpus uteri and ovary was lower than the European average. In 
the mid 1990s, the incidence rate of female lung cancer was about the European, 
but has risen so dramatically between the mid 1990s and early 2000 and is now 
above the European average. Cancers of the oral cavity and pharynx, oesophagus, 
colorectal, larynx, skin melanoma and breast were also more common among Dutch 
females than average among European females. Relative survival of Dutch cancer 
patients was in general about the same as the average in Europe and higher than 
average for patients with laryngeal and cervical cancer and skin melanoma. 
impact of changes in risk factor prevalence, primary and secondary 
prevention and cancer management on cancer trends 
Many efforts were made to lower the cancer incidence and mortality and improve 
the cancer prognosis by primary and secondary prevention programs and changes in 
cancer management (e.g. changes in diagnostics and therapies). In Chapter 3 and 4 
we illustrate how such efforts can influence cancer trends by using examples of cancer 
of the oesophagus, lung, ovary and prostate. We found in Chapter 3.1 indications 
that the lung cancer epidemic among females is beginning to come to an end: Lung 
cancer incidence and mortality trends were flattening out among young females 
(20-49 yrs) since 1999 as a result of an observed decrease among females born after 
the 1950s. The same birth cohort trend was seen for the smoking prevalence, which 
also declined among females born after the 1950s. This shows that lowering the 
risk factor prevalence by primary prevention (e.g. smoking prevention) does have a 
positive effect on the incidence and mortality trends although it takes a long time 
before the positive effects are visible because of the long latency times. 
 Cancer incidence and mortality can also decrease as a result of changes in 
behaviour among the population without the aid of any prevention campaign, 
as illustrated in Chapter 3.2 by the introduction of oral contraceptives in the mid-
1960s. In the Netherlands, we observed that ovarian cancer mortality rate decreased 
since the 1970s, coinciding with the introduction of the oral contraceptives, with a 
reduction of 36%, particularly among females born after the 1920s. Ovarian cancer 
incidence was reduced by 30% between 1989 and 2009, which was one of the largest 
reductions observed within Europe.
 In Chapter 4.1 we studied the prostate cancer trends and increased use of testing 
serum prostate-specific antigen level (PSA). Whether PSA testing is responsible for 
the observed decrease in the incidence of metastasized tumours and mortality in 
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the Netherlands was still questionable. We observed two periods of increasing 
incidence rates, at first, an increase in cT2-tumours (palpable tumours) between 
1989 and 1995 and secondly, an increase of cT1c-tumours (screen-detected tumours) 
since 2001. The incidence of metastasized tumours (cT4/N+/M+) decreased between 
1993 and 2006 and prostate cancer mortality started to decrease from 1996. The 
increase of prostate cancer incidence in the early 1990s was probably caused by 
increased prostate cancer awareness among clinicians combined with diagnostic 
improvements (transrectal ultrasound, (thin) needle biopsies), but not caused by 
PSA testing, which was not widely used at the time. PSA testing must have caused 
the second period of incidence increase in the 2000s. The decline in mortality from 
1996 onwards is probably due to the increased detection of cT2-tumours in the early 
1990s; it remains unclear what the contribution is of the increase of cT1c-tumours to 
the decreasing mortality. 
 At last, changes in cancer management showed to be effective to improve 
survival of cancer patients. For example, over the last two decades treatment of 
epithelial ovarian cancer patients with advanced disease improved; more patients 
received (neo-)adjuvant chemotherapy and underwent optimal debulking surgery. 
These changes in treatment partly explained the survival improvement of ten 
percent of ovarian cancer (Chapter 4.2). In Chapter 4.3, we found that surgery 
by a consultant gynaecologist oncologist also improved survival in ovarian cancer 
patients. For patients younger than 75 years operated by a gynaecologist oncologist 
the reduction in risk of dying was almost 30% adjusted for age, stage, type of hospital 
and chemotherapy compared to patients operated by a general gynaecologist. For 
oesophageal cancer, we found in Chapter 4.4 a reduction in postoperative morbidity, 
length of hospital stay, in-hospital mortality which declined from 14% to 4.7% and 
2-year survival improved from 38% to 54% after centralisation of oesophageal 
resections in the mid-western part of the Netherlands. 
Framework for interpretations of changes in cancer trends
Measuring progress against cancer has become an important issue to evaluate 
(national) cancer programs during recent decades. There are many parameters 
which can indicate progress, most of which are difficult to measure and monitor 
with the standard surveillance instruments: mainly cancer registries. Several of these 
parameters are influencing cancer incidence, survival and mortality, which can be 
monitored over time. In Chapter 5.1 we proposed a conceptual framework where 
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we combined incidence, survival and mortality to achieve an objective assessment 
of progress against cancer while avoiding misinterpreting findings from one of 
these measures separately. In the Netherlands, a largely positive pattern of progress 
against cancer since the late 1980s was observed. Optimal progress (defined as 
decreasing incidence and/or improving survival accompanied by declining mortality) 
was observed in 12 of 19 cancer types among males: laryngeal, lung, stomach, 
gallbladder, colon, rectal, bladder, prostate and thyroid cancer, leukaemia, Hodgkin 
and non-Hodgkin lymphoma. Among females, optimal progress was observed in 12 
of 21 cancers: stomach, gallbladder, colon, rectal, breast, cervical, uterus, ovarian 
and thyroid cancer, leukaemia, Hodgkin and non-Hodgkin lymphoma. Deterioration 
(defined as increasing incidence and/or deteriorating survival accompanied by 
increasing mortality rates) occurred in three cancer types among males: skin 
melanoma, oesophageal and kidney cancer, and among females in six cancer types: 
skin melanoma, oral cavity, pharyngeal, oesophageal, pancreatic and lung cancer.
 In Chapter 5.2 we showed the possible causes of a deteriorating survival 
over time or of inferior survival rates compared to other countries. First of all, 
deterioration of care is the worse cause of deteriorating survival, but almost never 
occurs in practice. Another, more common, cause of deteriorating survival rates is 
improved diagnosis of premalignant lesions, which causes survival statistics to reflect 
only the most aggressive cancers-those with the poorest prognosis. In addition, 
deleterious changes in the distribution of prognostic factors and in the distribution 
of sociodemographic characteristics may negatively affect cancer survival, as well as 
changes in completeness and quality of the cancer registry.
Conclusions
 – The proposed conceptual framework for measuring progress against cancer can 
be useful to evaluate (national) cancer programs and to prioritize and monitor 
activities in the field of prevention and clinical research.
 – A largely positive, but mixed pattern of progress against cancer was observed for 
the Netherlands since the late 1980s: 
 – Optimal progress (defined as decreasing incidence and/or improving survival 
accompanied by declining mortality) was observed in 12 of 19 cancer types 
among males: laryngeal, lung, stomach, gallbladder, colon, rectal, bladder, 
prostate and thyroid cancer, leukaemia, Hodgkin and non-Hodgkin lymphoma. 
Among females, optimal progress was observed in 12 of 21 cancers: stomach, 
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gallbladder, colon, rectal, breast, cervical, uterus, ovarian and thyroid cancer, 
leukaemia, Hodgkin and non-Hodgkin lymphoma. 
 – Deterioration (defined as increasing incidence and/or deteriorating survival 
accompanied by increasing mortality rates) occurred in three cancer 
types among males: skin melanoma, oesophageal and kidney cancer, and 
among females in six cancer types: skin melanoma, oral cavity, pharyngeal, 
oesophageal, pancreatic and lung cancer.
 – Primary and secondary prevention showed to have bigger impact on cancer 
trends than new diagnostics and treatment.
 – Anti-smoking campaigns can be considered as a success of primary prevention 
resulting in decreasing incidence and mortality of smoking related cancers. 
However smoking prevalence rates are still high, particularly among Dutch 
women who showed to have higher rates of smoking related cancers than the 
average rates among European women. 
 – Screening for cancer can have different effects on cancer trends depending 
on detection of pre-malignancies (decreasing incidence and sometimes even 
deteriorating survival) or early stages of disease (increasing incidence and 
improving survival). It is not certain what will happen to colorectal cancer 
incidence after introduction of screening.
 – New effective diagnostics or treatment showed to improve cancer survival often 
coinciding with subspecialisation of clinicians and regionalisation of cancer care 
showed to be effective to improve survival (for instance ovarian and oesophageal 
cancer). 
recommendations
 – The proposed conceptual framework for measuring progress against cancer 
should be used to monitor cancer trends as a basis for future scenarios which can 
be useful to determine clinical capacity and to prioritize activities in the field of 
prevention and clinical research.
 – Cancer epidemiologists should make sure that policy makers are well informed 
on newly occurring trends in occurrence, mortality or prognosis from cancer, 
and should also inform them on (new/emerging) risk factors, in order to try and 
minimize delays in taking action when new risk factors are detected.
 – Primary prevention needs to be back on the governmental agenda, e.g. campaigns 
against smoking, obesity and excessive sun exposure remain important to lower 
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future cancer incidence. Particularly, the incidence of obesity related cancers 
such as oesophageal and colorectal cancer is high compared to other European 
countries.
 – Cancers of the oesophagus, stomach, gallbladder, pancreas and lung need our 
attention because of their stable poor prognosis (5-year relative survival below 
25%). Scenario calculations could be useful to get more insight in the possibilities 
of prevention, early detection and improved cancer management.
 – In the future it is important to evaluate the colorectal cancer screening by 
monitoring incidence and prognosis of and mortality from colorectal cancer, 
over time and also by birth cohort. The same is valid for evaluating the effects of 
using HPV DNA test as primary screen test in the cervical screening program and 
HPV vaccination among 12-year old girls since 2009 to prevent cervical cancer.
 – The cost-effectiveness of new targeted (often expensive) therapies should be 
studied and their effect on the overall cancer prognosis and mortality.
 – It is important to assess progress against cancer by age and gender because of 
the diversity on causes, detection and treatment, and to see whether special 
attention is needed for certain groups. 
 – Assessing progress against cancer by socioeconomic status (SES) should be also 
interesting to monitor the gap between SES groups which was found recently. 
 – To make the assessment of progress against cancer more complete it will be 
interesting to incorporate disease-specific mortality (especially for the long-term 
side effects of cancer treatment and therefore linking death causes with the NCR 
is highly recommended), quality of life (e.g. differs between stage of disease, 
cancer treatments) and/or costs invested in prevention programs and spent on 
(new) diagnostics and therapies.
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NEDErlANDsE sAmENVAttiNg
Vanaf de tweede helft van de vorige eeuw is kanker uitgegroeid tot een belangrijk 
gezondheidsprobleem. In Nederland is het vóórkomen (incidentie) van kanker met 
50% gestegen sinds de jaren ‘70. Echter de overleving van kankerpatiënten is enorm 
verbeterd sinds de jaren ’70 (gemiddeld met 20%) en vanaf eind jaren ’80 is de 
sterfte aan kanker in de bevolking gedaald met 20%.
 Vanaf de jaren ’70 is in Nederland veel geld en energie geïnvesteerd in de 
verbetering van het vroeg ontdekken en de behandeling van kankerpatiënten en 
preventiecampagnes. Een veel voorkomende vraag is dan ook of deze investeringen 
wat hebben opgeleverd. In dit proefschrift wordt een poging gedaan om een 
antwoord op deze vraag te krijgen op basis van geobserveerde trends in drie 
belangrijke parameters: incidentie en overleving van en sterfte aan kanker. 
 Allereerst hebben we de trends in incidentie, overleving en sterfte van 21 
Europese landen beschreven om daarmee een beeld te krijgen hoe Nederland er 
voor staat binnen Europa. Vervolgens zijn in dit proefschrift de Nederlandse trends 
van slokdarmkanker, longkanker, eierstokkanker en prostaatkanker in meer detail 
bestudeerd om zo meer inzicht te krijgen in de impact van veranderingen in het 
vóórkomen van risicofactoren, primaire en secundaire preventie, diagnostiek en 
behandeling op kankertrends. Binnen het project ‘Progress against cancer in the 
Netherlands since the 1970s‘ (gefinancieerd door de KWF Kankerbestrijding) zijn 
ook de trends van 21 andere kankersoorten in meer detail bestudeerd. Vanwege de 
diversiteit van de trends in incidentie, overleving en sterfte (bijv. de incidentie stijgt 
harder dan de sterfte) laten we tot slot zien hoe belangrijk het is om naar deze drie 
trends gecombineerd te kijken en geven we een overzicht van de vooruitgang die 
geboekt is in onze strijd tegen kanker in Nederland vanaf eind jaren ’80. 
waar staat Nederland binnen Europa?
In Hoofdstuk 2 worden trends in incidentie, prognose en sterfte van 17 
kankersoorten binnen Europa beschreven van midden jaren ’90 tot begin 2000. 
De trends in kankerincidentie zijn over het algemeen het meest gunstig in Noord- 
en West-Europa, behalve voor de kankersoorten die gerelateerd zijn aan obesitas. 
De trends in incidentie en sterfte van rookgerelateerde kankersoorten (met name 
longkanker) lieten een daling zien bij mannen in Noord-, West- en Zuid-Europa, 
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maar stegen juist voor mannen in Centraal Europa. In vrijwel geheel Europa stegen 
de incidentie en sterfte van deze kankersoorten bij vrouwen. Over de gehele linie 
verbeterde de prognose van kanker, waarschijnlijk door een betere toegang tot 
gespecialiseerde diagnostiek en behandeling. De effecten van vroege opsporing, 
mede door screening, waren te zien voor melanoom, borstkanker en prostaatkanker 
in de rijkere landen. Trends in kankersterfte waren over het algemeen ook gunstig, 
behalve voor rookgerelateerde kankers bij vrouwen. 
 Bij Nederlandse vrouwen komen melanomen en kanker van de mond- en 
keelholte, strottenhoofd, slokdarm, long en borst vaker voor dan onder andere 
Europese vrouwen. Zo kwam longkanker in de midden jaren ’90 bij Nederlandse 
vrouwen net zo vaak voor als elders in Europa, maar na een enorme stijging in de 
longkankerincidentie zitten ze nu boven het Europese gemiddelde. Daarentegen 
komen kanker van de maag, alvleesklier, baarmoeder, baarmoederhals en 
eierstok minder vaak voor bij Nederlandse vrouwen. Bij Nederlandse mannen is 
een positiever beeld te zien. Kwam midden jaren ’90 longkanker vaker voor bij 
Nederlandse mannen dan bij andere Europese mannen, begin 2000 zaten ze op het 
Europese gemiddelde. Kanker van de mond- en keelholte, strottenhoofd, maag, 
alvleesklier, prostaat en testis komen minder vaak voor bij Nederlandse mannen. 
Daarentegen komen slokdarmkanker en Hodgkin lymfoom vaker voor onder 
Nederlandse mannen. De relatieve overleving van kankerpatiënten in Nederland 
was over het algemeen gelijk aan de gemiddelde overleving in Europa en was zelfs 
hoger dan het gemiddelde voor patiënten met melanoom, strottenhoofdkanker en 
baarmoederhalskanker. 
impact van veranderingen in het vóórkomen van risicofactoren, primaire 
en secundaire preventie, diagnostiek en behandeling op kankertrends
In de Hoofdstukken 3 en 4 laten we zien hoe veranderingen in het vóórkomen 
van risicofactoren, preventie, diagnostiek en behandeling kankertrends kunnen 
beïnvloeden aan de hand van 4 voorbeelden: slokdarmkanker, longkanker, 
eierstokkanker en prostaatkanker. 
 In Hoofdstuk 3.1 beschrijven we indicaties die aantonen dat het einde van de 
longkankerepidemie bij vrouwen in zicht is, ondanks de alsmaar stijgende incidentie. 
De longkankerincidentie en –sterfte bij jonge vrouwen (20-49 jaar) stabiliseerde 
vanaf 1999. Dalende longkankersterfte en rookprevalentie werd waargenomen bij 
vrouwen geboren ná 1950. Dit is een duidelijk voorbeeld van hoe het terugdringen 
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van een bepaalde risicofactor door primaire preventie (bijv. anti-rook campagnes) 
uiteindelijk zijn vruchten afwerpt: een dalende incidentie en sterfte. 
 Kankerincidentie en -sterfte kunnen ook dalen doordat veranderingen in het 
gedrag van de bevolking plaatsvinden zonder de hulp van preventiecampagnes. 
Hoofdstuk 3.2 laat hier een voorbeeld van zien. In Nederland zien we vanaf de jaren 
’70 een enorme daling in de eierstokkankersterfte van 36%, met name bij vrouwen 
die geboren zijn ná 1920. Deze daling gaat gepaard met de toename in het gebruik 
van de pil als anticonceptiemiddel. De incidentie van eierstokkanker daalde met 
27% tussen 1989 en 2009, een van de sterkste dalingen binnen Europa.
 In Hoofdstuk 4.1 hebben we de prostaatkankertrends en de mogelijke invloed 
van het toegenomen gebruik van de PSA-test daarop bestudeerd. Het is namelijk nog 
steeds de vraag of de afname van de gemetastaseerde prostaatkankertumoren en 
sterfte in Nederland toe te schrijven is aan de toename in het aantal PSA-testen over 
de tijd. Wij vonden twee perioden van stijgingen in de prostaatkankerincidentie. 
Ten eerste een stijging van cT2-tumoren (tumoren die door de huisarts of uroloog 
voelbaar zijn bij rectaal onderzoek) in de periode 1989-1995 en als tweede een stijging 
van cT1c-tumoren (tumoren die opgespoord kunnen worden via een PSA-test) vanaf 
2001. Zowel cT1c- en cT2-tumoren worden beschouwd als ‘vroege’ prostaattumoren, 
en hebben een zeer gunstige prognose. De incidentie van gemetastaseerde tumoren 
(cT4/N+/M+) daalde tussen 1993 en 2006. De prostaatkankersterfte begon te dalen 
vanaf 1996. De eerste van bovengenoemde stijgingen in de incidentie, die van begin 
jaren ’90, is waarschijnlijk veroorzaakt door een toename in de bewustwording 
onder medici gecombineerd met verbeteringen in de diagnostiek. Deze stijging is 
nog te vroeg om als effect te zien van de PSA test, want die werd op dat moment 
nog niet vaak gebruikt werd in Nederland. De tweede stijging vanaf 2001 lijkt 
echter wel veroorzaakt te zijn door het toegenomen gebruik van de PSA test. De 
dalende prostaatkankersterfte vanaf 1996 is zeer waarschijnlijk een gevolg van de 
eerste stijging van cT2-tumoren. Het blijft vooralsnog onduidelijk wat de bijdrage is 
van de stijging in cT1c-tumoren op de prostaatkankersterfte.
 Verandering in diagnostiek en behandeling kunnen van veel betekenis zijn 
voor het (verder) verbeteren van de overleving van kankerpatiënten. Een voorbeeld 
hiervan is eierstokkanker. De laatste 20 jaar is de behandeling van patiënten met 
gemetastaseerde epitheliale eierstokkanker verbeterd: meer patiënten kregen 
(neo-)adjuvante chemotherapie en ondergingen een chirurgische ingreep met 
optimale debulking. Deze veranderingen verklaren voor een deel de verbetering 
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in de 5-jaars overleving van deze patiënten die steeg van 18% naar 28% in de 
periode 1989-2009 (Hoofdstuk 4.2). In Hoofdstuk 4.3 vonden we dat wanneer 
de chirurgische ingreep werd uitgevoerd door een gynaecologisch oncoloog de 
overleving verbeterde voor de patiënten met eierstokkanker. Bij patiënten jonger 
dan 75 jaar, geopereerd door een gynaecologisch oncoloog daalde het risico op 
sterfte met bijna 30% in vergelijking met patiënten die geopereerd waren door 
een algemeen gynaecoloog, gecorrigeerd voor leeftijd, stadium van de ziekte, 
type ziekenhuis en al dan niet behandeling met chemotherapie. Voor patiënten 
met slokdarmkanker vonden we in Hoofdstuk 4.4 een daling in de post-operatieve 
morbiditeit, lengte van ziekenhuisverblijf, sterfte tijdens het ziekenhuisverblijf 
nadat het chirurgisch verwijderen van de slokdarm werd gecentraliseerd in bepaalde 
ziekenhuizen in de regio Leiden-Den Haag. Voor deze chirurgische ingreep komt 
slechts ongeveer 30% van de slokdarmkankerpatiënten in aanmerking. De sterfte 
tijdens het ziekenhuisverblijf daalde van 14% naar 5% en de 2-jaars overleving van 
deze beperkte groep slokdarmkankerpatiënten verbeterde zelfs van 38% naar 54%. 
meten van vooruitgang in de strijd tegen kanker
Om kankerbestrijdingprogramma’s die opgesteld zijn door (regionale) overheden te 
kunnen evalueren is het meten van verbetering belangrijk geworden, juist omdat 
er zo gemakkelijk schijnbare vooruitgang kan worden geboekt door bijvoorbeeld 
vroege opsporing van kanker. Er zijn vele parameters waarmee vooruitgang is te 
meten, maar de meeste (zoals kwaliteit van leven) zijn niet zonder meer te meten 
en te monitoren door kankerregistraties. Echter de parameters incidentie, prognose 
en sterfte kunnen wel gemeten worden door de meeste kankerregistraties. Om een 
goed overzicht te krijgen van de voor- of achteruitgang in de strijd tegen kanker is 
het van belang om deze drie parameters per tumorsoort te laten zien. Vaak wordt 
slechts naar één van deze parameters gekeken en worden verkeerde interpretaties 
gedaan.
 In Nederland is vanaf eind jaren ’80 voor 16 veel voorkomende kankersoorten 
vooruitgang geboekt (Hoofdstuk 5.1). Maagkanker en galblaaskanker kwamen steeds 
minder vaak voor bij zowel mannen als vrouwen sinds eind jaren ’80. Daarnaast was 
een daling in incidentie zichtbaar bij mannen voor strottenhoofdkanker, longkanker 
en blaaskanker en bij vrouwen voor baarmoederhalskanker en eierstokkanker. Het 
percentage patiënten dat 5 jaar na diagnose nog in leven is, was toegenomen bij 
zowel mannen als vrouwen voor dikke darmkanker, rectumkanker, schildklierkanker, 
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longkanker, leukemie, Hodgkin en non-Hodgkin lymfomen. Bij mannen was 
eenzelfde verbetering zichtbaar voor maagkanker en prostaatkanker en bij vrouwen 
voor borstkanker, baarmoederhalskanker, baarmoederkanker en eierstokkanker. 
Al deze verbeteringen leidden ertoe dat steeds minder mensen overleden aan 
deze kankersoorten. Voor sommige vormen van kanker werd achteruitgang 
gemeten: bij zowel mannen als vrouwen bleek dat slokdarmkanker en melanoom 
steeds vaker voorkomen. Gelukkig was de overleving van deze kankersoorten 
wel sterk verbeterd sinds eind jaren ‘80, waardoor de sterfte niet in gelijke mate 
steeg. Daarnaast kwam bij mannen nierkanker steeds vaker voor en bij vrouwen 
mondholte- en keelholtekanker, alvleesklierkanker en longkanker. Bij geen van de 
kankersoorten werd een verslechtering van de overleving geobserveerd. Al blijven 
slokdarmkanker, maagkanker, alvleesklierkanker, galblaaskanker en longkanker 
onze aandacht vereisen vanwege hun slechte prognose (5-jaars overleving < 25%).
 In Hoofdstuk 5.2 wordt een overzicht gegeven van de mogelijke oorzaken 
van een verslechtering in de overleving over de tijd of wanneer overleving verschilt 
tussen landen. Vaak wordt alleen gedacht aan het slechtste scenario, namelijk 
verslechtering van de zorg. In de praktijk is dit echter gelukkig bijna nooit het geval. 
Een vaker voorkomende oorzaak is dat tumoren vaker in een goedaardig stadium 
worden ontdekt (bijvoorbeeld bij baarmoederhalskankerscreening). Hierdoor 
neemt het aantal tumoren af die worden geregistreerd in de kankerregistratie 
en neemt verhoudingsgewijs het aandeel agressieve kwaadaardige tumoren 
met een slechte prognose toe ten opzichte van het totaal aantal geregistreerde 
tumoren waarop de overleving wordt berekend. Dit leidt logischerwijze tot 
slechtere overlevingscijfers. Veranderingen in de stadiumverdeling en verdeling 
van subtypes van tumoren, veranderingen in het vóórkomen van bijkomende 
ziektes (bijv. diabetes), veranderingen in socio-demografische karakteristieken (bijv. 
toename van bevolkingsgroep met laag sociaal economische status), toename van 
compleetheid en/of kwaliteit van een kankerregistratie kunnen de overleving van 
kankerpatiënten ook nadelig beïnvloeden. 
Conclusies
 – Het meten van vooruitgang in de strijd tegen kanker door middel van incidentie, 
prognose en sterfte is zeer bruikbaar bij het evalueren van (nationale) 
kankerbestrijdingsprogramma’s. Discussie over prioriteiten en gericht monitoren 
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van activiteiten ten behoeve van preventie en klinisch onderzoek kunnen 
hierdoor op een hoger niveau plaatsvinden. 
 – In Nederland is vanaf eind jaren ’80 over het algemeen veel vooruitgang geboekt 
in onze strijd tegen kanker.
 – Een dalende incidentie en/of verbetering in de overleving samengaand 
met een dalende sterfte werd bij 12 van de 19 onderzochte kankersoorten 
geobserveerd voor mannen: kanker van het strottenhoofd, long, maag, 
galblaas, dikke darm, blaas, prostaat en schildklier, leukemie, Hodgkin en 
non-Hodgkin lymfomen. 
 – Voor vrouwen werd dit bij 12 van 21 onderzochte kankersoorten geconstateerd: 
kanker van de maag, galblaas, dikke darm, borst, baarmoederhals, baarmoeder, 
eierstok en schildklier, leukemie, Hodgkin en non-Hodgkin lymfomen. 
 – Primaire en secundaire preventie (vroege opsporing van kanker) hebben laten 
zien een grotere impact te kunnen hebben op kankertrends dan nieuwe 
diagnostiek en behandeling.
 – Anti-rook campagnes als primaire preventive kunnen als succesvol worden 
bestempeld omdat ze geleid hebben tot een afname van incidentie en 
sterfte van rookgerelateerde kankersoorten. Echter, vergeleken met veel 
andere landen is de prevalentie van roken nog steeds hoog in Nederland, 
met name bij de vrouwen. Dit is een van de oorzaken waarom kankersoorten 
zoals longkanker, strottenhoofdkanker en mond- en keelholtekanker vaker 
vóórkomen bij Nederlandse vrouwen dan in andere Europese landen. 
 – Kankerscreening kan verschillende effecten hebben op kankertrends 
afhankelijk van het feit of er gescreend wordt op voorstadia van kanker 
(met als resultaat een dalende incidentie en soms zelfs een verslechterde 
overleving) of vroege stadia van kanker (met als resultaat een stijgende 
incidentie en verbeterde overleving). 
 – Nieuwe effectieve diagnostiek en behandeling bleken buiten de trials ook tot 
verbeteringen te hebben geleid in de overleving van kankerpatiënten. Deze 
ontwikkelingen gaan vaak samen met subspecialisatie van clinici en regionalisatie/
centralisatie van de behandeling (zoals bij eierstokkanker en slokdarmkanker).
Aanbevelingen
 – Primaire preventie moet weer terug op de politieke agenda (zoals campagnes 
tegen roken, obesitas en te veel blootstelling aan UV-licht) om zo de 
Nederlandse samenvatting | 299
kankerincidentie en ook andere chronische ziekten terug te dringen. Dit geldt 
met name voor de obesitas-gerelateerde kankersoorten: slokdarm- en dikke 
darmkanker die veel vóórkomen in Nederland vergeleken met andere Europese 
landen.
 – Slokdarmkanker, maagkanker, alvleesklierkanker, galblaaskanker en longkanker 
vereisen onze aandacht vanwege hun slechte prognose (5-jaars overleving < 
25%). Belangrijk hierbij is het exploreren van de mogelijkheden op het gebied 
van primaire preventie (blootstelling aan risicofactoren terugdringen), secundaire 
preventie (vroege opsporing), behandeling en centralisatie/regionalisatie van de 
zorg.
 – Het monitoren van trends in incidentie, prognose en sterfte is van belang bij 
het evalueren van de nieuwe ontwikkelingen op het gebied van secundaire 
preventie, zoals bevolkingsonderzoek dikke darmkanker, HPV tests binnen het 
bevolkingsonderzoek baarmoederhalskanker en HPV- vaccinatie van 12-jarige 
meisjes. 
 – Het is belangrijk om de kosten-effectiviteit van nieuwe kankertherapieën 
(vaak de zgn. dure geneesmiddelen) te bestuderen, maar ook de impact van 
deze therapieën op de trends in overleving van en sterfte aan kanker op 
bevolkingsniveau. 
 – Om meer inzicht te krijgen in de vooruitgang of achteruitgang is het interessant 
om ook naar kankertrends te kijken in de diverse leeftijdsgroepen (bijvoorbeeld 
kinderen, adolescenten, mensen van middelbare leeftijd en ouderen) en naar 
geslacht vanwege de diversiteit in de oorzaken, detectie en behandeling. 
 – Het meten van vooruitgang zou ook voor de verschillende sociaaleconomische 
groepen in de bevolking gedaan moeten worden om zo de geconstateerde 
verschillen tussen deze groepen te kunnen monitoren. Recent is namelijk 
gebleken dat in Nederland bij mensen met een laag sociaaleconomische 
status vaker kanker vóórkomt, kanker vaker gediagnosticeerd wordt met een 
vergevorderd stadium en dat deze groep een slechtere overleving heeft dan de 
hoge sociaaleconomische groepen.
 – Bij het meten van vooruitgang in de strijd tegen kanker is het interessant om als 
uitkomstmaten toe te voegen:
 – ziekte-specifieke sterfte, met name om meer inzicht te krijgen in de lange 
termijn effecten van kankertherapieën (hiervoor is wel noodzakelijk dat de 
kankerregistratie toegang heeft tot het doodsoorzakenregister!)
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 – kwaliteit van leven, dit verschilt per stadium en therapie
 – geïnvesteerde kosten in preventie, (nieuwe) diagnostiek en behandeling. 
Recent is namelijk gebleken dat de sterfte aan kanker in de VS sterker gedaald 
is dan in Europa en dat de overlevingscijfers hoger zijn in de VS mogelijk als 
een gevolg van een hogere investering in de gezondheidszorg. 
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DANKwoorD
En nu is het zover, het is af! Wie had dat ooit kunnen denken. Zelf was ik degene 
die het hardst heeft geroepen dat promoveren niet mijn ding is en heb bij mijn 
start in 2007 tegen vrijwel niemand gezegd dat het om een promotietraject ging. 
Sommigen van jullie weten pas sinds kort dat ik druk bezig was met een ‘boekje’. 
Maar ik zal eerlijk bekennen: ik ben gezwicht toen dit interessante project voorbij 
kwam en ik niet anders kon dan er gewoon heel enthousiast in te stappen met dit 
proefschrift als resultaat! 
 Mijn promotoren, prof.dr. Jan Willem Coebergh, prof.dr. Bart Kiemeney 
en co-promotor dr. Esther de Vries, wil ik allereerst bedanken voor alle steun en 
het vertrouwen dat zij in mij hadden. Zij hebben er zeker aan bijgedragen dat ik 
enthousiast bleef. Jan-Willem wat heb ik veel van je geleerd. We hadden heerlijke 
gesprekken die gingen over verklaren van kankertrends tot dure medicijnen, van 
promoveren tot bevallingen en zo kan ik nog wel even doorgaan. Bart, jij zat fysiek 
verder weg, maar dat was niet te merken als ik je om hulp vroeg. Ik ben je erg 
dankbaar voor de altijd kritische blik en je wist me altijd terug te brengen tot de 
essentie waar het om draaide. Een mooiere combinatie van promotoren had ik me 
niet kunnen wensen! Esther, bij jou kon ik altijd terecht met mijn vragen of voor een 
gezellig ‘onderonsje’ eerst bij je op de kamer en later via de skype (en wat mis ik dat 
nu zeg!). Ik heb onze samenwerking als ontzettend fijn ervaren en je enthousiasme 
voor het onderzoek werkte altijd aanstekelijk en dat doet het nog steeds. Ik hoop 
dat we in de toekomst nog eens wat samen gaan doen, is het niet op het gebied 
van onderzoek dan wel met de kinderen. En van die nominatie tot co-promotor van 
het jaar is het nooit gekomen, maar ik roep je hierbij uit tot beste co-promotor aller 
tijden! 
 Begin juli 2012 was het dan zover, het proefschrift kon verstuurd worden ter 
goedkeuring. Ik wil de leden van de kleine commissie, prof.dr.ir. Floor van Leeuwen, 
prof.dr. Jaap Verweij en prof.dr. Curt Burger bedanken voor de tijd en de energie 
die zij gestoken hebben in het kritisch bekijken van mijn proefschrift. De andere 
leden van de promotiecommissie wil ik danken voor deelname aan de oppositie. 
Special thanks to Dr. David Forman for his visit to the Netherlands to take place in 
my defence commission.
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Al de artikelen die binnen het grote ‘Progress against cancer’-project zijn 
gepubliceerd, waarvan een aantal in dit proefschrift staan, zouden niet tot stand 
gekomen zijn zonder de enthousiaste inzet van alle (co)auteurs die er te veel zijn om 
op te noemen. Bedankt voor het kritisch meedenken en schrijven! Ruben Cremers, 
Anne van Altena, Mirjam Engelen, Michel Wouters en Esther de Vries als eerste 
auteurs van artikelen die in dit proefschrift staan, wil ik jullie nog even extra in ’t 
zonnetje zetten. Ontzettend bedankt voor jullie bijdrage aan dit mooie geheel en 
het enthousiasme, waarmee jullie altijd je (klinische) kennis met mij deelden. Maar 
ook met Dorry Boll (leuk dat je langs kwam in Wenen!), Carlijn Witjes en Miep 
van der Drift als eerste auteurs van de andere artikelen heb ik een speciale band 
opgebouwd. Bedankt voor de fijne samenwerking!
 Zonder onze registratiemedewerkers die dag in en uit in de ziekenhuizen 
de medische dossiers napluizen, zouden we geen enkel artikel over kankertrends 
kunnen schrijven. Dat laat zien hoe belangrijk hun werk is. Bedankt voor jullie inzet 
en ga zo door!
 De KWF Kankerbestrijding wil ik hartelijk bedanken voor het mogelijk maken 
van het project ‘ Progress against cancer’ door middel van financiële ondersteuning. 
 Mijn MGZ collega’s wil ik bedanken voor de fijne tijd in Rotterdam. Er was 
altijd wel een gezellig moment in het keukentje of op de gang. Yvonne, jou wil ik 
bedanken voor al je hulp rondom mijn proefschrift. Mijn ‘koffiemaatjes’, Ida, Hein, 
Inge en Meeke, bedankt voor de gezellige wandelingen naar de DE. Eefje, met jou 
deelde ik kamer AE-107 en wat heb ik het met jou getroffen. Inge, jij was onze vaste 
stamgast. We deelden lief en leed en hadden vaak de grootste lol, dank daarvoor. 
En Eefje, wat ik ben blij dat je vandaag naast me staat!
 In Eindhoven voelde ik me ook altijd welkom en daarvoor wil ik mijn IKZ-
collega’s bedanken. Ook voor de interessante, stimulerende en gezellige brainstorms 
die we samen hadden.
 Wat was het heerlijk om naast het werk afleiding te hebben. We zagen elkaar 
helaas niet veel, maar als we elkaar zagen was het weer als vanouds. Marieke, 
Corina en Carla, bedankt voor jullie onvoorwaardelijke vriendschap! Corina, jou wil 
ik nog extra bedanken voor het mooie ontwerp van de voorkant. Carla, leuk dat 
je vandaag mijn paranimf wil zijn. We begonnen onze middelbare schoolcarrière 
in dezelfde schoolbank en dat is goed afgelopen, dus dat moet vandaag ook goed 
komen met jou naast me!
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Also thanks to the Vienna Baby Club-moms, Christiana, Katherina, Emanouella, 
Mary-Jane, San-San, Barbara and Verena for our nice time together with our kids. 
Every week, I looked forward to seeing you for a chat in one of the great playgrounds 
in Vienna. Hopefully, see you soon again and it’s time for a ladies night to celebrate 
this event!
 Thea, bij jou kon ik na een drukke werkdag altijd mijn verhaal kwijt en vaak 
kon ik nog een hapje mee-eten ook. Je stond samen met Wim en Lisanne altijd 
voor me klaar. Eind vorig jaar kwam je zelfs een week langs in Wenen om te komen 
oppassen, zodat ik nog hard aan de slag kon met dit boekwerk, bedankt daarvoor! 
 Paps en mams, jullie horen eigenlijk als eersten genoemd te worden. Maar ik 
zou willen zeggen: de laatsten zullen de eersten zijn. Jullie hebben me altijd de 
vrijheid gegeven om te doen wat ik wilde en me daarin gesteund, ook al was dat niet 
altijd even makkelijk. En dan de rest van de familie. Bij wie moet ik beginnen, want 
ondertussen zijn we uitgegroeid tot een twintigtal. Ons samenzijn betekent altijd 
een gezellige drukke boel. Iedereen bedankt voor alle afleiding! Joost en Jantine, 
jullie hebben je ‘kleine zusje’ altijd van goede adviezen voorzien, dank daarvoor. 
Zus, we moeten vooral doorgaan met onze interessante discussies over de zorg! En 
dan m’n maatje en ‘broertje’ Pieter. Samen hebben we elkaar weten te stimuleren. 
Jij mij bij dit boekwerk en ik jou bij het schrijven van jouw masterscriptie. Jij hebt 
je bul al binnen en nu ik nog. En dan op naar ons volgend doel, jij als minister-
president en ik als minister van Volksgezondheid (knipoog).
 Tot slot, mijn lieve Reza, waar was ik zonder jou. Jij hebt me gestimuleerd 
om deze stap te wagen en wat riep je vaak bij weer een publicatie: ‘Ik word toch 
maar huisman’. Je hebt er veel voor over gehad, want de laatste 1,5 jaar heb je 
veel avonden aaneen jezelf moeten vermaken. Ik beloof je dat het komend jaar 
echt vaker een gezellig avondje op het balkon wordt of ergens op het terras in het 
mooie Wenen. Lieve Norah, mama’s ‘meissie’, je snapt er waarschijnlijk nog niks 
van, maar mama is je ontzettend dankbaar. De laatste 1,5 jaar heb ook jij je heel 
wat ochtenden zelf moeten vermaken, terwijl mama hard aan het werk was in de 
studeerkamer. Afgezien van een keer brandje stoken in de keuken, ben je heel braaf 
geweest, dikke kus! En dan als allerlaatste een dikke knuffel voor mijn kleine lieve 
kereltje, Ruben. Alsof je het aanvoelde dat mama klaar was met schrijven, want tot 
dat moment sliep je heerlijk ’s avonds en ’s nachts door en daarna was het over. 
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